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Lymphocytes, mainly CD4+ T cells, have been identified as one of the key mediators of tissue 
damage and autoreactivity after stroke. However, potential therapies targeting delayed infiltration of 
CD4+ T cells are largely unexplored. Here, I investigated the effects of delayed infiltration of CD4+ 
T cells on tissue remodeling, functional recovery and autoreactive responses by B cells post stroke.   
Ischemic stroke was induced by 60 minute middle cerebral artery occlusion (MCAo) in wild type 
(WT) C57Bl/6 and 2D2 mice in which CD4+ T cells had been genetically modified so that their 
autoreactive T cell receptors recognize myelin oligodendrocyte glycoprotein. Delayed infiltration of 
CD4+ T cells was blocked by monoclonal antibodies starting on day 3 after stroke. Tissue 
remodeling was evaluated by quantitative real-time polymerase chain reaction and histology. 
Leukocyte infiltration and B-cell autoreactivity were quantified by histology and flow cytometry. 
Functional recovery was monitored by gait analysis and neurological scoring.  
CD4+ T cells infiltrated earlier and accumulated significantly more in the ischemic hemisphere on 
day 14 in 2D2 mice compared with WT mice. Additionally, the infarct size on day 1 post stroke in 
2D2 mice was also significantly larger than in WT mice. 
The anti-mouse CD4 antibody completely depleted CD4+ cells in the blood, spleen and ischemic 
brain. Even though infarct size was not significantly reduced, CD4 depletion significantly impaired 
the entry of B cells as well as the proliferation of activated macrophages and periendothelial cells in 
2D2 mice on day 14 post stroke. However, the absence of CD4+ T cells and subsequent blockage of 
B-cell infiltration had limited influence on tissue fibrosis and motor recovery. The inhibition of B-
cell infiltration by CD4 depletion was not significant in WT mice on day 14 post stroke. 
In both 2D2 and WT mice with control treatment, infiltrating B cells formed follicle-like aggregates 
in the ischemic hemispheres. In WT mice, B cells could form follicle-like aggregates up to 7 weeks 
post stroke. Interestingly, the delayed impairment of memory was more severe at 7 weeks than at 2 
weeks post stroke. 
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In conclusion, migration of B cells towards the ischemic brain depended on the infiltration of 
autoreactive CD4+ T cells. Follicle-like B cell aggregates temporally correlated with cognitive 
decline post stroke. Therefore, approaches to prevent delayed infiltration of adaptive immune cells 
might serve as a potential treatment for stroke patients. Further investigation into improving the 

















Lymphozyten, hauptsächlich CD4+ T-Zellen, wurden als einer der Schlüsselfaktoren für 
Gewebeschäden und Autoreaktivität nach Schlaganfall identifiziert. Potentielle Therapien, die die 
verzögerte Infiltration von CD4+ T-Zellen verhindern, sind jedoch weitgehend unerforscht. In 
meiner Doktorarbeit untersuchte ich die Auswirkungen der verzögerten Infiltration von CD4+ T-
Zellen auf die Gewebeumstrukturierung, die funktionelle Erholung und die Autoreaktivität von B-
Zellen nach Schlaganfall.  
 
Ein ischämischer Schlaganfall wurde durch 60 minütige Okklusion der mittleren zerebralen Arterie 
(middle cerebral artery occlusion, MCAo) in Wildtyp (WT) C57Bl/6- und 2D2 Mäusen induziert. 
2D2 Mäuse besitzen genetisch modifizierte CD4+ T-Zellen so, dass ihre T-Zell-Rezeptoren das 
Myelin Oligodendrozyten Glykoprotein erkennen und die somit hohes autoreaktives Potenzial 
aufweisen. Die verzögerte Infiltration von CD4+ T-Zellen wurde in den Mäusen durch 
Verabreichung monoklonaler Antikörper blockiert, beginnend am Tag 3 nach dem Schlaganfall. Die 
Gewebeumstrukturierung wurde mittels quantitativer real-time Polymerase-Kettenreaktion und 
Histologie untersucht. Leukozyteninfiltration und B-Zell-Autoreaktivität nach Schlaganfall wurden 
durch Histologie und Durchflusszytometrie quantifiziert. Zur Untersuchung der funktionellen 
Erholung wurden Ganganalyse und neurologische Scores eingesetzt. 
 
In 2D2 Mäusen infiltrierten CD4+ T-Zellen früher und an Tag 14 in größerer Zahl in die 
ischämische Hemisphäre verglichen mit WT-Mäusen. Zusätzlich war die Infarktgröße am Tag 1 
nach Schlaganfall in 2D2-Mäusen signifikant größer als die in WT-Mäusen. 
 
Der anti-Maus CD4 Antikörper führte zur vollständigen Depletion von CD4+ Zellen in Blut, Milz 
und im ischämischen Gehirn. Obwohl die Infarktgröße durch die Behandlung nicht signifikant 
reduziert wurde, beeinträchtigte die CD4-Depletion signifikant den Eintritt von B-Zellen, die 
Proliferation von aktivierten Makrophagen sowie periendothelialen Zellen in 2D2-Mäusen am Tag 
14 nach dem Schlaganfall. Die Abwesenheit von CD4+ T-Zellen und die resultierende Blockierung 
von B-Zellen hatten jedoch einen begrenzten Einfluss auf die Gewebsfibrose und die motorische 
Erholung. Die Hemmung der B-Zell-Infiltration durch CD4-Depletion war am Tag 14 nach 
Schlaganfall in WT-Mäusen nicht signifikant. 
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Sowohl in 2D2 Kontrollen als auch in WT Mäusen mit Kontrollbehandlung bildeten B-Zellen 
follikelartige Aggregate in ischämischen Hemisphären. In WT-Mäusen konnten B-Zellen bis zu 7 
Wochen nach Schlaganfall follikelartige Aggregate aufrechterhalten. Die längerfristige 
Beeinträchtigung des Gedächtnisses nach 7 Wochen war dabei schwerer als 2 Wochen nach dem 
Schlaganfall. 
 
Zusammenfassend konnte ich in dieser Arbeit zeigen, dass die Migration von B-Zellen ins 
ischämische Gehirn von der Infiltration autoreaktiver CD4+ T-Zellen abhängt. Follikelartige B-Zell-
Aggregate korrelieren zeitlich mit kognitiver Beeinträchtigung nach Schlaganfall. Daher könnten 
Ansätze zur Verhinderung einer verzögerten Infiltration von adaptiven Immunzellen als potentielle 
Behandlung von Schlaganfallpatienten dienen. Weitere Untersuchungen zur Verbesserung unseres 














Stroke is the fifth leading cause of adult death and a leading cause of long-term disability in the 
United States (Association 2016). Moreover, the United States has 6.4 million stroke survivors 
(prevalence of 3%), and there are approximately 600,000 new strokes and 200,000 recurrent strokes 
per year (Benjamin, Griggs et al. 2016). Of all strokes, about 87% of are ischemic infarctions, 10% 
primary hemorrhages, and 3% subarachnoid hemorrhages (SAHs) (Benjamin, Griggs et al. 2016). 
Advanced imaging techniques further enable the distinction between “strokes” (involving abrupt 
onset of sudden weakness and difficulty with vision, speaking, thinking or coordination) and “silent 
brain infarction” (a temporary blockage of blood flow to the brain, lacking clinically overt stroke-
like symptoms) (Fisher 1965, Vermeer, Longstreth et al. 2007, Benjamin, Griggs et al. 2016). 
However, the so-called “silent strokes” are not merely silent; they are associated with subtle deficits 
and future risk for stroke and dementia (van Rooij, Schaapsmeerders et al. 2014, Smith, Saposnik et 
al. 2017). 
Acute ischemic stroke (AIS) is characterized by the sudden loss of blood circulation to an area of the 
brain, typically in a vascular territory, resulting in a corresponding loss of neurologic function 
(Catanese, Tarsia et al. 2017). Either thrombotic or embolic occlusion of a cerebral artery can be the 
cause of AIS (Benjamin, Griggs et al. 2016). Large-artery infarctions often involve thrombotic in 
situ occlusions on atherosclerotic lesions in the carotid, vertebrobasilar, and cerebral arteries, 
typically proximal to major branches. However, large-artery infarctions (14-30%) may also be 
cardioembolic (Arboix and Alio 2010). 
The brain is perfused by paired carotid and vertebral arteries. The common carotid arteries bifurcate 
into the internal and external carotid arteries. The middle cerebral artery (MCA) is the largest branch 
of the internal carotid artery and is the single largest artery most commonly affected by ischemic 
stroke (Benjamin, Griggs et al. 2016). The territory supplied by MCA involves the outer convex 
brain surface, nearly all the basal ganglia, and the posterior and anterior internal capsules. Therefore, 
infarcts that occur within the vast distribution of MCA lead to diverse neurologic sequelae 
(Benjamin, Griggs et al. 2016). 
Recanalization strategies, including intravenous recombinant tissue-type plasminogen activator (rt-
PA) and endovascular procedure (Catanese, Tarsia et al. 2017), are mainly considered for stroke 
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patients when attempting to establish revascularization so that the ischemic penumbra, where 
reduction of blood flow leads to only mild excitotoxicity and inflammation with delayed cell death, 
can be rescued before irreversible injury occurs (Mergenthaler, Dirnagl et al. 2004). To date, rt-PA 
is the only drug approved by the US Food and Drug Administration (FDA) to treat ischemic stroke. 
It needs to be administered within 4.5 hours after stroke onset and only after computed tomography 
scanning has ruled out hemorrhagic stroke or (early) signs of tissue damage. Moreover, 
endovascular approaches to remove the blood clot, namely mechanical thrombectomy, have recently 
been proven to be effective in patients with occlusion in the internal cerebral artery and proximal 
MCA if administered within 6 hours of acute stroke symptoms (Catanese, Tarsia et al. 2017). 
2.2 Animal models of ischemic stroke 
Stroke is the leading cause of adult disability in industrialized countries. In addition to acute 
neurological deficits that can be directly attributed to the affected brain areas, additional cognitive 
decline (Makin, Turpin et al. 2013) and long-term psychiatric consequences, such as post-stroke 
depression (Robinson and Jorge 2016), may emerge without a correspondingly injured brain region 
in patients with chronic stroke (Sommer 2017). Therefore, stroke research has increasingly focused 
on the sub-acute and chronic phases after stroke because more patients might be eligible for 
therapeutic interventions in a prolonged time window. These delayed mechanisms include critical 
pathophysiological pathways such as post-stroke inflammation, activation of adaptive immunity, 
vascular remodeling, neuronal plasticity and regeneration (Becker 2010, Iadecola and Anrather 
2011). Experimental stroke models with clinical relevance, low mortality and high reproducibility 
are required to analyze these mechanisms and to subsequently evaluate novel drug targets. To meet 
this need, preclinical stroke researchers perform experimental stroke, preferably on rodents, 
especially mice, for which a broad spectrum of transgenic models are available (Fluri, Schuhmann et 
al. 2015).  
Proximal occlusion of the MCA via the intraluminal suture technique (so called filament or suture 
model) is probably the most frequently used animal stroke model (Carmichael 2005). The filament 
MCA occlusion (MCAo) model offers the advantage of inducing reproducible transient or 
permanent ischemia of the MCA territory in a relatively non-invasive manner, while the coagulation 
model needs a craniotomy right above the MCA branch for applying focal electrocoagulation and 
cannot induce transient occlusion (Fluri, Schuhmann et al. 2015). Moreover, filament occlusion of 
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the MCA with reperfusion after 60 min results in reproduction of pan-necrotic lesions in the cortex 
and striatum (Engel, Kolodziej et al. 2011). In contrast, models of distal (to the branching of the 
lenticulo-striate arteries) MCAo typically spare the striatum and primarily injure only the neocortex 
(Llovera, Roth et al. 2014). 
Human strokes are mostly small in size ranging from 28–80 mm3 and translating to 4.5–14% of the 
ipsilateral hemisphere (Carmichael 2005). Only malignant infarction can damage over 30% of one 
hemisphere. There is a clear risk that many studies of MCAo in mice do not model the usual cases 
of small and focal human stroke, but instead model malignant infarction (Carmichael 2005) with 
extensive cytotoxic edema, diminished collateral flow and only a relatively small rim of penumbra 
(Heiss 2016). When the infarct size extends into larger volumes of the hemisphere, the damage 
involves regions supplied by the MCA as well as deep regions such as the hippocampus, 
hypothalamus and/or thalamus (El Amki, Clavier et al. 2015). This limitation makes it harder to 
model human stroke, which damages only specific neuronal circuits (such as in the motor cortex), 
and the recovery following a functional reorganization in the brain. Nevertheless, the MCAo model 
with larger infarction has the advantage of providing measurable pathophysiology to study vascular 
remodeling and adaptive immune responses in the ischemic brain during subacute and even chronic 
phases. 
2.3 Immunology of stroke 
2.3.1 Cerebral ischemia induced immunodepression and susceptibility to infections 
Although early mortality results from direct complication after large strokes, infections, and 
pneumonia in particular, are the leading cause of death in the post-acute phase of stroke. Infections 
after central nervous system (CNS) injury, such as stroke, traumatic brain injury (TBI) and spinal 
cord injury (SCI), may be attributed to exposure to invasive medical procedures and prolonged 
hospitalization, dysphagia, aspiration, etc. (Meisel, Schwab et al. 2005). The high incidence of 
infections in stroke patients is likely to be caused by an impaired immune function and subsequent 
susceptibility to infection (Dirnagl, Klehmet et al. 2007). As early as 1974, an immunosuppressive 
state was conceptualized in stroke (Howard and Simmons 1974). In a mouse model of focal cerebral 
ischemia with bacterial infection developing spontaneously within 24 hours after the onset of stroke, 
rapid suppression of peripheral cellular immune responses involving mainly lymphocyte apoptosis 
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and defective interferon (IFN)-ɣ production by T and natural killer (NK) cells preceded the bacterial 
infection (Prass, Meisel et al. 2003). Blocking the sympathetic nervous system but not the 
hypothalamic-pituitary-adrenal (HPA) axis prevented the occurrence of infection after stroke. 
Another study using a similar MCAo model demonstrated that stroke induced short activation of 
hepatic invariant NKT (iNKT) cells and changed their phenotype towards producing 
immunosuppressive type 2 helper T cell (Th2) cytokine, interleukin (IL)-10 (Wong, Jenne et al. 
2011). Furthermore, in both studies administration of β-adrenoceptor blocker propranolol retained 
inflammatory type 1 helper T cell (Th1) phenotype of lymphocytes and dramatically reduced 
infection after stroke.  
The nervous and immune systems actively communicate with each other. The central and peripheral 
autonomic nervous systems have sensors for the status of the immune system (Felten, Felten et al. 
1987). After processing input from the CNS, in particular the frontal premotor cortex (fpmCTX), the 
hypothalamus, the pituitary and the brain stem, homeostatic signals can be sent to various organs via 
three major pathways of neuroimmunomodulation: the HPA axis, the sympathetic-adrenal-
medullary (SAM) axis and the para sympathetic nervous system (vagus nerve) (Meisel, Schwab et 
al. 2005). Production of glucocorticoid hormones and catecholamines in the blood upon activation 
of the HPA and the SAM axes results in suppressive immunomodulation of both immune cell 
activation and inflammatory cytokine production. This anti-inflammatory response was considered 
adaptive and protective to limit an overwhelming systemic inflammatory response which could 
result in shock and multiple organ failure (Meisel, Schwab et al. 2005). It was later determined that 
CNS injury induces a disturbance in the normally well-balanced interplay between the immune 
system and the CNS. This is the mechanism by which CNS injury leads to secondary 
immunodeficiency (CNS injury-induced immunodepression, CIDS) (Figure 1) and infection 




















Figure 1. Schematic representation of stroke injury-induced immunodepression (SIDS).  
Stroke-induced immunosuppression is characterized by impaired function of invariant natural killer T cells as 
well as other immune cells, including helper T cells and antigen-presenting cells through over-activation of 
stress pathways, especially those of the sympathetic nervous system. The resulting breakdown of 
antimicrobial defenses and neurologic deficits (such as dysphagia and unconsciousness) following stroke, 
frequently lead to pneumonia that in turn may worsen outcome. Adapted from Meisel and Meisel (2011). 
 
To maximally fight infection secondary to stroke-induced immunodepression and related mortality, 
stroke patients are routinely prescribed antibiotics if there is evidence of ongoing infection in the 
clinical setting. Considering that infection usually develops within a fixed time window of 2-7 days 
after stroke onset (Meisel 2015), preventative antibiotic treatment might also be appropriate. At least 
in experimental stroke it has been proven that a preventative approach similarly reduces post-stroke 
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mortality and enables better neurologic outcome compared to the standard approach (Hetze, Engel et 
al. 2013). However in the Preventative Antibiotics Stroke Study (PASS), preventive ceftriaxone 
does not improve functional outcome at 3 months in adults with acute stroke (Westendorp, Vermeij 
et al. 2015). Surprisingly, post-hoc subgroup analysis in PASS suggests that preventive antibiotic 
therapy improves neurological outcome only in patients simultaneously treated with intravenous 
thrombolysis. A subsequent clinical trial (STROKE-INF) assessed the effectiveness of antibiotic 
prophylaxis in reducing pneumonia in patients with dysphagia after acute stroke and recommended 
no antibiotic prophylaxis since only urinary tract infections (UTIs), and not post-stroke pneumonia, 
were less frequent in the antibiotics group (Kalra, Irshad et al. 2015). In addition, no benefit of 
antibiotic prophylaxis was reproduced in a subgroup of patients with intravenous thrombolysis. 
Therefore further trials are still needed to investigate the potential mechanism.  
It is also worth mentioning that infection or systemic inflammation can exacerbate functional 
outcome of acute stroke by boosting cellular immune responses towards a more destructive T helper 
1 (Th1) response against CNS antigens rather than a protective T regulatory (Treg) response 
(Becker, Kalil et al. 2011). To exclude the confounding effect of infection, it is beneficial to employ 
preventative antibiotic treatment in experimental stroke with a focus on investigating the effects of 
immunological modulation on post-stroke recovery. 
2.3.2 Drainage of CNS antigens and extravasation of leukocytes into brain parenchyma 
CNS is classically considered an “immune privileged” site owing to the presence of the blood-brain 
barrier (BBB) restricting entry of immune cells into the CNS and the lack of a classical lymphatic 
drainage system within the CNS parenchyma. Usually, systemic inflammation or infections cannot 
induce bystander damage beyond the blood-brain barrier, while the constant immune surveillance of 
the CNS only takes place within the meningeal compartment (Kipnis, Gadani et al. 2012, Ransohoff 
and Engelhardt 2012). This phenomenon and stroke-induced immunodepression jointly serve as an 
endogenous mechanism to prevent autoimmune responses directed against brain antigens after CNS 
injury. However, two major extracellular fluids, cerebrospinal fluid (CSF) in the ventricles and 
subarachnoid spaces and interstitial fluid (ISF) in the extracellular spaces of the brain and spinal 
cord parenchyma, can carry CNS antigens which are released after CNS injury or antigen-presenting 
cells (APCs) to cervical or lumbar lymph nodes (Louveau, Smirnov et al. 2015). Neuronal antigens 
are present in cervical lymph nodes (CLN) of multiple sclerosis (MS) patients (van Zwam, Huizinga 
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et al. 2009). Moreover, brain proteins have been detected in the CSF and blood as well as carried on 
APCs in draining LN of stroke patients (Planas, Gomez-Choco et al. 2012), and their concentration 
is related to the extent of brain damage (Jauch, Lindsell et al. 2006). In mice at 24 hours after 
there is significantly increasing drainage of CNS antigen, mainly proteolipid protein (PLP) and 
neurofilament light (NF-L) positive cells, in both superficial and deep CLNs compared with 72 
hours after MCAo (van Zwam, Huizinga et al. 2009). This process, which takes place both in the 
draining LNs and the spleen, facilitates recognition of CNS antigens (usually not available to the 
immune system in a healthy state) by peripheral lymphocytes and initiates the development of 
detrimental autoreactivity against CNS antigens (Ren, Akiyoshi et al. 2012, Ortega, Noorbhai et al. 
2015, Zierath, Kunze et al. 2015) or potentially protective tolerance (Steinman and Nussenzweig 
2002, Becker 2009, Gee, Zierath et al. 2009).  
In addition to drainage and presentation of CNS antigens to the periphery, ischemia/reperfusion 
injury is also associated with immune cell recruitment, which contributes to both damage of the 
vessels and the surrounding tissue. Neurons can respond rapidly to focal ischemia, which is 
attributed to functional coupling with CNS vessels. The anatomical structure is the so-called 
neurovascular unit (NVU) which is composed of a monolayer of specialized endothelial cells (ECs) 
interconnected by complex tight junctions (TJs), the underlying endothelial basement membrane 
(BM) and a second BM, known as the parenchymal BM as it marks the border to the CNS 
parenchyma (Enzmann, Mysiorek et al. 2013) (Figure 2). Together with the ensheathing layer of 
astrocyte endfeet, the parenchymal BM defines the glia limitans (Engelhardt and Wolburg 2004), 
interconnecting to the surrounding neurons. Only capillaries have just one composite BM fused by 
endothelial and parenchymal BMs, while in all brain parenchymal vessels the endothelial and 
parenchymal BMs are structurally and biochemically distinct entities. Perivascular space, namely 
“Virchow-Robin space” or the “perivascular cuff”, is formed between these two BMs. Extravasation 
and aggregation of leukocytes within the perivascular space is typically seen in the inflamed brain 
under immunofluorescent microscopy (Figure 2). Activated leukocytes expressing adhesion 
molecules, selectins, and integrins roll, activate and attach to the brain endothelium via ligation with 
their corresponding receptors and finally transmigrate through the endothelial layer of BBB 
(Engelhardt 2006, Wilson, Weninger et al. 2010). Only recently have CNS inflammation studies 
(Wu, Ivars et al. 2009, Yousif, Di Russo et al. 2013) highlighted the contribution of the following 
acellular BM layers to lymphocyte extravasation and hence barrier functions at the level of post-
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capillary venules. Furthermore, disease symptoms are only induced upon leukocyte penetration of 
the final parenchymal BM as well as glial limitans and entry into CNS parenchyma (Agrawal, 






Figure 2. Cellular and acellular architecture of CNS blood vessels. 
Schematic representation and immunofluorescence examples of cell and basement membrane (BM) layers 
supporting CNS blood vessels. Larger blood vessels consist of an inner endothelial cell layer with BM 
(containing laminins α4 and α5), bordered by the meningeal epithelium and its BM (containing laminin α1), 
and an outer astroglial BM (containing laminin α2) and astrocyte endfeet. Meningeal and astroglial BMs are 
collectively termed the parenchymal BM as they delineate the border to the brain parenchyma. Endothelial 
and parenchymal BMs usually merge as one layer. Only the accumulation of inflammatory immune cells 
(“perivascular cuff”) in the perivascular space makes endothelial and parenchymal BMs distinguishable. 




2.3.3 Inflammation-induced tissue remodeling after ischemic stroke 
Apart from basement membranes that are composed of complex assemblies of four major 
glycoprotein families, laminins, collagen type IV isoforms, nidogens, and heparan sulfate 
proteoglycans, brain lacks another form of extracellular matrix (ECM): interstitial matrix of the 
stroma in most tissues. In brain, the fibrogenic stromal cells are restricted only to blood vessels and 
meninges, hence, there is normally little or no fibrous protein, such as collagen types I and III or 
fibronectin (Engelhardt and Sorokin 2009). However, disruption of the BBB and inflammation can 
cause scar formation or tissue fibrosis (a ubiquitous healing mechanism to compensate tissue 
defects) in CNS parenchyma. The fibrotic scar is characterized by the deposition of fibrous ECMs in 
the neural parenchyma such as collagens, laminins and fibronectin. These molecules are deposited 
by invading stromal cells (myofibroblasts), which are normally absent. The stromal cells may 
originate from meningeal precursors (eg, pial cells of the leptomeningeal lining), perivascular 
fibroblasts or pericytes (“type A pericytes”) (Fernandez-Klett and Priller 2014). No contribution of 
bone marrow-derived cells is reported (Fernandez-Klett, Potas et al. 2013). 
Pericytes (PCs), the most abundant vascular mural cells, are embedded within BMs and positioned 
at the interface between endothelial cells, neurons and astrocytes.  They contribute to the modulation 
of blood flow (Fernandez-Klett and Priller 2015) and determine the formation and integrity of the 
BBB (Armulik, Genove et al. 2010). After experimental traumatic brain injury, at ultrastructural 
level some PCs acutely migrate into the parenchyma adjacent to blood vessels while others 
degenerate (Dore-Duffy, Owen et al. 2000). In spinal cord injury models, a novel subpopulation of 
vascular mural cells share with PCs the perivascular location and a common set of markers, 
including platelet-derived growth factor receptor beta (PDGFRβ). These cells proliferate extensively 
into fibroblast-like cells that generate fibrous ECMs and outnumber astrocytes after spinal cord 
injury (Goritz, Dias et al. 2011). Most relevantly, it was reported that capillary PCs are rapidly lost 
after cerebral ischemia in both experimental and human stroke, while perivascular PDGFRβ+ 
stromal cells induce scar formation in mouse ischemic brain (Fernandez-Klett, Potas et al. 2013). 
Moreover, nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF) and vascular 
endothelial growth factor a (VEGFa) might also be involved in tissue remodeling since both 
neurogenesis and angiogenesis can contribute to neural plasticity and recovery after ischemic stroke 
(Font, Arboix et al. 2010). 
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Astrocytes react to CNS injury by building a dense wall of filamentous processes, namely “glia 
scar”, to seal the lesion (Cregg, DePaul et al. 2014). They undergo only modest proliferation in 
response to injury, and this proliferation is confined to a thin layer at the lesion margin without 
invasion into the ischemic core (Faulkner, Herrmann et al. 2004, Jiang, Zhao et al. 2016).  For years 
it has been thought that the glia scar was the main impediment to regenerating axons attempting to 
reach their distal targets residing in the lesion. However, with a complex of interacting cell types in 
the lesion, the glia scar can have both detrimental and beneficial properties (Cregg, DePaul et al. 
2014, Raposo and Schwartz 2014).  
Fibrosis is part of inflammation. Breakdown of the BBB and leakage of inflammatory cytokines and 
profibrotic factors into the CNS parenchyma are considered key events in scar formation. Indeed, 
cytokines such as IL-1β, IL-6 and tumor necrosis factor (TNF)-α that aggravate fibrosis in 
peripheral tissues (Duffield, Lupher et al. 2013) are also expressed by activated microglia or 
infiltrating inflammatory cells in the injured CNS. The appearance of alternatively activated 
macrophages can also secrete anti-inflammatory and profibrotic factors such as tissue growth factor 
(TGF)-β1 and PDGF that has been associated with the accumulation of (myo)fibroblasts and the 
deposition of fibrillar ECMs (Murray and Wynn 2011). ECMs, such as chondroitin sulfate 
proteoglycans (CSPGs) with covalently bound glycosaminoglycans (GAGs), can enhance cell 
migration through their ability to bind L-selectins and P-selectins as well as inflammatory 
chemokines (Raposo and Schwartz 2014). However, no studies have carefully examined whether T 
lymphocytes are actively involved in scar formation and could possibly play a modulatory role in 
tissue remodeling after stroke. 
2.3.4. Innate immune responses after ischemic stroke 
Ischemic stroke causes sterile inflammation with chronic potential caused by the diminished 
immunosuppression during the delayed phase of injury. Both innate immunity and adaptive 
immunity can sense “danger signals” from dying and dead cells in the penumbra and the infarct 
Besides extracellular nucleotides and neurotransmitters, a wide variety of molecular signals are also 
released from the intracellular compartment or are generated by the action of lytic enzymes escaped 
from dead cells on matrix proteins (Iadecola and Anrather 2011). The so-called danger-associated 
molecular pattern molecules (DAMPs) activate pattern recognition receptors including Toll-like 
receptors (TLRs) and scavenger receptors, which are widely expressed on microglia, perivascular 
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macrophages and brain endothelial cells (Marsh, Williams-Karnesky et al. 2009). Thus it takes only 
hours to active innate immunity after stroke onset. 
Microglia arise from the embryonic yolk sac and function as innate immune cells of the CNS. 
Following activation, microglia contribute to post-stroke inflammation by producing TNF, IL-1β, 
reactive oxygen species (ROS) and other proinflammatory mediators. Blood monocytes are direct 
precursors of tissue macrophages. After cerebral ischemia, inflammatory monocytes are rapidly 
recruited to the site of injury where they differentiate into macrophages and dendritic cells (DCs) 
(Felger, Abe et al. 2010). Functional macrophages can be classified into two groups: M1 
macrophages that produce proinflammatory cytokines (IL-1β, IL-12, IL-23 and TNF), chemokines, 
ROS and NO, promoting a Th1 immune response, and M2 macrophages that produce anti-
inflammatory cytokines (IL-10 and TGF-β1), IL-1ra and arginase (Mantovani, Biswas et al. 2013). 
Microglia and infiltrating macrophages constitute the predominant phagocytes that remove dead 
cells and tissue debris after stroke (Schilling, Besselmann et al. 2005, Denes, Vidyasagar et al. 
2007). DCs are specialized APCs and therefore act as the interface between innate and adaptive 
immunity. Cells with DC markers appear in the brain parenchyma after focal ischemia and originate 
from resident and blood-borne cells (Felger, Abe et al. 2010). Neutrophils are also rapidly recruited 
to the site of tissue infection or inflammation. They have been frequently associated with tissue 
damage after cerebral ischemia for their expression of matrix metalloproteinases (MMPs) which are 
involved in degradation of BMs, leading to disruption of the BBB and hemorrhagic transformation 
(Hamann, Okada et al. 1995), and abundant proteases that are considered the main causes of 
neuronal cell death. However, it is under debate whether neutrophil can infiltrate into the ischemic 
brain or simply accumulate within NVU (Enzmann, Mysiorek et al. 2013, Perez-de-Puig, Miro-Mur 
et al. 2015).  
2.3.5 Adaptive immune responses after ischemic stroke 
In the acute phase of ischemia, innate immune cells as well as a subset of effector lymphocytes, such 
as IL-17 producing γδT cells recognizing nonpeptide antigens, can contribute to early damage 
(Shichita, Sugiyama et al. 2009). Nevertheless, to initiate cellular immunity during the delayed 
phase of ischemia, T cells require major histocompatibility complex (MHC)-restricted antigen 
presentation by APCs and recognition of antigens via highly variant TCRs. Therefore, the activation 
of adaptive immunity usually is delayed by an interval of 7–10 days, from antigen presentation to 
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clonal expansion of autoreactive T cells and immune attack on the target organ. CD4+ T cells (MHC 
class II-restricted) become helper T cells which coordinate and modulate immune responses, while 
CD8+ T cells (MHC class I restricted) have the actual cytotoxic function following ischemic stroke 
(Li, Wang et al. 2013). It is the cytokine environment that determines the differentiation and 
polarization of naïve CD4+ T cells in ischemic brain (Figure 3). Development of Th1 effector cells is 
promoted by IL-12 produced by activated macrophages. Th1 cells secrete IFN-ɣ and TNF which 
further stimulate innate and T cell-induced immune responses leading to cytotoxicity. However, T 
cells can also be protective. TGF-β produced by neurons, glia, microglia and macrophages promotes 
the development of Treg cells secreting the protective cytokine IL-10 and inhibiting Th1 and Th2 
responses. On the other hand, induction of mucosal tolerance with CNS antigens can lead to the 
establishment of anti-inflammatory Th2 cells producing IL-10 (Frenkel, Huang et al. 2005) and Treg 
cells producing IL-10 and TGF-β (Gee, Zierath et al. 2009). Therefore, it is more relevant to 
modulate T cells and evaluate their interconnection with other immune cells and delayed effects on 

























Figure 3. Pro and anti-inflammatory roles of T cells in stroke. 
In the acute phase of cerebral ischemia, unprimed T cells and activated microglia/macrophages contribute to 
tissue damage in an antigen-independent manner (innate immunity). In the delayed phase of ischemia, naïve 
T cells are activated by APCs and produce inflammatory cytokines which damage the CNS. However, 
subsets of T cells can also be protective. Adapted from Iadecola, C. and Anrather, J. (2011). 
 
Antigen presentation leads to the development of not only cellular but also humoral immunity 
directed against the recognized antigens. Antibodies against CNS antigens develop after ischemic 
stroke (Dambinova, Khounteev et al. 2003). Intrathecal synthesis of immunoglobulins has also been 
reported in stroke patients (Pruss, Iggena et al. 2012). Data from investigating post-mortem brain 
slices from stroke patients indicate that activated lymphocytes can chronically accumulate in 
ischemic brain and are strongly involved in the synthesis of autoreactive immunoglobulins which 
potentially impairs cognition (Doyle, Quach et al. 2015). Besides stroke-induced autoantibodies, 
preexisting autoantibodies can also take part in the lesion evolution in ischemic stroke. For example, 
autoantibody against water channel aquaporin-4 (AQP4) plays a direct pathological role in 
neuromyelitis optica (NMO) patients. Purified NMO-IgG can exacerbate infarct size in rats treated 
with 30 min MCAo compared to treatment with immunoglobulins from healthy controls 
(Juenemann, Braun et al. 2015). A more complex situation is seen with preexisting autoantibodies 
against the N-methyl-D-aspartate-receptor NMDAR subunit NR1 (NMDAR1). The BBB integrity 
before an acute ischemic stroke can influence whether autoantibodies against NMDAR1 are 
beneficial or detrimental for modulating the evolution of infarct size (Zerche, Weissenborn et al. 
2015). However the detailed kinetics of B cell infiltration into the ischemic brain and their 
functional interaction with innate immune cells and T cells have not been fully investigated.  
2.4 Modulation of lymphocytes in animal model of ischemic stroke 
Lymphocytes, in particular T cells, have been indicated as a key mediator of local inflammation and 
tissue remodeling in ischemic brain (Brait, Arumugam et al. 2012). Activated lymphocytes are 
increasingly recognized as a target for anti-inflammatory stroke therapies (Frenkel, Huang et al. 
2003). Modulation of T lymphocytes can dramatically influence the outcome after stroke (Iadecola 
and Anrather 2011). Induction of 90 min MCAo in mice with severe combined immunodeficiency 
(SCID) lacking T and B cells results in reduction of total infarct volume at 22 hours compared to 
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WT mice (Hurn, Subramanian et al. 2007). Two papers (Yilmaz, Arumugam et al. 2006, Shichita, 
Sugiyama et al. 2009) similarly described that in recombination activating gene 1 (RAG1)-deficient 
mice, the absence of functional T and B cells reduces infarct volume and neurologic deficits at 24 
hours after 60 min MCAo, and this protection can be reversed upon reconstitution of RAG1-/- mice 
with T cells from wild-type littermates. Detailed analysis of lymphocyte subsets revealed that B-
cell-deficient mice failed to show improvement following ischemic stroke injury (Yilmaz, 
Arumugam et al. 2006). However, it was later demonstrated that B cells are critical in governing 
infarct size and that MCAo-induced changes are prevented in B-cell-deficient (μMT-/-) mice after 
transfer of highly purified WT B cells, but not IL-10-deficient B cells, implicating IL-10-secreting B 
cells as a major regulatory cell type in stroke (Ren, Akiyoshi et al. 2011, Chen, Bodhankar et al. 
2012, Bodhankar, Chen et al. 2014).  
A transgenic approach is quite convenient for an experimental setup but not applicable in clinical 
practice. Therefore immunomodulators, adoptive transfer and monoclonal antibodies have been 
tested as potential therapies. Anti-inflammatory Tregs have been targeted in several studies. The 
cerebroprotective role of Treg with dependence on IL-10 signaling was first reported in acute 
experimental stroke (Liesz, Suri-Payer et al. 2009). However, a more recent study demonstrated that 
Tregs might also have a detrimental effect on microvascular thrombus formation in cerebral 
ischemia (Kleinschnitz, Kraft et al. 2013). Additional research demonstrated that Tregs can 
accumulate and proliferate up to 30 days after 60 min MCAo but do not promote neurological 
recovery (Stubbe, Ebner et al. 2013). Modulation of lymphocyte entry into CNS parenchyma has 
also led to controversial conclusions. The inhibition of leukocyte very late antigen-4 (VLA-4) and 
endothelial vascular cell adhesion molecule-1 (VCAM-1)-mediated brain invasion by monoclonal 
antibody (anti-CD49d) against α4 integrin shields the brain against deleterious neuroinflammation 
after stroke (Liesz, Zhou et al. 2011). But a later study reported that blocking α4 integrin does not 
protect from acute ischemic stroke in mice (Langhauser, Kraft et al. 2014). Recently, a randomized 
controlled preclinical study involving several researching groups found that anti-CD49d treatment 
does not reduce lesion size or affect leukocyte invasion after transient proximal occlusion of the 
MCA, which induces large lesions (Llovera, Hofmann et al. 2015). These results suggest that infarct 
severity and localization may determine the benefits of immune-targeted approaches.  
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It is necessary to point out that earlier dynamic studies (Gelderblom, Leypoldt et al. 2009, Chu, Kim 
et al. 2014) addressed the infiltration of lymphocytes into ischemic brain occurring three hours after 
transient cerebral ischemia and reaching its peak around day 3. Therefore, the majority of previous 
studies in rodents required the modulation of T lymphocytes during the acute phase or even before 
onset of stroke. However, recent studies (Gronberg, Johansen et al. 2013, Stubbe, Ebner et al. 2013, 
Romer, Engel et al. 2015) support the fact that due to the prerequisite of CNS antigen drainage (van 
Zwam, Huizinga et al. 2009, Planas, Gomez-Choco et al. 2012, Urra, Miro et al. 2014) and 
presentation by APCs to activate naïve lymphocytes in the periphery, massive lymphocyte 
infiltration occurs during the delayed phase of stroke (between 7 and 14 days), while the early (24 
hours) detrimental T cell effects on experimental stroke are related neither to adaptive immunity nor 
to thrombus formation (Kleinschnitz, Schwab et al. 2010). Along the same line, a new study 
demonstrated that the pharmacological ablation of B cells, beginning 5 days post injury using anti-
CD20 antibody, prevents the appearance of delayed cognitive impairment following experimental 
stroke (Doyle, Quach et al. 2015).  However, modulation of T cells in the delayed phase of stroke 
and its effects on tissue remodeling or functional recovery are not reported. 
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3. AIMS OF THE STUDY 
CD4+ T cell is the dominant subtype of T cells that infiltrates into the peri-infarct region, and it acts 
as the interface between cellular and humoral immune responses. CD4+ T cell is also a necessary 
mediator of autoreactive immune responses and long-term consequences post ischemic stroke. To 
narrow down the spectrum of CNS antigens related autoreactivity and also use this autoreactivity to 
harvest more CNS-infiltrating CD4+ T cells for further analysis, 60 min MCAo was induced mainly 
in 2D2 mice with the majority of CD4+ T cells expressing TCR recognizing myelin oligodendrocyte 
glycoprotein (MOG) (Bettelli, Pagany et al. 2003). WT mice also received similar procedures since 
they have an almost normal immune system to investigate stroke-induced autoreactive responses, 
whereas 2D2 mice are more prone to CNS-autoreactivity. The scope of my doctoral thesis focuses 
on investigating whether delayed depletion of CD4+ T cells affects tissue remodeling and functional 
recovery after ischemic stroke. To elucidate this, the following key questions were addressed: 
 
1. When do CD4+ T cells massively infiltrate into ischemic brain parenchyma following 60 min 
MCAo in 2D2 mice? Does the accumulation of CD4+ T cells temporally correlate with 
deposition of fibrotic ECMs within infarction?  
 
2. Is delayed CD4+ depletion using monoclonal antibody able to prevent entry of CD4+ T cells 
into the ischemic brain? Does CD4+ depletion influence tissue remodeling and motor 
recovery after stroke, and if so, how? 
 
3. Does delayed CD4 depletion affect local phagocytes and CNS infiltrating immune cells in 
stroke-induced 2D2 mice? Does the same effect exist in WT mice after ischemic stroke? 
 
4. When and how do B cells infiltrate the ischemic brain? Is there an autoreactive antibody-
response in the ischemic brain after stroke? Does B cell accumulation have any impact on 









C57Bl/6J Charles River Laboratories, Sulzfeld, Germany 
2D2 TCR 
strain name: C57BL/6-Tg (Tcra2D2,Tcrb2D2)1Kuch/J 
stock number: 006912 
The Jackson Laboratory, Bar Harbor, ME, USA 
 
4.1.2 Veterinary drugs and chemicals for in vivo application 
Name Provider 
2% Xylocain gel AstraZeneca GmbH, Wedel, Germany 
2.5% enrofloxacin Baytril, Leverkusen, Germany 
Bromdesoxyuridin (BrdU), 10mg/ml BD Biosciences, Franklin Lakes, NJ, USA 
Heparin-Rotexmedica 25000 I.E./5 ml ROTEXMEDICA GmbH, Trittau, Germany 
InVivoMAb anti-mouse CD4 (Clone: GK1.5) Bio X Cell, West Lebanon, NH, USA 
InVivoMAb Rat IgG2b Isotype control (Clone: LTF-2) Bio X Cell, West Lebanon, NH, USA 
Isoflurane Forene, Abbott, Wiesbaden, Germany 
Isotonic saline (0.9%) 
Fresenius Kabi Deutschland GmbH, Bad 
Homburg, Germany 
Ketamine Deltaselect, Dreieich, Germany 
MARBOCYL 10% Vetoquinol GmbH, Ravensburg, Germany 





1,4-Diazabicyclo[2.2.2]octane (DABCO)  Carl Roth GmbH-Co. KG, Karlsruhe, Germany 
2-methylbutan Carl Roth GmbH-Co. KG, Karlsruhe, Germany 
2-propanol Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
4',6-diamidino-2-phenylindole (DAPI) Invitrogen, Life Technologies GmbH, Darmstadt, 
Germany 
Agarose Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
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BD FACS™ Lysing Solution BD Pharmingen, Franklin Lakes, NJ, USA 
Bovine serum albumin (BSA) fraction V Sigma-Aldrich, St Louis, MO, USA 
Chloroform Carl Roth GmbH-Co. KG, Karlsruhe, Germany 
Diethyl pyrocarbonate (DEPC) ThermoFisher Scientific Inc., Waltham, MA USA 
Disodium phosphate Sigma-Aldrich, St Louis, MO, USA 
D(+)-sucrose Carl Roth GmbH-Co. KG, Karlsruhe, Germany 
Ethanol Rotipuran, Carl Roth GmbH & Co. KG, 
Karlsruhe, Germany 
Ethylene glycol Sigma-Aldrich, St Louis, MO, USA 
Glycerol Merck, Darmstadt, Germany 
Paraformaldehyde (PFA) Sigma-Aldrich, St Louis, MO, USA 
Red blood cell (RBC) lysis buffer QIAGEN GmbH, Hilden, Germany 
Sodium azide Carl Roth GmbH-Co. KG, Karlsruhe, Germany 
Sodium dihydrogen phosphate monohydrate Sigma-Aldrich, St Louis, MO, USA 
Tissue-Tek O.C.T Compound 
 
Sakura Finetek Europe B.V. KvK, Leiden, V.A.T., 
Netherlands 
Triton X LABORAT GmbH, Germany 
Tween-20 Carl Roth GmbH-Co. KG, Karlsruhe, Germany 
 
4.1.4 Cell culture media and supplements 
Name Provider 
Ampuwa distilled water Fresenius Kabi Deutschland GmbH, Bad 
Homburg, Germany 
Easycoll gradient Biochrom AG, Berlin, Germany 
Fetal calf serum (FCS Gold) PAA Laboratories, Pasching, Austria 
Gibco® PBS (10X), without Ca & Mg, pH 7.4 Thermo Fisher Scientific Inc., 
Waltham, Massachusetts, USA 
L-alanyl-L-glutamine Biochrom AG, Berlin, Germany 
Normal goat serum BIOZOL Diagnostica Vertrieb GmbH, Germany 
Penicillin-streptomycin Biochrom AG, Berlin, Germany 
Dulbecco's PBS (1x), without Ca & Mg PAA Laboratories, Pasching, Austria 
Roswell Park Memorial Institute (RPMI) 1640 
Medium, w/o L-Glutamine 
Biochrom AG, Berlin, Germany 
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Dulbecco’s MEM (DMEM) Liquid Medium With 1.0 
G/L D-Gluocose, w/o L-Glutamine 
Biochrom AG, Berlin, Germany 
Trypan blue 0.5%* in physiol. saline Biochrom AG, Berlin, Germany 
 
4.1.5 Polymerase chain reaction (PCR) primers and reagents 
Name Provider 
PCR primers  
β-actin 5‘: ACCCACACTGTGCCCATCTA EuroFins MWG Operon, Ebersberg, Germany 
β-actin 3‘: GCCACAGGATTCCATACCCA EuroFins MWG Operon, Ebersberg, Germany 
BDNF 5‘: GGCTAAGTGGAGCTGACATAC EuroFins MWG Operon, Ebersberg, Germany 
BDNF 3‘: CACTGTTAGGTAATGTAGGCAC EuroFins MWG Operon, Ebersberg, Germany 
ColI 5‘: CCTCCAGGTCCCAAGGGTAAC EuroFins MWG Operon, Ebersberg, Germany 
CXCL13 5‘: TACGCCCCCTGGGAATGGCT EuroFins MWG Operon, Ebersberg, Germany 
CXCL13 3‘: AGTGGCTTCAGGCAGCTCTTCT EuroFins MWG Operon, Ebersberg, Germany 
ColI 3‘: GGCTCCTCGTTTTCCTTCTTCTCC EuroFins MWG Operon, Ebersberg, Germany 
CCR2 5’: GATCCTGCCTCCACTCTACTC EuroFins MWG Operon, Ebersberg, Germany 
CCR2 3’: GCATAGTGAGCCCAGAATG EuroFins MWG Operon, Ebersberg, Germany 
NGF 5’: GGTTTTGCCAAGGACGCAGC EuroFins MWG Operon, Ebersberg, Germany 
NGF 3’: GCTGAAGTTTAGTCCAGTGGG EuroFins MWG Operon, Ebersberg, Germany 
PDGFRβ 5’: GGGAGACACTGGGGAATAC EuroFins MWG Operon, Ebersberg, Germany 
PDGFRβ 3’: GTCTCAGTGACATCCGTGAC EuroFins MWG Operon, Ebersberg, Germany 
Reep5 3’: CTGATAGGT TTC GGATACCCAG EuroFins MWG Operon, Ebersberg, Germany 
Reep5 5’: GACTCGTGCTTGAGGAAGATAG EuroFins MWG Operon, Ebersberg, Germany 
TGFβ1 5’: CGTTACCTTGGTAACCGGCTG EuroFins MWG Operon, Ebersberg, Germany 
TGFβ1 3’: GCTGATCCCG TTGATTTC EuroFins MWG Operon, Ebersberg, Germany 
VEGFa 5’: GCTGTAACGATGAAGCCCTGG EuroFins MWG Operon, Ebersberg, Germany 
VEGFa 3’: GGTCTGCATTCACATCTGC EuroFins MWG Operon, Ebersberg, Germany 
PCR reagents  
2-Log DNA ladder (0.1-10.0 kb) NEB, Frankfurt am Main, Germany 
dNTPs Roche, Mannheim, Germany 
LightCycler® 2.0 Roche, Mannheim, Germany 
LightCycler® FastStart DNA Master SYBR Green I Roche, Mannheim, Germany 
NucleoSpin RNA clean-up KIT (740948.250) Machery-Nagel GmbH&Co. KG, Düren, Germany 
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M-MLV-RT 200U/ul Promgea, Madison, USA 
M-MLV-RT reaction buffer 5x Promgea, Madison, USA 
RNA-Sin 40U/ul Promgea, Madison, USA 
RQ1 RNase-free DNase Promgea, Madison, USA 
RQ1 RNase-free DNase 10x reaction buffer Promgea, Madison, USA 
TRIzol® Reagent ThermoFisher Scientific Inc., Waltham, USA  
 
4.1.6 Fluorescence-activated cell sorting (FACS) staining panel for phenotyping 2D2 mice 
Antibody Conjugation Clone Per 100ul Provider 
IgG2α κ chain APC - 1ul BD Pharmingen, Franklin Lakes, NJ, USA 
IgG2β κ chain PE - 1ul BD Pharmingen, Franklin Lakes, NJ, USA 
Rat anti-Vβ11 PE RR3-15 1ul BD Pharmingen, Franklin Lakes, NJ, USA 
Rat anti-CD4 APC RM4-5 1ul BD Pharmingen, Franklin Lakes, NJ, USA 
 
4.1.7 FACS staining panel for proliferation study 
Antibody Conjugation Clone Per 100ul Provider 
Rat anti-CD45 PE-Cy7 30F11 0.5ul BD Pharmingen, Franklin Lakes, NJ, USA 
Rat anti-B220 PerCP RA3-6B2 0.5ul BD Pharmingen, Franklin Lakes, NJ, USA 
Rat anti-CD4 A700 GK1.5 0.5ul BioLegend, San Diego, CA, USA 
Rat anti-CD44 APC-Cy7 IM-7 0.5ul BD Pharmingen, Franklin Lakes, NJ, USA 
Rat anti-CD8a PB 53-6.7 0.5ul BD Pharmingen, Franklin Lakes, NJ, USA 
Rat anti-Vα3.2 APC RR3-16 1ul BD Pharmingen, Franklin Lakes, NJ, USA 
Rat anti-Vβ11 PE RR3-15 1ul BD Pharmingen, Franklin Lakes, NJ, USA 
Anti-BrdU FITC BU20A 1ul eBioscience, San Diego, CA, USA 
 
4.1.8 FACS staining panel for CD4 depletion study 
Antibody Conjugation Clone Per 100ul Provider 
Rat anti-CD45 PE-Cy7 30-F11 0.25ul BD Pharmingen, Franklin Lakes, NJ, USA 
Rat anti-CD19 FITC 1D3 0.25ul BD Pharmingen, Franklin Lakes, NJ, USA 
Rat anti-B220 PO RA3-6B2 0.5ul Life Technologies, Darmstadt, Germany 
23 
 
Rat anti-CD3ε APC 145-2C11 0.5ul BD Pharmingen, Franklin Lakes, NJ, USA 
Rat anti-CD3ε FITC 145-2C11 0.5ul BD Pharmingen, Franklin Lakes, NJ, USA 
Rat anti-CD3ε PerCP-Cy5.5 17A2 1.25ul BioLegend, San Diego, CA, USA 
Rat anti-CD16/32 - 2.4G2 0.5ul BD Pharmingen, Franklin Lakes, NJ, USA 
Rat anti-CD11b PE-TR M1/70.15 0.25ul Life Technologies, Darmstadt, Germany 
Rat anti-CD4 A700 GK1.5 0.25ul BioLegend, San Diego, CA, USA 
Rat anti-CD44 APC-Cy7 IM7 0.25ul BD Pharmingen, Franklin Lakes, NJ, USA 
Rat anti-CD8α APC-Cy7 53-6.7 0.5ul BD Pharmingen, Franklin Lakes, NJ, USA 
Rat anti-CD8α PB 53-6.7 0.25ul BD Pharmingen, Franklin Lakes, NJ, USA 
Rat anti-CD138 PE 281-2 0.25ul BioLegend, San Diego, CA, USA 
Rat anti-Foxp3 PE FJK-16s 1ul eBioscience, San Diego, CA, USA 
Mouse Anti-
Human Ki67 
FITC MOPC-21 12ul BD Pharmingen, Franklin Lakes, NJ, USA 
*For surface staining of blood samples, amount of antibody was doubled. 
4.1.9 FACS staining panel for B cell kinetic study 
Antibody Conjugation Clone Per 100ul Provider 
Rat anti-CD45 AF 700 30F11 1ul BioLegend, San Diego, CA, USA 
Rat anti-CD19 FITC 6D5 1ul BioLegend, San Diego, CA, USA 
Rat anti-CD93 PE AA4.1 2ul eBioscience, San Diego, CA, USA 
Rat anti-CD23 PE-Cy7 B3B4 1ul eBioscience, San Diego, CA, USA 
Rat anti-CD21 PB 4E3  1ul eBioscience, San Diego, CA, USA 
Rat anti-CD138 V605 281-2 0.5ul BioLegend, San Diego, CA, USA 
Rat anti-IgD APC-Cy7 11-26C 1ul eBioscience, San Diego, CA, USA 
Rat anti-IgM PerCP-Cy5.5 RMM-1 1ul BioLegend, San Diego, CA, USA 
Rat anti-CD3ε APC 17A2 1ul eBioscience, San Diego, CA, USA 
Rat anti-CD11b APC M1/70 1ul eBioscience, San Diego, CA, USA 
Rat anti-Gr1 APC RM6-8C5 1ul (1:40 
predilution) 




4.1.10 Antibodies for immunofluorescent microscopy 
Antibody Clone Dilution Provider 
Primary antibodies    
Goat anti-CXCL 13 AF470 1:50 R&D, Minneapolis, MN, USA 
Mouse anti-NeuN A60 1:200 Merck, Darmstadt, Germany 
Rabbit anti-CD3 Polyclonal 1:200 Abcam, Cambridge, UK 
Rabbit anti-collagen type I Polyclonal 1:200 Merck, Darmstadt, Germany 
Rabbit anti-laminin 1+2 Polyclonal 1:400 Abcam, Cambridge, UK 
Rabbit anti-Ki67 Polyclonal 1:200 Abcam, Cambridge, UK 
Rat anti-CD4 L3T4 1:200 BD Biosciences, Franklin Lakes, NJ, USA 
Rat anti-CD140b 
PDGF Receptor b) 
APB5 1:200 eBioscience, San Diego, CA, USA 
Rat anti-CD13 ER-BMDM1 1:200 Bio-Rad, Puchheim, Germany? 
Rat anti-CD68 FA-11 1:200 Bio-Rad, Puchheim, Germany 
Rat anti-CD45RO/B220, 
Alexa Fluor® 488 conjugated 
RA3-6B2 1:200 BioLegend, San Diego, CA, USA 
Secondary antibodies    
Donkey anti-goat, Alexa Fluor® 594 1:400 Life Technologies, Darmstadt, Germany 
Goat anti-rat, Alexa Fluor® 488 1:400 Life Technologies, Darmstadt, Germany 
Goat anti-rat, Alexa Fluor® 594 1:400 Life Technologies, Darmstadt, Germany 
Goat anti-rabbit, Alexa Fluor® 488 1:400 Life Technologies, Darmstadt, Germany 
Goat anti-rabbit, Alexa Fluor® 568 1:400 Life Technologies, Darmstadt, Germany 
Goat anti-rabbit, Alexa Fluor® 594 1:400 Life Technologies, Darmstadt, Germany 
Goat anti-mouse Oregon Green® 488 1:400 ThermoFisher, Waltham, MA USA 
 
4.1.11 Commercial kits 
Name Provider 
Anti-Mouse/Rat Foxp3 Staining Set PE eBioscience, San Diego, CA, USA 
FITC BrdU Flow Kit BD Biosciences, Franklin Lakes, NJ, USA 
Mouse CXCL13/BLC/BCA-1 DuoSet ELISA R&D, Minneapolis, MN, USA 




4.1.12 Laboratory consumables 
Name Provider 
0.19±0.01 mm diameter silicon-rubber-coated 
monofilament 
Doccol Corporation, MA, USA 
100-µm, 70-µm, 40-µm cell strainer BD Falcon, Franklin Lakes, NJ, USA 
14ml BD FalconTM round-bottom tube, snap cap BD Falcon, Franklin Lakes, NJ, USA 
15ml, 50ml BD FalconTM tube, dome-seal screw cap BD Falcon, Franklin Lakes, NJ, USA 
1ml, 2ml, 5ml syringe BD Discardit, Franklin Lakes, NJ, USA 
35x10 (mm) tissue culture dish BD Falcon, Franklin Lakes, NJ, USA 
48-well cell culture plate Falcon (Franklin Lakes, NJ, USA) 
5ml, 10ml, 25ml BD Falcon™ serological pipets, 
individually wrapped BD Falcon, Franklin Lakes, NJ, USA 
BD FalconTM 12x75(mm) tube with and without cell 
strainer cap BD Falcon, Franklin Lakes, NJ, USA 
BD Vacutainer® spray-coated K2EDTA tube, 13x75 
(mm) BD Biosciences, Franklin Lakes, NJ, USA 
BD Vacutainer® Plus Plastic Serum Tubes,  
13x75 (mm) 
BD Biosciences, Franklin Lakes, NJ, USA 
CountBright™ Absolute Counting Beads, for flow 
cytometry ThermoFisher Scientific Inc., Waltham, MA USA 
Fuchs-Rosenthal chamber  
(depth 0.200mm, area 0.0625mm2) 
Paul Marienfeld GmbH & Co. KG;  
Lauda-Königshofen, Germany 
Eppendorf® Safe-Lock microcentrifuge tubes, 1.5 mL Eppendorf, Köln, Germany 
LightCycler® Capillaries (20ul) Roche, Mannheim, Germany 
Low Profile 819 Disposable Blades Leica, Wetzlar, Germany 
Microscope slides (SuperFrost Plus) R. Langenbrinck, Emmendingen, Germany 
Pur-Zellin cotton pads  Paul Hartmann AG, Heidenheim, Germany 
Sterile scalpel #21  B.Braun AESCULAP, Tuttlingen, Germany 
Stainless Steel Beads, 5 mm QIAGEN GmbH, Hilden, Germany 






4.1.13 Laboratory equipment 
Name Provider 
1H (300 MHz) mouse head surface radiofrequency 
(RF) coil 
RAPID Biomedical GmbH, Rimpar, Germany 
20 mm diameter quadrature transmit/receive mouse 
head volume resonator RAPID Biomedical GmbH, Rimpar, Germany 
7T Bruker PharmaScan 70/16 magnet Bruker BioSpin, Ettlingen, Germany 
CasyTon cell counter 
Casy-Technology, Innovatis AG, Reutlingen, 
Germany 
CatWalkTM  XT system Noldus Information Technology, Wageningen, The Netherlands 
Centrifuge, Universal 30 RF Thermo Electron, Oberhausen, Germany 
Centrifuge 5804 R Eppendorf, Köln, Germany 
Electrophoresis chamber Criterion Bio-Rad, Munich, Germany 
Fluorescence microscope, DMRA2 Leica, Wetzlar, Germany 
Eppendorf 5810R centrifuge Eppendorf, Köln, Germany 
Fluorescence microscope, DMI 6000B Leica, Wetzlar, Germany 
FACSCanto II flow cytometer BD Pharmingen, Franklin Lakes, NJ, USA 
Homoeothermic blanket system Harvard Apparatus, Holliston, MA, USA 
LC Carousal centrifuge 2.0 Roche Diagnostics, Indianapolis, IN, USA 
Lightcycler 2.0 Roche, Mannheim, Germany 
Leica confocal microscope Leica TCS SPE, Nussloch, Germany 
LSR II flow cytometer BD Pharmingen, Franklin Lakes, NJ, USA 
Mastercycler gradient Eppendorf , Köln, Germany 
Microtome MICROM HM 330 Thermo Scientific, Waldorf, Germany 
Mini Rocking Platform, Biometra WT 17 Biometra GmbH, Göttingen, Germany 
NanoDrop ND2000 spectrophotometer Thermo Scientific, Asheville, NC, USA 
pH 522 pH-meter Wissenschaftlich-Technische Werkstätten GmbH, 
Weilheim, Germany 
SpectraMax 190 Microplate Reader Molecular Devices, LLC., Sunnyvale, CA, USA 
Recovery box MediHEAT PecoServives Ltd. Brough, Cumbria, UK 
RET-3 rectal probe for mice  Physitemp Instruments Inc., Clifton, NJ, USA 
Rodent Brain Matrix – Mouse, Adult 30g,  
Coronal Sections   
ASI Instruments, Inc., Warren, MI, USA 
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Sliding microtome Leica SM2000R, Nussloch, Germany 
Thermomixer 5436 heating block 
Eppendorf Vertrieb Deutschland GmbH, 
Hamburg, Germany 
TissueLyser LT QIAGEN GmbH, Hilden, Germany 
TissueLyser Bead Dispensers QIAGEN GmbH, Hilden, Germany 
Vet ABC Animal blood counter scil animal care company GmbH, Viernheim, Germany 
 
4.1.14 Analytical software 
Name Provider 
Bruker Paravision 6.0 Bruker BioSpin, Ettlingen, Germany 
CasyTon cell counter and analyser system Innovatis AG, Reutlingen, Germany 
FACSDiva 6.1.3 BD Pharmingen, Franklin Lakes, NJ, USA 
FlowJo 10.0.8r1  Tree Star, Ashland, OR, USA 
ImageJ 
ImageJ 1.42q Wayne Rasband, NIH, Bethesda, 
USA 
LightCycler Software (build 4.1.1.21) Roche Molecular Biochemicals, Basel, Switzerland 
LEICA LAS AF Lite Leica, Wetzlar, Germany 
Mayo Clinic Analyze 5.0 Biomedical Imaging Resource, Analyze Direct, Overland Park, KS, USA 
Noldus software for CatWalk Noldus Information Technology, Wageningen, The Netherlands 
Stereo Investigator software® MBF Bioscience, VT, USA 
GraphPad Prism 6.0 GraphPad, San Diego, CA, USA 




4.2.1 Animal experiments 
4.2.1.1 Animals and Housing 
Gender-mixed WT C57BL/6J mice (10-12 weeks old) and MOG TCR transgenic 2D2 mice (see 
4.1.1) with C57BL/6J background (10-16 weeks old) were used in this study. Animals were 
randomly assigned either to a control group or CD4 depletion group. Animals with different 
treatments were mixed in a cage and housed at the Charite animal facility with a 12 h light/dark 
cycle (lights on between 6:00 and 18:00). Cages were lined with chip bedding, enriched with a 
mouse tunnel and igloo (Plexx BV). Mice had ad libitum access to food (standard chow) and water 
(where study design indicates, water was replaced with an antibiotic solution). After MCAo surgery, 
enrichment was removed and for the first three post-operative days soft pellet food (standard chow 
softened with water/antibiotic solution) was given in addition. All animal experiments were 
conducted in accordance with the European Community Council Directives 86/609/EEC and 
German national laws and approved by the local authority (Landesamt für Gesundheit und Soziales, 
Berlin, Germany). 
4.2.1.2 Middle cerebral artery occlusion 
MCAo was performed adhering to the standard operating procedures of the laboratory (Engel, 
Kolodziej et al. 2011). In brief, anesthesia was induced with 2.5% isoflurane (Forene, Abbott) in 1:2 
mixtures of O2 / N2O and maintained at 1.0%–1.5% isoflurane. Silicon rubber-coated monofilament 
with a diameter of 0.19 ± 0.01 mm (Doccol) was introduced into the common carotid artery, 
advanced along the internal carotid artery towards the origin of the MCA, and either withdrawn 
immediately to allow instant reperfusion (sham operation) or left there for 60 min. For reperfusion, 
the inserted filament was withdrawn and the internal carotid artery was ligated in mice under 
anesthesia. Body temperature was maintained with a heating pad. A drop of 2% Xylocain gel was 
applied to the wound for pain relief. Success of MCAo was verified using the modified Bederson 
score (Bederson, Pitts et al. 1986). Animals were randomly allocated into different operators. After 
surgery, animals were allowed to recover in a heated cage before returning to their home cages. 
Animals with unsuccessful stroke, as confirmed by MRI assessment or death on the day of 
operation, were excluded.  
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4.2.1.3 T2-weighted Magnetic Resonance Imaging (MRI) for infarct size determination 
To quantify the ischemic lesion, animals were subjected to a T2-weighted MRI at 24 h and 7 days 
after MCAo. Anesthesia was induced at 2.0% isoflurane in O2 / N2O mixture (1:2) and maintained at 
1.0%-1.5% isoflurane through a vaporizer and delivered through a face mask. Body temperature was 
kept stable at 36.5±0.5 °C with a heating pad. Respiratory rate was monitored with the Small 
Animal Monitoring and Gating System. The mouse’s head was fixed in a magnet bore. Axial T2-
weighted images were obtained using a 7T Bruker PharmaScan 70/16 magnet with a 20 mm 
diameter quadratum transmit/receive mouse head volume resonator radiofrequency coil and Bruker 
Paravision 6.0 software using Rapid Acquisition with Relaxation Enhancement (RARE) sequence 
(TE 36 ms, TR 4200 ms, FOV 28 mm, 20 contiguous slices with a thickness of 500 µm and 
interslice distance 500 µm, matrix=256 × 256, field of view=25.6 mm x 25.6 mm, repetition 
time=4200 ms, echo time=36 ms, RARE factor=8, 6:43 min). Axial slices covered the distance 
between the olfactory bulb and the cerebellum. Acquired images were analyzed semi-automatically 
with Mayo Clinic Analyze software version 5.0. The volume difference between the contralateral 
hemisphere and non-infarcted ipsilateral hemisphere was divided by the volume of the whole 
ipsilateral hemisphere. The calculated percentage was expressed as edema-corrected infarct size. 
Mice with an infarct size less than 5% were excluded from the final analysis. 
4.2.1.4 Drug and antibody treatment 
To minimize the influence of infection on stroke-induced autoreactivity and outcome parameters 
(Hetze, Engel et al. 2013), preventive antibiotic marbofloxacin (5mg/kg, diluted in saline to 1mg/ml, 
prepared fresh daily) was administered 24 h before and until day 6 after MCAo. Alternatively, in 
some experiments preventative antibiotic enrofloxacin (diluted in drinking water at 0.35 mg/ml) was 
administered 24 h before and until day 7 after MCAo. In addition, mice received 10 mg/kg of 
enrofloxacin injected intraperitoneally (i.p.) once a day for the first 3 days after MCAo. On day 3, 
mice were randomly allocated into either the CD4 depletion (clone GK1.5) group or the isotype 
control (clone LTF-2) group. On the same day, mice in the CD4 depletion group received 
intraperitoneal (i.p.) injection of 200ug CD4 depleting antibody (diluted in sterile PBS at 1mg/ml). 
Three more injections were administered on days 5, 7 and 9 after MCAo. In total, one mouse 
received 800ug CD4 depleting antibody to eliminate CD4+ T cells in the blood circulation and 
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secondary lymphoid organs. The control group received only the same amount of isotype control 
antibody (diluted in sterile PBS at 1mg/ml) according to the same injection scheme.  
For mice undergoing analysis of cellular proliferation, 100ul 10mg/mL solution of BrdU diluted in 
sterile 1X DPBS (BD) was injected i.p. into each animal 2 hours before sacrifice. 
4.2.1.5 Neurological Deficit Score (De Simoni) 
The Neuroscore was performed blindly as described (Orsini, Villa et al. 2012), 3 days before and 3, 
7 and 13 days after MCAo or sham surgery when necessary. This test was used to evaluate the 
general health status and focal neurological malfunction after MCAo. The score ranges from 0 (no 
deficits) to 56 (representing the worst performance in all items). The Neuroscore results include the 
following general deficits: fur (0-2), ears (0-2), eyes (0-4), posture (0-4), spontaneous activity (0-4), 
and epileptic behavior (0-12); and the focal deficits: body symmetry (0-4), gait (0-4), climbing on a 
surface inclined at 45° (0-4), circulating behavior (0-4), front-limb symmetry (0-4), compulsory 
circulating behavior (0-4) and whisker sensation to light touch (0-4). The sum of all items was 
calculated to measure the general and focal deficits of each animal. 
4.2.1.6 Catwalk and gait analysis 
Quantitative gait analysis is useful for objective assessment of walking ability and exploring new 
parameters as targets for neuroprotective treatment. CatwalkTM XT is a computer-assisted automated 
gait analysis system which was originally developed as a tool to enhance assessment of functional 
outcome in spinal cord injury (SCI) models (Hamers, Koopmans et al. 2006). It has also been 
reported as a promising tool to assess mid to long-term outcome in experimental stroke (Hetze, 
Romer et al. 2012). Animals were trained on three consecutive days before baseline measurement. 
They acquired a minimum of 3 compliant runs, fulfilling a minimum run duration of 0.5s, maximum 
run duration of 5s, and a maximum speed variation of 60%. Runs were excluded if an animal turned, 
and the animal was given another try. A second measurement was carried out at 10 days after 
MCAo to monitor mid-term recovery. Data was analyzed using the Catwalk XT software according 
to the manufacturer’s instructions. 
Gait parameters can be classified into three main categories (Hamers, Koopmans et al. 2006): 
parameters related to (a) individual paws, such as width and length of a paw print, duration of paw 
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contact, the pressure caused by a paw, etc. (b) the position of footprints, for instance relative print 
position, stride length and base of support and (c) the time-dependent relationship between 
footprints, such as phase dispersion and support formula. A summary of impairments in the right 
hind limb was designed post hoc. Reductions in maximal contact area, normalized swing speed, 
stand and stride length of the right hind limb were summed as an overall impairment score. For each 
item, only reduction got one point.   
4.2.1.7 Y maze and memory evaluation 
Spatial working memory performance of mice was assessed using the Y maze test (Maurice, 
Hiramatsu et al. 1994). This test is based on the natural tendency of mice to explore novel 
environments more than familiar ones. Accordingly, mice with intact working memory alternate 
among different arms of the maze during subsequent entries. Spontaneous alternation behavior 
during an 8-minute session was recorded on day -1, day 13 and day 48 after 60 min MCAo. The 
wooden maze, painted black, consisted of three arms positioned at 120° to each other (arm 
dimensions: 40cm long, 10.5 cm high and 3 cm wide). The test was performed in a testing room 
with diffused dim light (35 lux) to provide a less anxiogenic environment. Each mouse was placed at 
the end of one arm and allowed to move freely throughout the duration of the test. An entry was 
considered complete when all four limbs crossed a line located 6.5 cm from the arm entrance. The 
series of arm entries were recorded by video camera (Panasonic, CCTV camera), and alternation 
was defined as successive entries into three different arms in overlapping triplet sets. The percentage 
of alternation was calculated as a ratio of performed to total possible alternations multiplied by 100. 
Before and after testing each animal, the maze was cleaned thoroughly with Decosept AF to 
minimize influence of odor trails from previous animal.  
Induction of stroke with extensive lesions can reduce mice’s overall locomotor activity, which can 
be a confounding factor in a memory test that requires motor activity. For this reason, mice that 
performed less than 12 entries during an 8-minute session were excluded from the final analysis. 
4.2.1.8 Multiple collections of blood from living animals 
Methods for obtaining blood samples from mice are generally difficult. In order to get multiple 
blood samples from living animals, submandibular bleeding of mice using a lancet (Golde, Gollobin 
et al. 2005) was used in this study. The blood collection tubes, either with anti-coagulant 
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ethylenediaminetetraacetic acid (EDTA) (blood sample for harvesting leukocytes) or without EDTA 
(blood sample for harvesting serum), were used to collect approximately 100ul blood. After blood 
collection, a sterile gauze pad was simply applied with a little compression for less than a minute to 
stop the bleeding. After release, the mice groomed themselves and within a short time showed no 
evidence of the blood draw.  
Blood was left to clot undisturbed at room temperature. 30 minutes later, the clot was removed by 
centrifuging at 1000g for 10 minutes in a refrigerated centrifuge. Following centrifugation, the 
liquid component (serum) was immediately transferred to a clean 1.5ml polypropylene tube. The 
samples were maintained at 4°C while handling. If the serum was not analyzed immediately, the 
serum was stored at –20°C. 
4.2.1.9 Perfusion and tissue processing 
At the endpoint of the study, mice were deeply anesthetized with an intraperitoneal injection of 
ketamine (150mg/kg, Deltaselect) and Xylazine (15mg/kg, Bayer Vital) diluted with 0.9% NaCl. 
Mice were laid on their back and fixed on a board. Body and fur were cleaned with 70% ethanol 
before abdominal incision. Under sterilized condition, up to 500ul whole blood was collected from 
the inferior vena cava using a 1ml syringe and placed into a blood collection tube without 
anticoagulants. Spleen, thymus, lymph nodes (cervical, lumbar and mesenteric) were removed and 
kept in Phosphate Buffered Saline (PBS, dilute 10x stock solution with sterilized water, GIBCOTM) 
on ice.  
Each animal was then transcardially perfused with 20ml of ice-cold PBS at 80cm water height. After 
careful removal of the skull, the whole brain was dissected without the cerebellum and kept in ice-
cold complete Roswell Park Memorial Institute (RPMI) 1640 medium (medium supplemented with 
10% fetal calf serum (FCS), 50U/ml penicillin, 50ug/ml streptomycin, 2mM L-alanyl-L-glutamine). 
The tissue was processed immediately. For the experiment designed for immunohistochemistry, 
perfusion was first done with 20ml ice-cold saline, followed by 20ml ice-cold 4% paraformaldehyde 
(PFA) in 0.1 M Sörensen buffer (consisting of 80 mM disodium phosphate, 20 mM sodium 
dihydrogen phosphate monohydrate in distilled water; pH 7.4) per animal. Brains were collected and 
post-fixed overnight in 4% PFA. After a short rinse in PBS, the fixed brains were transferred to 30% 
33 
 
D (+)-sucrose solution in 0.1M Sörensen buffer for cryoprotection. After 3 days, when the brains 
had totally sunk to the bottom, they were snap-frozen using 2-methylbutan (Carl Roth) and dry ice. 
4.2.2 Molecular, immunological and immunohistochemistry methods 
4.2.2.1 Isolation of leukocytes from spleen, lymph node, brain and blood 
Brains, stored in complete RPMI 1640 medium, were transferred to 35 mm-diameter tissue culture 
dishes containing the same medium. Brains were separated into the ipsilateral and contralateral 
hemispheres using a sterile scalpel. Each hemisphere was pressed through a 70 μm pore-size cell 
strainer into a 50 ml Falcon tube filled with complete RPMI 1640 medium using a 2-ml syringe 
stamp. The same procedure was repeated until the medium, refilled in strainer, became clear. Cell 
suspension was washed once with complete RPMI 1640 medium by centrifugation at 1500 rpm at 
room temperature (RT) for 10 min. 6 ml single-cell suspension with 35% Easycoll gradient prepared 
in complete RPMI 1640 medium was cautiously pipetted using only gravity onto 4 ml 70% Easycoll 
gradient. After centrifugation at 2400 rpm and RT without brake for 30 min, the interface with 
mononuclear cells (MNCs) between two gradients was isolated. After washing isolated cells once 
again with complete medium, a small portion of MNCs were stained with Trypan Blue dye and 
counted under a light microscope using a Fuchs-Rosenthal chamber.  
Spleens and lymph nodes were forced through a 100 μm pore-size cell strainer with a 2-ml syringe 
stamp and washed once with complete RPMI 1640 medium. Erythrocytes in the spleen were lysed 
during 2 min incubation of cell pellets with RBC lysis solution and occasional shaking with fingers. 
After resuspension with complete medium, splenocytes and lymphocytes were pipetted through a 40 
μm pore-size cell strainer and washed once again. Splenocytes were quantified with automated 
CasyTon cell counter (with a program configured for counting mice splenocytes). Lymphocytes 
from lymph nodes were counted using the Trypan Blue method described above. 
The peripheral blood was collected either by submandibular bleeding, as described, (Golde, 
Gollobin et al. 2005) from living animals (baseline and any intermediate time points) or from the 
inferior vena cava in deeply anesthetized mice at the endpoint. In both cases, whole blood was 
immediately collected into K2EDTA-coated blood collection tubes with occasional shaking to 
prevent coagulation and placed at RT until FACS staining on the same day. All cells were washed 
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once again with FACS buffer containing 2% FCS in sterile PBS before following staining procedure 
for flow cytometry. 
4.2.2.2 FACS analysis 
4.2.2.2.1 FACS analysis of peripheral blood for phenotyping 2D2 mice 
Blood samples from 2D2 mice were collected into EDTA-coated tubes and transferred at RT from 
the animal facility to the lab. Phenotyping using FACS was done on the same day. Erythrocytes 
were lysed with 1ml 1x Pharm Lyse lysis buffer (diluted in distilled water) per 50 ul blood sample 
using vortex. After 10 min of incubation at RT, samples were centrifuged at 1500rpm at RT for 5 
min. After removal of supernatant, cell pellets were resuspended in 200 ul FACS buffer (PBS with 
2% FCS + 15.4 mM sodium azide) and transferred to a new FACS tube filled with 2 ml FACS 
buffer. After centrifugation at 1500 rpm at 4°C for 5 min and removal of supernatants, blood 
leukocytes were stained with 50 ul 1:100 mixture of monoclonal antibodies containing APC 
conjugated anti-CD4 and PE conjugated anti-TCR Vβ11 (detecting MOG TCR transgenic CD4+ T 
cells). Antibodies were incubated on ice for 30 min with light protection. Isotype control was stained 
with APC-rat IgG2α κ chain and PE-rat IgG2β κ chain. Samples were washed once again with 
FACS buffer and centrifuged to remove unbound antibodies. Final acquisition was done on 
FACSCanto II flow cytometer and analyzed with FlowJo software V10. Animals with over 80% of 
CD4+ T cells positively expressing TCR Vβ11 were considered transgenic 2D2 mice and allowed 
into further experiments. 
4.2.2.2.2 FACS analysis of leukocytes proliferation by flow cytometry 
106 BrdU-pulsed splenocytes, thymocytes, leukocytes from lymph nodes and whole brain MNCs 
from each hemisphere were added to 12x75-mm FACS tubes, washed in FACS buffer and 
centrifuged at 260 g at 4 °C for 5 min. Cells were resuspended in 50 ul FACS buffer. Fluorescent 
antibodies specific for cell-surface markers (CD45-PE-Cy7, CD4-A700, CD8a-PB, B220-PerCP, 
TCR Vα3.2-APC, and TCR Vβ11-PE) diluted with 50 ul staining buffer were added per tube and 
mixed well. Cells were incubated with an antibody mixture in the dark for 15 min on ice and later 
washed with 1ml staining buffer with centrifugation at 260 g at 4 °C for 5 min.  
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After discarding supernatants, cells were fixed, permeabilized and intracellularly stained following 
the protocol supplied with the staining kit (BD BrdU Flow Kit). At the end of incubation, cells were 
washed once and resuspended with 1 mL of 1x BD Perm/Wash Buffer before acquisition on BD 
LSR II flow cytometer with gating strategy illustrated below (Figure 4). For optimal resolution, 
acquisition was run at a rate no greater than 400 events per second. Cells from the thymus were used 





Figure 4. Gating strategy for FACS analysis of proliferating leukocytes in ischemic brain. 
After gating out debris and doublets, the mononuclear cells were divided into CD45hi peripheral leukocytes 
and CD45dim local microglia (A). Within the CD45hi leukocytes, CD8+ T cells were gated out (B) and their 
activation and proliferation were analyzed based on their expression of CD44 and labeling of BrdU (C). 
Similarly, proliferative microglia was labeled with BrdU (D). B220+ B cells and CD4+ T cells (E) were also 
gated out from the CD45hi leukocytes. The proliferation of B cells was gated in (F). 2D2 T cells were double 
labeled with TCRα3.2 and TCRβ11 (G) within the CD4 compartment. The activation and proliferation of 
2D2 T cells were analyzed by staining with CD44 and BrdU (I). 
 
4.2.2.2.3 FACS analysis of blood leukocytes following CD4 depletion 
0.5 ul of each antibody (CD11b-APC, NK1.1-PE, CD19-FITC, CD3- PerCP-Cy5.5, CD4-PE-Cy7 
and CD8a-PB) was added to 50 ul of EDTA whole blood. The mixtures were vortexed for 10 
seconds and incubated in the dark for 15 min at RT. After adding 0.5 ml of 1x lysing solution (10x 
BD FACS Lysing Solution diluted with Millipore water), the mixtures were incubated in the dark 
for another 15 min at RT. Lysis of each sample was stopped by adding 0.5 ml of PBS and 
centrifuged at 300 g for 5 min at 4 °C. All supernatants were carefully removed and vortexed again. 
3 ml of FACS buffer (PBS with 2% FCS + 15.4mM sodium azide) was added and samples were 
centrifuged again at 300 g for 5 min at 4°C. After removal of supernatants, samples were vortexed 
and 100 ul of FACS buffer were added. The samples were immediately put on ice and protected 
from light. In order to improve the accuracy of estimating cell counts, 20ul of CountBright Absolute 
Counting Beads (0.55 * 10^5 beads/50 ul) were added to the cell suspensions. Each mixture of cells 
and counting beads was vortexed and measured immediately on FACSCanto II flow cytometer. 
4.2.2.2.4 FACS analysis of leukocytes in ischemic brain with or without CD4 depletion 
Brain MNCs and 106 splenocytes were resuspended in a FACS buffer and centrifuged at 260 g at 
4°C for 6 min. Samples were treated with anti-CD16/32 antibody to block unspecific binding of 
immunoglobulins and Fc receptors at 4°C for 15 min. Cellular surface markers were stained with a 
mixture of monoclonal antibodies: CD45-A700, CD11b-PE-TR, CD19-FITC, CD3-PerCp-Cy5.5, 
CD4-PE-Cy7, CD8a-PB, CD138-PE (only brain MNCs). Samples were incubated on ice for 30 min 
with light protection. Excessive unbound antibodies were washed away by washing with FACS 
buffer. After centrifugation, cell pellets were re-suspended in 100 ul FACS buffer and measured 
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immediately on BD LSR II flow cytometer using FACSDiva software version 6.1.3. Data were 










Figure 5. Gating strategy for FACS analysis of immune cells infiltrating ischemic brain. 
A. Potential leukocytes with proper size (forward scatter, FSC) and granularity (side scatter, SSC) were 
separated from debris. B. Single cells were separated from doublets by cross-checking FSC-area (A) and 
FSC-height (H). C. Resting microglia cells expressing a low level of CD11b were separated from CD45hi 
infiltrating leukocytes. Within the CD45hi population, CD11b+ myeloid cells were separated from CD11b- 
lymphocytes. D. Lymphocytes were further divided into CD19+ B cells and CD3+ T cells. E. CD8+ and CD4+ 
T cells are two main subpopulations within CD3+ T cells. F. Within B cells, a small population of naïve B 
cells can differentiate into CD138+ plasmablasts/plasma cells upon activation. 2D2 mice have far more CD4+ 




4.2.2.2.5 FACS analysis of B cell subsets in WT mice after ischemic stroke 
Brain MNCs and 106 splenocytes were washed with 1 mL FACS buffer and stained using standard 
techniques (see 4.2.2.3.4.). The fluorescence-conjugated monoclonal antibodies were used to stain 
different subsets in the B cell compartment (Table 1). The same antibody mixture was used to stain 
blood samples following a suitable staining protocol (see 4.2.2.3.3.). Finally, samples were 
resuspended in 100 ul FACS buffer and immediately acquired on BD LSR II flow cytometer using 
FACSDiva software version 6.1.3. Data were analyzed with FlowJo software 10.0.8r1. The detailed 
gating strategy for distinguishing B cell subsets based on differential expression of combined 
surface markers is illustrated in Figure 6. 
 
Table1. Differential expression of surface markers by CD19+ B cell subsets. 
CD19+ B cell subpopulation Surface markers 
Follicular  CD138-, CD93-, CD21midIgMlo-hi, CD23+, IgD+  
Marginal zone (MZ) CD138-, CD93-, CD21+, IgM+  
      -MZ mature CD138-, CD93-, CD21+, IgM+, IgD-/low, CD23-  
      -MZ progenitors CD138-, CD93-, CD21+, IgM+, IgDhi, CD23+  
Memory CD138-, CD93-, CD23-, IgD-, IgM-  
Transitional CD138-, CD93+ , CD23+, IgM+ 
Immature CD138-, CD93+, CD23-, IgM+, IgD- 
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Figure 6. Gating strategy for FACS analysis of B cell subsets in ischemic brain and spleen.  
Similarly, leukocytes prepared from brains or spleens were separated from debris and doublets. CD45+ 
leukocytes were selected (A) and CD19+ B cells (B) were grouped together. The dump channel was prepared 
by three antibodies with the same conjugation so that Gr1+ granulocytes, CD11b+ myeloid cells and CD3+ T 
cells were all excluded from analysis with a focus only on B cells. CD138+ plasmablasts/plasma cells were 
gated out from the B cell population (C). Non-plasma B cells expressing CD93 (D) were gated by CD23 and 
IgD. CD23 and IgD double positive cells were gated as transitional B cells (E). Within the IgM+ CD23- 
population (E) and with the absence of IgD, CD19+ immature B cells (F) were gated. Marginal zone (MZ) B 
cells and non-MZ B cells were separated from non-plasma B cells with no expression of CD93 (D) by 
differential expression of CD21 and IgM (G). CD21+IgM+ MZ B cells are composed of IgDhi CD23+ MZ 
progenitors and IgD-/low CD23- mature MZ B cells (H). Follicular B cells (I) express CD21midIgMlo-hi IgD+, 
CD23+. (J) Memory B cells (J) are negative for IgD, CD23 and IgM.  
 
4.2.2.3 Gene expression with quantitative real-time polymerase chain reaction 
Quantitative real-time polymerase chain reaction (qRT-PCR) was used to analyze mRNA expression 
of growth factors in both the ipsilateral and contralateral hemispheres. All qPCR were run with 
LightCycler 2.0 (Roche). At the endpoint, mice were perfused with 20 ml ice-cold saline. Whole 
brain tissue including olfactory bulb and cerebellum was placed in brain matrix. Brain was sliced 
into four 2mm sections with five microtome blades that were pushed through every two notches 
between bregma 3.14mm and -5.46mm. The third and fourth sections were cut into two hemispheric 
parts. Brain sections from each hemisphere were harvested in Trizol (1ml per hemispherical 
sample).  
Tissue homogenates were prepared with TissueLyzer LT (QIAGEN). Following chloroform 
extraction, pellets containing RNA were solved in DEPC-treated water. After DNase digestion, a 
NucleoSpin RNA clean-up Kit (Macherey Nagel) was used to remove PCR inhibitors. Total RNA 
concentration was determined with NanoDrop (Thermo Scientific), and probes were uniformly 
diluted. RNA was reversely transcribed to complementary DNA (cDNA) with M-MLV reverse 
transcriptase and random hexamers. LightCycler-FastStartDNA-Master SYBR-Green-I Kit (Roche) 
was used for qRT-PCR. Amplification and detection were supported by LightCyclerRelative 
Quantification Software (Roche Molecular Biochemicals). All PCRs were repeated twice. The 
relative expression of each gene of interest (GOI) was calculated compared to the reference gene 
(ref) by the delta Cp (crossing point) method with efficiency correction using the equation: E (GOI) 
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–Cp (GOI) / E (ref) –Cp (ref) (Pfaffl, Horgan et al. 2002). Mean values of duplicates were determined. 
The gene β-actin was chosen as a reference because it exhibits the most stable expression pattern in 
ischemic brain. In all experiments, amplification efficiencies (E) were determined for each primer 
pair by a serial dilution curve and calculated using LightCycler 2.0 software. Polymerase chain 
reaction (PCR) was performed on LightCycler 2.0 using the following program: 1) initial 
denaturation at 98°C for 30 seconds (1 cycle); 2) denaturation at 98°C for 10 seconds, annealing at 
the primer-specific temperature for 30 seconds, extension at 72°C for 1 min (45 cycles); 3) final 
extension at 72°C for 5 min and holding at 4°C (1 cycle). Specificity of PCR products was 
confirmed with melting curve analysis (LightCycler Software) and electrophoresis using 1.5% 
agarose gel.  
4.2.2.4 Immunohistochemistry and fluorescent microscopy 
4.2.2.4.1 Immunohistochemistry with cryosections 
Frozen brains without cerebellums were embedded in Tissue-Tek ® O.C.T™ Compound. 8-10 um, 
coronal sections were collected from a +1.5 to 2.0 mm area around bregma using LEICA Cryostats. 
All brain slices were thaw-mounted on SuperFrost plus slides. Areas with slices in the middle were 
outlined using oil slide marker. Sections were then air-dried at RT for 30 min and later washed with 
PBS. Unspecific binding was blocked from incubation with blocking solution (PBS with 5% BSA) 
for 30 min. Primary antibodies (rat anti-mouse CD4, rabbit anti-mouse collagen type I, rat anti-
mouse PDGFRβ) were diluted in blocking solution and incubated with the sections overnight in a 
moisture chamber at 4°C. The next day, slides were washed 3 times with PBS and incubated further 
with secondary antibodies (goat anti-rat Alexa 594 and goat anti-rabbit Alexa 488) for one hour in a 
dark moisture chamber at RT. After the final washing step, slides were mounted with DABCO anti-
fading mounting medium reagent (25 mg/mL of 1, 4-diazabicyclo [2.2.2] octane in 50% 
glycerol/PBS, pH 8.6) and carefully covered with coverslips. The slides were left to air-dry for 30 
min in the dark, and the edges were sealed with nail polish. Staining with omission of primary 
antibodies served as a negative control. Microscopical analysis of thin sections was performed with 





4.2.2.4.2 Immunohistochemistry with floating sections 
Brain tissues were fixed on the plate using Tissue-Tek of a sliding microtome and sectioned into 30 
um slices. For long-term storage, floating sections were stored in cryoprotectant (25% ethylene 
glycol, 25% glycerol, 50% 0.1M PBS, v/v %) at -20°C. After washing with PBS, free-floating 
sections were blocked against unspecific binding with blocking solution (PBS with 10% normal goat 
serum and 0.3% Triton) for one hour at RT on a shaker. Primary and secondary antibodies were 
diluted in the same antibody diluent (PBS with 1% NGS and 0.3% Triton). Sections were incubated 
with primary antibodies at 4°C overnight on a shaker. Primary antibodies were specific for B220 (B 
cells), CD4 (CD4+ helper T cells), CD68 (activated microglia/macrophages), CD13 
(endothelial/periendothelial cells), NeuN (neurons), Iba-1 (microglia and macrophages), Ki67 
(proliferating cells), Laminin 1+2 (basement membrane), and Collagen IV (basement membrane). 
After thorough washing with PBS, sections were incubated at RT with secondary antibodies for two 
hours on a shaker. Nuclei were counterstained with DAPI. Sections were transferred onto 
SuperFrost Ultra Plus® slides and air-dried until slices were firmly attached. Several brain slices 
were mounted together with DABCO anti-fading mounting medium. The specificity of primary 
staining was confirmed by comparing it with control staining, omitting primary antibody.  
Fluorescent pictures were taken with a confocal microscope (Leica TCS SPE). 20um Z stack 
scanning with 5 steps for cells and 10 steps for vasculature were collected to generate maximal 
projection. Quantification of neurons, activated microglia/macrophages, infiltrating CD4+ helper T 
cells and B cells in 2D2 mice were performed by counting 9 frames (173um×173um) per 
hemisphere using LEICA LAF software. One slice around bregma including striatum and cortex 
lesions was chosen to represent each animal. Quantification of B cells in WT mice was performed 
using a stereology workstation equipped with a fluorescence microscope (LEICA DMRE 
Fluorescence Microscope) and Stereo Investigator Software (MBF Bioscience). Two slices at the 
level of bregma and hippocampus were chosen to represent each animal. The hemispheres were 
outlined beforehand to limit the area of interest. A meander scan was used to count all positive-





4.2.2.5 Enzyme-linked Immunosorbent Assay (ELISA) 
At endpoint and before deep anesthesia, 200ul whole blood was collected into spray-coated 
K2EDTA blood collection tubes by bleeding from the submandibular vein (see 4.2.1.8.). Cells were 
separated from plasma by centrifugation for 10 minutes at 1000x g using a refrigerated centrifuge. 
The resulting supernatants were apportioned into 50ul aliquots, and stored at –20°C until 
measurement. Mouse CXCL13/BLC/BCA-1 DuoSet (R&D Systems, DY470) was used for 
quantification of CXCL13 in mouse plasma. The manufacture’s manual was followed exactly while 
performing this assay. 
4.2.2.6 Serum Staining 
Rat brain tissue was perfused and frozen as previously described (see 4.2.1.9.). Frozen brain tissue 
was sectioned at 20 um with a LEICA Cryostats. After blocking unspecific staining with blocking 
solution (PBS with 2% BSA, 5% NGS and 0.1% Triton) at RT for one hour, serum samples with 
1:50 dilution were used as the primary antibody and incubated overnight in a moisture chamber at 
4°C. After washing with PBS, secondary goat anti-mouse antibody (Oregon Green® 488 dye) was 
applied for two hours at RT in a moisture chamber with light protection. Baseline control was 
obtained by comparing staining with paired serum samples collected before MCAo (submandibular 
bleeding) or serum samples from naïve or sham-operated mice. Gut tissue was stained in parallel to 
serve as negative control for CNS antigen. Fluorescent pictures were taken with a confocal 
microscope (Leica TCS SPE).  
4.2.3 Statistics 
Examinations of mice in the control treatment and with CD4 depletion were all conducted in a 
blinded manner. Data analyzed with non-parametric tests were expressed either as median only 
(N<=5) or median with interquartile range (IQR) (N>5). Data for Catwalk (N=10-20) were 
expressed as mean ± standard deviation (SD) because it was analyzed by a parametric test. Data in 
figures were presented as scatterplot using Prism 6.0 software (GraphPad). Normality of data 
distribution was verified with the Kolmogorov-Smirnov test using IBM SPSS Statistics 25 software 
for windows. Parametric data were analyzed with Student’s t-test (unpaired) or one-way analysis of 
variance (ANOVA) for s with Bonferroni correction. Non-parametric analysis was performed with 
the Mann Whitney U-test or one-way ANOVA on ranks (Kruskal-Wallis) with Dunn’s multiple-
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comparison test. Non-parametric paired data were analyzed with Wilcoxon matched-pairs signed 
rank test. Spearman’s rho correlation coefficient (non-parametric data) was used for correlations. 
Survival rate was analyzed by comparing the survival curves (Kaplan-Meier) with the log-rank 
(Mantel-Cox) test. All tests were two-sided and a significance level of α=0.05 was applied. P values 
<0.05 were considered significant (*p<0.05, **p<0.001, ***p<0.001). This was an exploratory 




This doctoral thesis is comprised of three experimental parts, each with its own focus: 
1) Data were summarized from experiments where 60 min MCAo were induced to either 2D2 or 
WT mice in order to demonstrate the influence of transgenic MOG TCR on behavior of CNS-
infiltrating CD4+ T cells in ischemic stroke (5.1.1). Moreover, results from a kinetic study of 
lymphocyte proliferation following ischemic stroke were presented to support the notion that 
autoimmune responses can be induced in the peripheral lymphoid organs prior to entry of 
autoreactive lymphocytes into the ischemic brain (5.1.2 and 5.1.3) 
2) In order to investigate the modulatory role of infiltrating CD4+ T cells on tissue remodeling and 
functional recovery, 2D2 mice following 60 min MCAo were treated either with isotype control 
antibody or anti-CD4 depleting antibody plus preventative antibiotic. The correlation between 
infiltration of CD4+ T cells and production of fibrotic fibers and growth factors that might be 
involved in tissue remodeling was summarized (5.2.1 and 5.2.2). Careful evaluation was then 
conducted of the effects of delayed CD4 depletion on infarct maturation as well as mid-term 
survival (5.2.3), accumulation of neuronal cells and activated microglia/macrophages (5.2.4), 
proliferation of periendothelial cells and activated microglia/macrophages (5.2.5), infiltration of B 
cells and patterns of B cell accumulation in ischemic brain (5.2.6), and motor functional recovery 
(5.2.7). 
3) I aimed to investigate whether CD4 depletion can induce similar effects in WT mice. The 
aforementioned experimental procedure in 2D2 mice was also given to WT mice. The effects of 
delayed CD4 depletion on infiltration of other lymphocytes, and the neurological score were 
compared between 2D2 and WT mice (5.3.1).  
4) Data presented were from experiments focusing on CNS infiltration (5.3.2) and phenotypical 
changes in B cell subpopulations both in ischemic brain and spleen (5.3.3) in WT mice. In order to 
investigate whether stroke can induce cognitive impairment, data collected from a Y maze at both 
day 13 and day 48 post stroke were analyzed (5.3.4). To further explore whether cognitive 
impairment post stroke might be related to the production of autoantibodies, I summarized the 
autoreactive patterns of antibodies in serum samples from WT mice before and after stroke (5.3.5).  
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5.1 CNS antigen-dependent activation of lymphocytes following stroke 
5.1.1 More pronounced infiltration of CD4+ T cells into the ischemic hemispheres of 2D2 mice 
than WT mice 
The transgenic CNS antigen-specific T cell receptor (TCR) recognizing MOG provides 2D2 mice 
with enhanced potential for fostering autoreactive immune responses (Bettelli, Pagany et al. 2003). 
Therefore, compared to WT littermates (72 (18-526.00) cells, data was expressed as median plus 
interquartile range), 2D2 mice (2159 (1619-3186) cells) exhibited significantly more infiltration of 
CD4+ T cells at 14 days post stroke (Figure 7A and 7B) and worse survival even with preventative 
antibiotic treatment (Figure 7C). The infarct volumes of 2D2 mice (36.61% (20.71-42.40) %) were 
also significantly larger than those of WT mice (16.00% (7.00-29.00) %) (Figure 7D). Larger 
infarction and stronger autoreactive potential in our experiments jointly promoted delayed (7-14 
days) but massive infiltration of CD4+ T cells into the ischemic brain of 2D2 mice. Hence, 2D2 mice 
were the main choice of animal model in this thesis to study the influence of autoreactivity from 





Figure 7. Autoreactivity linked with animal model and stroke outcome. 
(A) The significantly different amounts of CD4+ T cells infiltrating into ischemic brain were indicated with 
arrows in fluorescent staining of both WT and 2D2 brain slices from ipsilateral side. CD4 in red: surface 
marker for helper T cells; Pan-laminin in green: marker for basement membrane; DAPI in blue: marker for 
nuclei. Scale bar: 50µm. (B) Quantification of CNS-infiltrating CD4+ T cells in ischemic brain on day 14 
after stroke. A significantly higher number of CD4+ T cells accumulated in the ischemic brains of 2D2 mice 
than in WT mice (N=5 per group, p=0.008, Mann-Whitney U Test). (C) 14 days of survival among 2D2 mice 
(N=30) with 60 min MCAo and preventative antibiotic treatment was worse than in WT mice (N=18) with 
the same procedures. However, no significant difference was found (p=0.092, Log-Rank (Mantel-Cox) Test). 
(D) 2D2 mice (N=27) had significantly larger infarction compared to WT mice (N=15) at one day after 
MCAo (N=15, p=0.005, Mann-Whitney U Test). Three animals died in each group before quantification of 




5.1.2 Ischemic stroke-induced proliferation of lymphocytes in secondary lymphoid organs 
To prove stroke-induced proliferation of lymphocytes in vivo, 60 min MCAo was induced in 2D2 
mice. The kinetic proliferation of BrdU-labeled lymphocytes was analyzed separately in CNS 
draining lymph nodes (superficial and deep cervical lymph nodes, lumbar lymph nodes), non-CNS 
draining lymph nodes (mesenteric lymph nodes), and spleens on day 1, 3 and 7 after MCAo 
compared to controls (naïve and sham-operated mice). Brain tissues were collected only on day 7 
after MCAo. Edema-corrected average infarct sizes measured by MRI did not change significantly 
from days 1 to 7 after MCAo (Figure 8A). A significant decrease in the total count of splenocytes 
was detected in mice at 3 days (7.20×107 cells) after stroke compared to naïve mice (27.42×107 









Figure 8. Quantification of infarct volume and kinetic cell counts of splenocytes before and after 
ischemic stroke.  
(A) Edema-corrected infarct volume was measured with T2-weighted MRI at 24 hours post stroke. As 
expected, infarct volume of mice allocated into groups with indicated survival days revealed no significant 
differences. (B) Stroke-induced immunodepression down-regulated cell counts in spleen. Compared to naïve 
mice, splenocytes from mice on day 3 post stroke significantly decreased (Kruskal-Wallis, p=0.011; corrected 
for multiple comparisons, p=0.016). Sham-operated mice were sacrificed on day 1 after MCAo. All data from 
different groups were analyzed with Kruskal-Wallis test with Dunn’s multiple comparisons test. Each p value 
was adjusted to account for multiple comparisons. Data analyzed with non-parametric tests were expressed as 
median. Significance level was marked as: *p<0.05, **p<0.01; N=3-5. 
 
In contrast, proliferation of all CD4+ T cells was reduced in sham-operated mice (sacrificed on day 1 
after surgery) compared to naïve controls, while no difference was detected between sham and 
MCAo groups (Figure 9A). Data from pooled lymph nodes suggested that proliferation of CD8+ T 
cells was transiently induced in mesenteric lymph nodes, spleen and superficial lymph nodes on day 
1 post stroke (Figure 9B). The highest percentage of proliferating CD8+ T cells on day 1 after stroke 
was seen in superficial cervical lymph nodes. Proliferation of CD4+ T cells on day 1 after sham-
operation, day 1 and day 3 after ischemic stroke remained unchanged. Further analysis with 
lymphocyte subsets showed that B cell proliferation in spleen was significantly impaired on day 3 
(median=0.47%) compared to naïve control (median=7.08%) and day 1 post stroke (median=9.03%) 
(Figure 9C). The B cell population in all lymph nodes proliferated at a lower rate than in spleens at 
all time points except on day 3 after stroke. This data indicates that different lymphocytes responded 
differently to stroke and stroke-induced immunodepression. Compared to CD8+ T cells and B cells, 
CD4+ T cells maintained partial capacity to proliferate after stroke. It is also noteworthy that 

















Figure 9. Dynamic changes in proliferation of lymphocyte subsets in secondary lymphoid organs of 
2D2 mice after ischemic stroke.  
(A) Proliferation of CD4+ T cells reduced slightly in cervical lymph nodes but remained unchanged in other 
secondary lymphoid organs after stroke. (B) Proliferation of CD8+ T cells was decreased in sham-operated 
mice compared with naïve mice. There was transiently upregulated proliferation of B cells in mesenteric 
lymph nodes, spleen and superficial cervical lymph nodes on day 1 post stroke. (C) Proliferation of B cells in 
spleen was higher than in lymph nodes. Proliferation of B cells was significantly reduced on day 3 compared 
with day 1 (Kruskal-Wallis, p=0.006; corrected for multiple comparisons, p=0.040) and sham operation 
(Kruskal-Wallis, p=0.006; corrected for multiple comparisons, p=0.039). Abbreviations: deep cervical lymph 
node (DCLN), superficial cervical lymph node (SCLN), lumbar lymph node (LLN), mesenteric lymph node 
(MLN). All data from different groups (due to small sizes of LNs, lymphocytes from DCLN, SCLN and LLN 
at each time point were pooled together) were analyzed with Kruskal-Wallis test with Dunn’s multiple 
comparison test. Each p value was adjusted to account for multiple comparisons. Data analyzed with non-
parametric tests were expressed as median. Significance level was marked as: *p<0.05, **p<0.01; N=3-5. 
 
Since there was no differential regulation of the overall proliferation of CD4+ T cells, proliferation 
of MOG TCR+ T cells (CD4+ T cells expressing MOG TCR Vα3.2+ Vβ11+) among all proliferating 
lymphocytes was further investigated. Though the percentage of MOG TCR+ T cells among all 
CD4+ T cells was not affected by MCAo (Figure 10A), the representation of MOG TCR+ T cells in 
all proliferating CD4+ T cells strongly increased on day 1 in all CNS-draining LNs and MLNs 
(median=81.00%) compared with that of sham-operated mice (median=12.70%) (Figure 10B). 
Proliferation of effector-memory (CD44+ ) MOG TCR+ T cells significantly increased on day 1 after 
stroke in MLNs (median=8.52%) compared with naive group (median=3.20%)  and sham-operated 
group (median=3.70%) (Figure 10C). Generally speaking, only a small percentage of naïve MOG 
TCR+ T cells did proliferate after stroke. In spleen, a trend of impaired proliferation of naïve MOG 
TCR+ T cells on day 1 after stroke (median=0.30%) was detected compared with naïve group 
(median=0.38%), while MLNs had significantly more proliferation of naïve MOG TCR+ T cells on 
day 1 after stroke (median=0.38%) compared with that on day 1 after sham operation 
(median=0.08%) (Figure 10D). In summary, effector-memory MOG TCR+ T cells had higher 
proliferation than naïve MOG TCR+ T cells in both naïve and mice with MCAo. Both cell types had 






Figure 10. Dynamic changes in composition and proliferation of MOG TCR+ T cells in secondary 
lymphoid organs of 2D2 mice before and after ischemic stroke. 
(A) Percentage of MOG TCR+ T cells in CD4+ population did not change at different time points or in 
secondary lymphoid organs from the same time point. (B) Among all proliferative CD4+ T cells, the 
percentage of MOG TCR+ T cells generally increased on day 1 post stroke compared with other time points. 
Significantly more MOG TCR+  T cells proliferated on day 1 after stroke than on 1 after sham operation 
(Kruskal-Wallis, p=0.078; corrected for multiple comparisons, p=0.123) (C) Proliferation of effector-memory 
MOG TCR+ T cells (CD44+) significantly increased in MLNs on day 1 post stroke compared with naive 
group (Kruskal-Wallis, p=0.015; corrected for multiple comparisons, p=0.036). A similar trend was detected 
in MLNs between day 1 after stroke and sham operation (p=0.086). (D) Proliferation of naïve MOG TCR+ T 
cells (CD44-) was significantly up-regulated in MLNs on day 1 after stroke compared with sham operation 
(Kruskal-Wallis, p=0.003; corrected for multiple comparisons, p=0.013). A trend of reduced proliferation of 
naïve MOG TCR+ T cells in spleen was detected on day 1 after stroke compared to naïve group (Kruskal-
Wallis, p=0.053; corrected for multiple comparisons, p=0.113). Abbreviations: deep cervical lymph node 
(DCLN), superficial lymph node (SCLN), lumbar lymph node (LLN), mesenteric lymph node (MLN). All 
data from different organ groups were analyzed with Kruskal-Wallis test and with Dunn’s multiple 
comparison corrected for multiple comparison test. Each p value was adjusted to account for multiple 
comparisons. Data analyzed with non-parametric tests were expressed as median. Significance level was 
marked as: *p<0.05, **p<0.01; N=3-5. 
 
5.1.3 Ischemic brain was the favored place for proliferation of CNS-antigen reactive 
lymphocytes following stroke 
I investigated brain-infiltration by lymphocytes on day 7 post stroke and compared the proliferative 
capacity of lymphocytes between ischemic brain and peripheral lymphoid organs. Infiltration by 
lymphocytes was selective towards the ischemic hemisphere (ipsilateral side). Besides monocytes 
and macrophages, CD4+ T cells constituted the largest population among all lymphocytes. The 
absolute count of CD45+ leukocytes (median=27310 CD45+ cells) and CD4+ T cells (median=6367 
cells) were much increased in the ipsilateral hemisphere compared with the contralateral hemisphere 
(median=2794 CD45+ cells, median=458 CD4+ T cells) (Figure 11A). Furthermore, the total 
proliferative CD4+ T cells (median=287 cells) and MOG TCR+ T cells (median=112 cells) in the 
ipsilateral hemisphere together were more than those in the contralateral hemisphere (median=19 
proliferative CD4+ T cells, median=6 proliferative MOG TCR+ T cells) (Figure 11B). Although 
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CD8+ T cell and B cell counts did not differ between the hemispheres, the proliferation of CD8+ T 
cells (median=36 cells) and B cells (median=33 cells) tended to increase in the ischemic hemisphere 
compared with the contralateral hemisphere (median=9 proliferative CD8+ T cells, median=6 
proliferative B cells) (Figure 11B).   
 
 
Figure 11. CNS-infiltrating leukocytes and proliferation of 2D2 mice on day 7 post ischemic stroke.  
Absolute counts of leukocytes from the ipsilateral (ipsi.) and contralateral (contra.) hemispheres were 
presented separately. (A) Relatively more CD45+ leukocytes (p=0.125) and CD4+ T cells (p=0.125) infiltrated 
into the ischemic hemisphere. (B) Similar to subset comparison, more proliferative CD4+ T cells (p=0.063), 
MOG TCR+ T cells (p=0.063), CD8+ T cells (p=0.188) and B220+ B cells (p=0.063) were detected in the 
ipsilateral hemispheres than the contralateral hemispheres. All data were analyzed with Wilcoxon Signed 
Rank Test. Data analyzed with non-parametric tests were expressed as median. Significance level was 
marked as: *p<0.05, **p<0.01; N=4. 
 
Next, proliferative capacity of lymphocytes in ischemic brain was compared to that in spleen and 
non-draining mesenteric lymph nodes on day 7 post stroke. In line with our previous finding 
showing significant inhibition of B cell proliferation in spleen (see 5.1.2), the proliferation of B cells 
was further inhibited in spleen and mesenteric lymph nodes until day 7 after stroke. In contrast, the 
CNS-infiltrating B cells (2.61% (0.60-6.49) %) had significantly higher proliferation than the B cells 
residing in spleens (0.26% (0.22-0.49) %) (Figure 12A). Proliferation of both CD4+ (6.78% (5.57-
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7.25) %) and CD8+ T cells (8.13% (6.50-13.55) %) (Figure 12C) were also significantly up-
regulated in ischemic brain compared with the same populations in mesenteric lymph nodes (0.79% 
(0.53-0.97) % for CD4+ T cells, 1.57 % (0.89-2.67) % for CD8+ T cells).   
In addition, activation of CD4+ T cells significantly increased in ischemic brain (median=93.72%) 
compared with cells in the mesenteric lymph nodes (median=15.88%) (Figure 12D). Effector-
memory CD8+ T cells uniformly maintained high activation in both CNS and peripheral lymphoid 
organs (Figure 12E). Interestingly, the dominant phenotype of MOG TCR+ T cells within total CD4+ 
T cells in periphery was not seen in ischemic brain. The percentage of MOG TCR+ T cells was 
actually significantly decreased in ischemic brain (median=28.95%) compared with the percentage 
(median=76.35%) in the mesenteric lymph nodes (Figure 12F). Nevertheless, the percentage of 
proliferating MOG TCR+ T cells in total proliferating CD4+ T cells remained the same between 
ischemic brain and peripheral lymphoid organs (Figure 12G). After infiltrating into ischemic brain 
and being exposed to diverse CNS antigens, MOG TCR- CD4+ T cells (median=7.49%) could 
expand similar to MOG TCR+ CD4+ T cells (median=9.13%) (Figure 12H and 12I). In ischemic 
brain (median=7.49%) and spleen (median=9.05%), proliferation of MOG TCR- CD4+ T cells was 
higher than in MLNs (median=3.95%) (Figure 12H). The proliferation of MOG TCR+ T cells was 
significantly higher in the ischemic brain (median=9.13%) compared with the proliferation in the 
MLNs (median=0.20%) and the spleen (median=0.63%) (Figure 12I). Within the MOG TCR+ T cell 
compartment, the proliferation of CD44+ effector-memory MOG TCR+ T cells was significantly 
higher in the ischemic brain (median=9.58%) than in the MLNs (median=2.28%) (Figure 12J). The 
proliferation of naïve MOG TCR+ T cells was also partially up-regulated in the ischemic brain 
(median=1.94%) compared with the spleen (median=0.25%) and MLNs (median=0.10%) (Figure 
12K). In the ischemic brain, effector-memory MOG TCR+ T cells proliferated much more than 
naïve MOG TCR+ T cells. Although the majority of infiltrating CD8+ T cells (almost 80%) had 
effector-memory phenotype (CD44+), naïve CD8+ T cells (median=10.18%) proliferated slightly 






Figure 12. Comparison of lymphocyte proliferation and activation in the ipsilateral hemisphere of 
brain, spleen and mesenteric lymph nodes on day 7 post ischemic stroke 
(A) Compared to spleen, B lymphocytes in ischemic brain increased proliferation significantly (Kruskal-
Wallis, p=0.037; corrected for multiple comparisons, p=0.043). Proliferation of both CD4+ T cells (B, 
Kruskal-Wallis, p=0.001; corrected for multiple comparisons, p=0.007) and CD8+ T cells (C, Kruskal-Wallis, 
p=0.011; corrected for multiple comparisons, p=0.033) was significantly higher in ischemic brain than in 
MLNs. (D) Activation of CD4+ T cells in the ischemic brain was extremely higher compared to that of MLNs 
(Kruskal-Wallis, p=0.001; corrected for multiple comparisons, p=0.018). (E) However, activation of CD8 + T 
cells did not differ among the ischemic hemisphere, the spleen or the MLNs (Kruskal-Wallis, p=0.197). (F) 
Percentage of CD4+ MOG TCR+ (Vα3.2+ Vβ11+) T cells was quite different among ischemic brain, spleen and 
MLNs (Kruskal-Wallis, p=0.005). Significant difference was seen between the ipsilateral hemisphere and the 
MLNs (Kruskal-Wallis, p=0.005; corrected for multiple comparisons, p=0.018). G) Among all proliferating 
CD4+ T cells, a similar percentage of MOG TCR+ T cells was seen in ischemic brain and secondary lymphoid 
organs (Kruskal-Wallis, p=0.348). (H) MOG TCR- CD4+ T cells had a trend to proliferate more in the 
ischemic brain compared with the MLNs (Kruskal-Wallis, p=0.219; corrected for multiple comparisons, 
p=0.233). (I) MOG TCR+ CD4+ T cells significantly increased their proliferation in the ischemic brain 
compared with the MLNs (Kruskal-Wallis, p=0.001; corrected for multiple comparisons, p=0.007) and 
showed a trend of upregulation over spleen (Kruskal-Wallis, p=0.001; corrected for multiple comparisons, 
p=0.287). (J) Proliferation of effector-memory CD4+ MOG TCR+ T cells (CD44+) was significantly up-
regulated in the ischemic brain compared to MLNs (Kruskal-Wallis, p=0.018; corrected for multiple 
comparisons, p=0.024). (K) Proliferation of naive CD4+ MOG TCR+ T cells (CD44-) slightly increased in the 
ischemic brain compared to the spleen and MLNs (Kruskal-Wallis, p=0.419). (L) Although the population of 
naïve CD8+ T cells was smaller, they proliferated slightly more than CD44+ CD8+ T cells in the ipsilateral 
(ipsi.) hemispheres. All data from different groups were analyzed with Kruskal-Wallis test with Dunn’s 
multiple comparison test. Each p value was adjusted to account for multiple comparisons. Data analyzed with 










5.2 Effects of CD4+ T cells on tissue remodeling and mid-term functional recovery after stroke  
5.2.1 Kinetic infiltration of CD4+ T cells temporally correlated with deposition of fibrotic 
fibers in ischemic brain of 2D2 mice 
In accordance with the hypothesis that CD4+ T cells play a key role in post-stroke autoreactivity, I 
aimed to explore their role in tissue remodeling during chronic inflammation. Co-staining of CD4+ T 
cells and collagen type I fibers demonstrated that CD4+ T cells massively accumulated in the peri-
infarct area on day 14 (Figure 13B) compared to day 7 (Figure 13A) after stroke. CD4+ T cells 
transmigrated through inflamed vessels surrounding the infarcted area where collagen type I fibers 
were also deposited (indicated by the white arrow in Figure 13A). Moreover, accumulation of CNS-
infiltrating CD4+ T cells was temporally correlated with deposition of collagen type I fibers between 













Figure 13. Infiltration of CD4+ T cells temporally correlates with the deposition of fibrotic fibers in the 
ischemic brain. 
(A) Infiltration of CD4+ T cells and deposition of collagen type I fibers in inflamed brain vessels (indicated 
by white arrow) in the ischemic hemisphere on day 7 after stroke. (B) Increased accumulation of CD4+ T 
cells and deposition collagen type I fibers in infarcted area on day 14 post MCAo. Scale bar: 100µm. (C) 
Stroke-induced deposition of collagen type I fibers co-localized with upregulation of PDGFRβ in the 
ipsilateral hemisphere (ipsi.) on day 14 after stroke. In the contralateral (contra.) hemisphere, PDGFRβ was 
expressed at low level in the area surrounding brain vessels (indicated by white arrow). Scale bar: 50µm. 
Abbreviations: Col I (collagen type I). 
 
Collagen type I is not the basic component of the basement membrane (BM) of the blood-brain 
barrier, and there are no fibroblasts (main producer of collagen I in connective tissue or during tissue 
fibrosis) in the healthy brain parenchyma. It has been postulated that inflammation and autoreactive 
CD4+ T cells might be responsible for the induction of such abnormal deposition of fibrotic fibers 
(personal communication with Prof. Lydia Sorokin). In addition, based on the evidence that 
expression of platelet-derived growth factor receptor β (PDGFRβ) was exclusively induced in the 
ischemic hemisphere and its expression co-localized with deposition of collagen type I fibers 
(Figure 13C), I further investigated whether CD4+ T cells played a role in modulating the expression 
of PDGFRβ and in the deposition of fibrotic type I collagen fibers in the ischemic hemisphere. 
 
5.2.2 TGFβ1 rather than PDGFRβ was positively correlated with the deposition of fibrotic 
fibers in the ischemic hemisphere of 2D2 mice while CD4 depletion did not affect mRNA 
expression of genes related to tissue remodeling 
The role of CD4+ T cells in tissue remodeling was investigated by depleting this cell type starting at 
3 days after stroke using an antibody-based approach (Figure 14A). After four consecutive 
injections of CD4+ T cell-depleting antibody on days 3, 5, 7, and 9 after MCAo, CD4+ T cells were 
completely eliminated in the spleen. This phenotype was maintained at least until day 14 after stroke 
(Figure 14B). Accordingly, the entry of CD4+ T cells into the ischemic brain was also successfully 
blocked by the anti-CD4 treatment (Figure 14C). I then compared kinetic mRNA expression of 
collagen type I and other relevant growth factors in the ischemic brain on days 3, 7, 10, and 14 after 
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MCAo. Moreover, mice with control treatment (isotype control antibody) were compared to mice 







Figure 14. Experimental setups for 2D2 mice with anti-CD4 treatment and efficacy of depleting CD4+ T 
cells in the periphery and the brain. 
(A) 60 min middle cerebral artery occlusion (MCAo) was performed in 2D2 mice. Stroke-induced mice were 
monitored for 14 days. On day 1 after MCAo, infarct volume was measured by T2-weighted MRI. Isotype 
control antibody (control) or anti-CD4 antibody was intraperitoneally injected at four indicated time points. 
(B) At the endpoint (day 14), spleens were analyzed by flow cytometry to confirm success of CD4 depletion. 
(C) Infiltration of CD4+ T cells into the ischemic brain was blocked by anti-CD4 treatment. Pan-laminin 
(green) was used to visualize basement membrane of brain blood vessels. In sham-operated mice and mice 
with CD4 depletion, there were no positive stainings for CD4+ T cells (red) in the ipsilateral (ipsi.) 
hemisphere. Scale bar: 50µm. 
 
Since infarct size determines the extent of tissue injury and inflammation, infarct volumes on day 1 
were compared in all mice sacrificed at different time points after stroke. There were no significant 
differences between any of the groups (Figure 15A), although infarct volumes from one group (day 
7) appeared slightly smaller compared to the groups sacrificed at other time points. Although 
deposition of collagen type I fiber (fibrotic extracellular matrix produced in connective tissue or 
during tissue fibrosis of damaged peripheral organs) is only limited to the infarct region in the 
ischemic hemisphere (see 5.2.1), no correlation between infarct volume and mRNA expression of 





Figure 15. Quantification of infarct volume (day 1) and correlation between infarct volume and 
deposition of collagen type I fibrotic fibers in the ischemic hemisphere.  
(A) Similarly, infarct volume was quantified on day 1 post stroke. Infarct volume of 2D2 mice with different 
survival days (N=3 per time point) had no significant differences. (B) No significant correlation was detected 
between infarct size and deposition of collagen type I in the ischemic hemisphere. Abbreviations: arbitrary 
unit (AU), collagen type I alpha 1 chain (Col I α1), CD4 depletion (CD4 depl.). All data from multiple groups 
were analyzed with Kruskal-Wallis test with Dunn’s multiple comparison test. Each p value was adjusted to 
account for multiple comparisons. Data analyzed with non-parametric tests were expressed as median. 
Correlation was analyzed with nonparametric Spearman’s rho correlation coefficient.  
 
Firstly, mRNA expressions of collagen type I alpha subunit, transforming growth factor β type 1 
(TGFβ1, a strong modulator for tissue remodeling and fibrosis after injury) (Iadecola and Anrather 
2011) and C-C chemokine receptor type 2 (CCR2, chemokine for monocyte) (Gelderblom, Leypoldt 
et al. 2009) were investigated. At the mRNA level, expression of collagen type I expression was 
induced as early as day 7 after stroke, while in naïve mice it was not expressed at all (Figure 16A). 
However, CD4 depletion did not abolish the mRNA expression of collagen type I. The mRNA 
expression of TGFβ slightly increased on day 10 (median=0.020 AU) in the ischemic brain 
compared with that of naïve control (median=0.011 AU).  Significant upregulation of CCR2 
(median=0.044 AU) and TGFβ (median=0.020 AU) was measured in the ipsilateral hemisphere on 
day 10 compared with that of naïve control (median=0.009 AU and 0.006 AU, respectively) (Figure 
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16B and 16C). CD4 depletion did not affect expression of TGFβ1 and CCR2 in the ipsilateral 
hemisphere on day 14 post stroke. Nevertheless, plotting all paired data (without CD4 depletion) 
revealed a positive correlation between mRNA expressions of collagen type I and TGFβ1 in the 




Figure 16. The relative expressions of mRNA in fibrosis-related fibrotic fibers, growth factor and 
chemokine receptor before and after ischemic stroke. 
(A) Ischemic stroke induced slight upregulation of collagen type 1 in the ischemic hemisphere. (B) 
Expression of TGFβ1 significantly increased on day 10 after stroke in the ipsilateral hemispheres compared 
with that of naïve control mice (Kruskal-Wallis, p=0.064; corrected for multiple comparisons, p=0.049). (C) 
CCR2 was significantly upregulated on day 10 post stroke compared to naïve control (Kruskal-Wallis, 
p=0.025; corrected for multiple comparisons, p=0.034). (D) The mRNA expressions of collagen I and TGFβ1 
positively correlated with each other (p=0.031). (E) There was an extreme value in the previous graph. To 
investigate how much this value would contaminate the real correlation between the mRNA expressions of 
collagen I and TGFβ1, data was analyzed again without that value. A strong correlation was still observed 
(p=0.097). Abbreviations: arbitrary unit (AU), collagen type I alpha 1 chain (Col I α1), transforming growth 
factor β type 1 (TGFβ1), C-C motif chemokine receptor 2 (CCR2), CD4 depletion (CD4 depl.), contralateral 
(contra.), and ipsilateral (ipsi.). Comparison of the two hemispheres was analyzed with Wilcoxon matched-
pairs signed rank test. Comparison between control treatment and CD4 depletion in the ipsilateral hemisphere 
on day 14 were analyzed with Mann-Whitney U test. All data from multiple groups were analyzed with 
Kruskal-Wallis test with Dunn’s multiple comparison test. Each p value was adjusted to account for multiple 
comparisons. Data analyzed with non-parametric tests were expressed as median. Correlation was analyzed 
with nonparametric Spearman’s rho correlation coefficient. Significance level was marked as: *p<0.05, 
**p<0.01; N=3. 
 
In contrast to inflammation-related growth factors (e.g. TGFβ1) or chemokines (e.g. CCR2) which 
were exclusively induced in the ischemic hemisphere, the mRNA expressions of CNS growth 
factors or receptors were simultaneously affected in both hemispheres after stroke. The expressions 
of NGF and VEGFa in whole brain were reduced over 50% after stroke compared with naïve 
control. In the contralateral hemispheres, the expressions of NGF, BDNF and VEGFa were 
significantly reduced in mice with control treatment on day 14 after stroke compared with that of 
naïve mice (Figure 17A-C). 
PDGFRβ was evaluated to investigate whether pericytes and possibly fibroblasts are activated and 
contribute to the deposition of extracellular matrix (ECM) after stroke. In contrast to neuronal and 
vascular growth factors, mRNA expression of PDGFRβ did not undergo immediate reduction after 
stroke onset and showed a trend of upregulation in the ischemic hemispheres compared with the 
contralateral hemispheres (Figure 17D). Between the contralateral and the ipsilateral hemispheres, 
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no significant difference was detected. CD4 depletion also did not affect the expression of PDGFRβ. 
Data from qPCR indicated that stroke might modulate the genes related to tissue fibrosis and 














Figure 17. The relative mRNA expressions of CNS growth factors and pericyte-specific growth factor 
receptor before and after ischemic stroke. 
 (A) Ischemic stroke-impaired mRNA expression of NGF in both hemispheres. The expression of NGF in the 
ischemic hemispheres was reduced by over 80% on day 14 in mice with CD4 depletion compared with that of 
naïve controls (Kruskal-Wallis, p=0.012; corrected for multiple comparisons, p=0.034). There was a 
significant reduction of NGF on day 14 in the contralateral hemispheres of control animals compared with 
that of naïve controls (Kruskal-Wallis, p=0.028; corrected for multiple comparisons, p=0.020). (B) 
Significant reduction of BDNF in the contralateral hemispheres on day 14 with control treatment compared 
with that of naïve controls (Kruskal-Wallis, p=0.025; corrected for multiple comparisons, p=0.043). (C) 
Significantly impaired expression of VEGFa in the contralateral hemispheres of control animals on day 14 
after stroke compare with that of naïve control (Kruskal-Wallis, p=0.022; corrected for multiple comparisons, 
p=0.026). The expression of VEGFa in the ischemic hemispheres was strongly reduced on day 14 in mice 
with CD4 depletion compared with that of naïve controls (Kruskal-Wallis, p=0.023; corrected for multiple 
comparisons, p=0.055). (D) The reduction of PDGFRβ was delayed after stroke. Significant reduction was 
only detected until day 14 in the contralateral hemispheres in mice with control treatment compared with that 
of naïve controls (Kruskal-Wallis, p=0.005; corrected for multiple comparisons, p=0.009). Abbreviations: 
arbitrary unit (AU), nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), vascular 
epithelial growth factor a (VEGFa), platelet-derived growth factor receptor β (PDGFRβ), CD4 depletion 
(CD4 depl.), central nervous system (CNS), contralateral (contra.), and ipsilateral (ipsi.). Comparison 
between control treatment and CD4 depletion on day 14 were analyzed with Mann-Whitney U test. All data 
from multiple groups were analyzed with Kruskal-Wallis test with Dunn’s multiple comparison test. Each p 
value was adjusted to account for multiple comparisons. Data analyzed with non-parametric tests were 
expressed as median. Significance level was marked as: *p<0.05, **p<0.01; N=3. 
 
5.2.3 Survival until 14 days after stroke and infarct maturation on day 7 were not affected by 
CD4 depletion in 2D2 mice 
As mentioned previously (see 5.1.1), 2D2 mice generally have a lower survival rate than WT 
littermates. Since post-stroke infection influences survival, outcome and autoreactive immune 
responses after stroke (Romer, Engel et al. 2015), the preventative antibiotic treatment was given to 
all mice. In order to investigate the effect of CD4+ T cells on mid-term functional recovery and 
tissue remodeling after stroke, an antibody-mediated CD4+ T cell depletion experiment was 
designed (Figure 18A).  To avoid bias, before any analysis at endpoint, infarct volumes on day 1 in 
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both groups were compared. In each experiment there was no significant difference in initial infarct 
size between two treatments (Figure 18B). At endpoint, survival rate was not significantly changed 
by depleting CD4+ T cells after stroke (Figure 18C). Nevertheless, this also confirmed that neither 















Figure 18. CD4 depletion has no effect on 14-day survival. 
(A) CD4 depletion was performed as described before. Preventative antibiotic treatment with daily 
intraperitoneal injection of Marbofloxacin was used to prevent infection and related mortality. In all 
experiments, infarct size was measured on day 1 post stroke. In one experiment, infarct volume was measured 
once again on day 7 by T2-weighted MRI. Mid-term (day 10 after stroke) motor function was measured with 
Catwalk (see 5.2.7). Endpoint analysis included mainly immunofluorescent microscopy (see 5.2.4-5.2.6). (B) 
Animals with similarly averaged infarct size on day 1 post stroke were randomly allocated to either control 
treatment (N=28) or CD4 depletion (N=25). 2D2 mice that died before day 3 were not included. (C) Delayed 
CD4 depletion did not significantly influence 14-day survival in 2D2 mice with preventative antibiotic 
treatment. N indicates the number of mice that survived until day 14 and the number of mice that received at 
least one injection of antibody. Abbreviations: middle cerebral artery occlusion (MCAo); intraperitoneal 
(i.p.); CD4 depletion (CD4 depl.). Infarct size was analyzed with Mann-Whitney U Test. Data analyzed with 
non-parametric tests were expressed as median with interquartile range. Data were pooled from four 
experiments. 
 
Delayed CD4 depletion starting on day 3 had no effect on infarct volume on day 7 after stroke 
(Figure 19A). In both treatment groups, infarct size significantly shrank on day 7 (control=15.00% 
(10.11-21.16)%, CD4 depletion=10.00% (7.69-17.00)%) compared with that of day 1 
(control=19.00% (10.94-25.83)%, CD4 depletion=15.00% (10.79-19)%) (Figure 19B and 19C). 
There was no significant difference in infarct sizes on day 7 post stroke between control treatment 







Figure 19. CD4 depletion did not significantly influence infarct maturation on day 7 after stroke. 
(A) Representative T2-weighted images of infarction on day 1 and day 7 after stroke. (B) In control group 
(N=8, two mice had same infarct volumes at both time points), infarct size was significantly reduced on day 7 
compared to day 1 post stroke (Wilcoxon Matched-pairs Signed Rank Test, p=0.008). (C) In CD4-depleted 
group (N=7), infarct size was also significantly reduced on day 7 compared to day 1 post stroke (Wilcoxon 
Matched-pairs Signed Rank Test, p=0.047). However, there was no significant difference in infarct size on 
day 7 after stroke between control treatment and anti-CD4 depletion. Data analyzed with non-parametric tests 
were expressed as median with interquartile range. Significance level was marked as: *p<0.05, **p<0.01. 
 
5.2.4 CD4 depletion did not affect neuronal survival but does influence accumulation of 
myeloid cells in ischemic brain 
Neurons were stained with NeuN and quantified in both hemispheres. Stroke induced severe loss of 
neurons in the ipsilateral hemispheres (Figure 20A). In both treatment groups, the counts of NeuN+ 
neurons in the ischemic hemispheres (control=230 cells/slice, CD4 depletion=231 cells/slice) were 
significantly reduced compared with that of their correspondent contralateral hemispheres 
(control=347 cells/slice, CD4 depletion=340 cells/slice). However, there was no difference in the 
number of remaining neurons in the ischemic hemispheres between control treatment and CD4 
depletion (Figure 20B). Moreover, microglia and macrophages selectively accumulated in the 
ipsilateral hemisphere (Figure 20C). In both treatment groups, the counts of Iba1+ cells in the 
ischemic hemispheres (control=872 cells/slice, CD4 depletion=467 cells/slice) were significantly 
increased compared with that of their correspondent contralateral hemispheres (control=42 
cells/slice, CD4 depletion=42 cells/slice). Even without significant difference, a trend towards 
reduced accumulation of activated microglia/macrophages in the ipsilateral hemisphere was detected 











Figure 20. Reduced labeling of the neuronal marker and accumulation of Iba1+ microglia and 
macrophages remained unchanged in the ischemic hemispheres with CD4 depletion compared to 
control treatment. 
(A) Representative images from both hemispheres demonstrated lost immunoreactivity for neuronal marker 
(NeuN) exclusively in ischemic side. (B) Number of neurons were reduced in the ipsilateral hemisphere 
compared with the contralateral side (control p=0.063, CD4 depletion p=0.063, Wilcoxon Matched-Pairs 
Signed Rank Test). No significant difference was detected between control treatment and CD4 depletion 
regarding remaining neurons in the ipsilateral hemisphere (p>0.05, Mann-Whitney U Test). Scale bar: 25µm. 
(C) Representative images from both hemispheres demonstrated accumulation of Iba1+ activated microglia 
and macrophages with thicker processes exclusively in ischemic side. Resting microglia cells in the 
contralateral hemisphere had typically ramified morphology. Scale bar: 25µm. (D) In both groups, more 
activated microglia/macrophages accumulated in the ischemic hemispheres (control p=0.063, CD4 depletion 
p=0.125, Wilcoxon Matched-Pairs Signed Rank Test). There was no significant difference in the number of 
microglia and macrophages in the ischemic hemispheres between the control treatment and CD4 depletion 
(p=0.191, Mann-Whitney U Test). Abbreviations: contralateral (contra.), and ipsilateral (ipsi.). Data analyzed 
with non-parametric tests were expressed as median. Significance level was marked as: *p<0.05, **p<0.01. 
 
5.2.5 CD4 depletion significantly impaired proliferation of endothelial and periendothelial 
cells in peri-infarct area 
Both resting and activated microglia express Iba-1. As a result, the differential accumulation of 
activated microglia and macrophages might be covered up by the larger number of resting microglia. 
Therefore activated microglia and macrophages were visualized by using specific marker CD68, 
which predominantly localizes to lysosomes and endosomes with a smaller fraction circulating to 
the cell surface. Activated microglia and macrophages were able to proliferate in the ischemic 
hemisphere on day 14 after stroke (Figure 21A). Though the number of CD68+ activated 
microglia/macrophages was reduced in the CD4-depletion group (median=362 cells/slice) compared 
with that of the control group (median=534 cells/slice) (Figure 21B), the number of proliferating 
activated microglia and macrophages which double-labeled with CD68 and Ki67 (proliferating 
marker), showed a trend of reduced proliferation in mice with CD4 depletion (median=2 cells/slice) 
compared with that of the control treatment (median=20 cells/slice) (Figure 21C). This finding 
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suggests that the proliferation of activated microglia and macrophages during the delayed phase of 




Figure 21. CD4 depletion-impaired proliferation of activated microglia and macrophages in the 
ischemic hemisphere during the delayed phase of post-stroke inflammation. 
(A) Representative images from ischemic hemispheres demonstrated accumulation of CD68+ activated 
microglia and macrophages as well as co-expression of Ki67 by proliferating cells. Scale bar: 25µm. (B) 
Number of activated microglia and macrophages did not differ much with CD4 depletion (p=0.397, Mann-
Whitney U Test). (C) Proliferation of CD68+ cells exhibited a trend towards reduction by CD4 depletion 
(p=0.064, Mann-Whitney U Test). Abbreviations: CD4 depletion (CD4 depl.). Data analyzed with non-
parametric tests were expressed as median.  
 
Besides inflammatory cells, the proliferation of endothelial and periendothelial cells, which can 
react to ischemia and contact with immune cells during their active transmigration through the 
blood-brain barrier (BBB), was carefully analyzed. CD13 was chosen to label endothelial and 
periendothelial cells (partially pericytes) of blood vessels in brain parenchyma (Alliot, Rutin et al. 
1999). Macrophages can also express CD13. However by examining their morphology under 
immunofluorescent microcopy, staining of vessels can be easily distinguished from accumulation of 
macrophages within the infarct core. Similar to macrophages, there were also Ki67+ proliferating 
cells within inflamed vasculature in peri-infarct area (Figure 22A). Interestingly, proliferation of 
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endothelial and periendothelial cells was significantly affected by CD4 depletion (control=41 




Figure 22. Proliferation of endothelial and periendothelial cells. 
(A) Representative images from ischemic hemispheres showed proliferating endothelial and periendothelial 
cells in peri-infarct area. Image from CD4 depletion additionally included infarct core where 
immunoreactivity for CD13 was substantially up-regulated due to labeling of activated pericytes and 
macrophages. Scale bar: 25µm. (B) The number of proliferating endothelial and periendothelial cells 
significantly reduced with CD4 depletion compared to the control treatment (p=0.029, Mann-Whitney U 
Test). Abbreviations: CD4 depletion (CD4 depl.). Data analyzed with non-parametric tests were expressed as 
median. Data analyzed with non-parametric tests were expressed as median. Significance level was marked 
as: *p<0.05, **p<0.01. 
 
5.2.6 CD4 depletion significantly blocked CNS infiltration of B cells in 2D2 mice on day 14 
after stroke 
Since B cells also infiltrated ischemic brain and transiently proliferated at an early time point after 
stroke (see 5.1.2), the effect of CD4 depletion on the infiltration of B cells was evaluated.  
Compared with the control treatment (median=275 cells/slice), delayed CD4 depletion significantly 
blocked the infiltration of B cells into the ischemic hemispheres (median=0 cells/slice) in 2D2 mice 
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on day 14 after stroke (Figure 23A and 23B). Unlike CD4+ T cells that disseminated in the peri-
infarct area, B220+ B cells formed condensed follicle-like aggregates near inflamed vasculature 












Figure 23. Follicle-like aggregates formed by infiltrating B cells is significantly blocked by CD4 
depletion in 2D2 mice on day 14 after stroke. 
(A) Representative images from ischemic hemispheres demonstrated accumulation of B cells in 2D2 mice 
with either control treatment or CD4 depletion. Scale bar: 25µm. (B) CNS infiltration by B cells was 
significantly blocked by delayed CD4 depletion (p=0.016, Mann-Whitney U Test). (C) Typical distribution 
of CD4+ T cells and B cells in the ischemic hemisphere was obtained by counting all CD4 or B220 positively 
labeled cells in brain slice under fluorescent microscopy equipped with a Stereology workstation. (D) 
Representative image for B cell-rich follicle-like aggregates (indicated by white arrow) resided close to 
inflamed vasculature. Scale bar: 50µm. B cells (green) were labeled with B220+ and basement membrane 
was labeled with collagen type IV. Nuclei (blue) were counterstained with DAPI.  Data analyzed with non-
parametric tests were expressed as median. Significance level was marked as: *p<0.05, **p<0.01.
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5.2.7 Impact of CD4 depletion on functional outcome in 2D2 mice on day 10 after stroke 
Cerebral ischemia induced via occlusion of left MCA with filament results in paralysis on the right 
side of the mouse body. Typical motor deficits detected by CatWalk include decreased maximum 
contact area and stride length, increased run duration as well as decreased normalized swing speed, 
increased stand time, altered base of support (distance between front or hind paws) at 10 days after 
MCAo in WT mice (Hetze, Romer et al. 2012). In our experiments, 2D2 mice with control treatment 
also showed similar motor deficits such as significantly decreased maximum contact area with the 
right hind paw, significantly increased run duration, decreased stride length, increased stand time 
and altered phase dispersion (Table 2). This indicated that 2D2 mice with CD4+ T cells having 
transgenic MOG TCRs had similar patterns of gait impairments compared with WT littermates post 
stroke. Compared with control treatment, 2D2 mice with CD4 depletion had also significantly 
reduced maximal contact area and normalized swing speed in the right hind limb, but in general 
fewer gait parameters were significantly affected on day10 after stroke (Table 2).  
Since several significant differences already existed in baseline between the two treatments, change 
from baseline was calculated to represent post-stroke functional status. This revealed significantly 
prolonged run duration and shortened stride length with left front limbs in the control group on day 
10 after stroke (Table 2). Furthermore, the impairment score of the right hind limb was calculated to 
specifically detect stroke-induced deficits to the contralateral hind limb (Figure 24A). 2D2 mice 
with CD4 depletion had a lower impairment score of the right hind limb (median=2) compared with 





Table 2. Gait analysis (CatWalk) of 2D2 mice with control or CD4-depletion treatment before and 10 days after MCAo. 
Parameter Definition Paw 
Control (N=26) CD4 depletion (N=23) Control CD4 depletion 
Baseline Day 10 Baseline Day 10 Day 10 (Change from baseline) 
Day 10 (change from 
baseline) 
Spatial characteristics   
    
   




Maximal contact area of 
individual paws on glass 
plate 
  
RF 20.60±4.10 19.35±4.39 18.07±4.18§ 18.03±4.61  -1.26±5.67 -0.03±5.28 
RH 18.28±5.23 13.57±7.41* 17.77±4.64 12.62±4.77**  -4.71±9.04 -5.15±6.07 
LF 22.05±3.70 22.11±4.31 19.39±3.12§§ 20.70±3.08   0.06±5.00  1.31±3.76 
LH 20.24±5.31 18.55±7.35 17.84±4.78 16.07±5.75  -1.69±8.21 -1.77±7.87 
Kinetic characteristics         
Run durations (s) Time for passing through 
the walkway 





Swing speed (mm/s) x Run 
duration (s) 
RF 806.38±153.02 913.82±215.06* 1145.56±271.07§§§ 1097.61±225.54  107.45±156.87- -47.95±233.92# 
RH 721.73±178.05 675.93±225.65 1080.49±306.22§§§ 866.83±222.07*  -45.79±246.54 -213.66±207.52## 
LF 843.32±206.90 948.25±299.20 1174.16±271.85§§§ 1120.70±234.47  104.93±235.99 -53.46±234.02# 





Duration of individual paws 
contacting  
glass plate 
RF 0.17±0.03 0.20±0.04*** 0.19±0.03§ 0.21±0.04 0.04±0.04 0.02±0.05 
RH 0.15±0.02 0.15±0.05 0.18±0.04§§§ 0.16±0.04 0.01±0.06 -0.02±0.05 
LF 0.17±0.03 0.19±0.04** 0.20±0.04§ 0.21±0.03 0.03±0.05 0.01±0.05 
LH 0.16±0.02 0.18±0.05** 0.18±0.03§ 0.19±0.05 0.02±0.05 0.01±0.05 
Comparative statistics         
Regularity index (%) Regularity of gait   91.78±5.30 86.93±16.35 88.77±7.64 89.65±10.21 -4.85±16.68 0.85±13.29 
Base of support (mm) Distance between both front 
paws or hind paws 
RF-LF 10.15±6.98 10.47±8.09 11.83±7.63 10.70±7.62 0.32±11.72 -1.13±9.53 
  RH-LH 19.83±14.77 19.18±15.00 23.04±15.90 17.15±11.61 -0.65±23.76 -5.89±15.59 
Stride length (mm) Distance between  
successive steps of the same 
paw 
RF 41.35±7.91 37.89±5.80 47.10±9.64 47.88±8.18 -3.47±6.78 0.79±7.96 
  RH 37.41±9.38 34.21±8.20 42.92±8.35§ 43.87±9.72 -3.19±9.67 0.95±9.31 
  LF 41.67±7.77 37.57±6.08* 47.39±8.15§ 47.90±7.86 -4.10±6.51 0.51±7.03# 
  LH 38.50±8.57 33.28±6.08* 43.13±9.93 43.40±9.52 -5.22±10.14 0.27±10.40 






Contact of a target paw in 
relation to step cycle of 
another paw 
RF-LH 3.50±6.03 7.74±7.22* 4.63±5.41 8.57±8.19 4.23±9.78 3.94±9.68 
LF-RH 6.79±7.46 9.64±6.71 7.18±6.29 9.58±6.26 2.86±10.68 2.40±8.15 
RH-LH 39.13±9.34 41.88±9.21 41.78±7.47 42.73±9.77 2.75±12.15 0.95±11.73 
RF-LF 51.07±2.76 49.79±4.41 49.30±5.04 50.71±2.93 -1.29±4.69 1.41±5.51 
RF-RH 46.36±5.69 51.52±5.45** 46.44±5.61 50.75±7.59* 5.16±8.64 4.31±9.10 
  LF-LH 47.86±4.00 49.07±9.20 46.21±6.40 50.64±6.09* 1.22±10.03 4.43±7.87 
 
*comparison between baselines and paired measurements on day 10 after MCAo: Wilcoxon Signed Rank Test (*p<0.05, **p<0.01, ***p<0.001). 
§comparison between baselines in either treatment: Mann-Whitney U Test (§p<0.05, §§p<0.01, §§§p<0.001) 
#comparison of change from baseline between control and CD4 depletion treatments on day 10 after MCAo: Mann-Whitney U Test (#p<0.05, ##p<0.01) 




Figure 24. Functional deficits on day 10 after stroke in 2D2 mice measured by an impairment score are 
much reduced by CD4 depletion.  
(A) Reduction in maximal contact area, normalized swing speed, stand and stride length of the right hind 
limb was summed as an overall impairment score. For each item, only reduction compared with baseline got 
one point. (B) In the CD4-depletion group, the impairment score of the right hind limb was lower than that in 
the control group (Control=26, CD4 depletion=23, p=0.073, Mann-Whitney U Test). Abbreviations: right 
hind limb (RH); CD4 depletion (CD4 depl.). Data analyzed with non-parametric tests were expressed as 
median.  
 
5.3 B cells formed follicle-like aggregates in WT mice after stroke and were associated with 
autoantibody production and potential cognitive impairment  
5.3.1 Significant blockage of B cell entry by delayed CD4 depletion in ischemic brain was only 
detected in 2D2 mice but not in WT mice on day 14 after stroke 
Both T and B lymphocytes have been proven to infiltrate into ischemic brain, however the 
interdependence between CD4+ T cells and B cells have not been reported in stroke. In order to 
confirm the significant impairment of B cell infiltration into ischemic brain of 2D2 mice seen with 
immunohistochemistry, I alternatively quantified CNS-infiltrating B cells and myeloid cells from 
control and CD4 depletion groups with flow cytometry. Moreover, I compared the effect of CD4 
depletion additionally in WT mice to validate whether strong blockage of B cell infiltration by CD4 
depletion seen in 2D2 mice was also effective in WT mice. Besides the same CD4-depletion 
procedure and preventative antibiotic treatment, a neurological Deficit Score (De Simoni) (Orsini, 
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Villa et al. 2012) was repeatedly performed to evaluate the general health status as well as focal 
deficits (Figure 25A).  Functional deficits developed on day 3, and they showed a tendency to 
further deteriorate between day 7 and day 13 in the control group, while mice with CD4 depletion 
showed peak neurologic deficits on day 7 with subsequent recovery on day 13 compared with the 
earlier time points (Figure 25B). 2D2 mice with CD4 depletion had lower neurological scores 
(median=4.5) compared with that of the control group (median=20) on day 13 after stroke. WT mice 
developed a similar severity of functional deficits on day 3, compared to 2D2 mice, but experienced 








Figure 25. Comparison of neurological score between control treatment and CD4 depletion in 2D2 and 
WT mice following stroke. 
(A) 60 min MCAo and CD4 depletion were performed. Preventative antibiotic (Enrofloxacin) was given one 
day before the operation and administered until day 7 after stroke. Mice with either treatment surviving until 
day 13 had similar initial infarct sizes on day 1 post stroke (data not shown, Mann-Whitney U Test, control 
vs. CD4 depletion in 2D2 mice, p=0.619; control vs. CD4 depletion in WT mice, p=0.994). The neurological 
deficit score was evaluated before operation and repeated on days 3, 7 and 13 after stroke. At endpoint (day 
14), mononuclear cells from ischemic hemispheres were analyzed by flow cytometry. Serum samples were 
also prepared from peripheral blood for chemokine analysis. (B) 2D2 mice with CD4 depletion exhibited 
recovery on day 13 compared to the control treatment after stroke (Control=3, CD4 depletion=6, Mann-
Whitney U Test, p=0.114). (C) CD4 depletion did not affect neurological recovery in WT mice compared to 
the control treatment on day 13 after stroke (Control=5, CD4 depletion=5). Data analyzed with non-
parametric tests were expressed as median.  
 
Even though CD4 depletion did not significantly promote neurological recovery in 2D2 mice, the 
strong blockage of B cells infiltrating into the ischemic hemisphere was reproducible with FACS 
analysis. Quantitatively speaking, our data reaffirmed that CD4 depletion during the delayed phase 
not only significantly blocked the entry of CD4+ T cells (median=14 cells) but also significantly 
impaired the infiltration of B cells (median=1936 cells) and their follicle-like aggregation in the 
ischemic hemispheres compared with that of the control group (CD4+ T cells=64599 cells; B 
cells=39658 cells) (Figure 26A). However, using the same experimental setup, there was no such 
significant blockage of the B cells’ infiltration with CD4 depletion in WT mice (Figure 26B). Only 
CD4+ T cells were successfully depleted in the ischemic hemispheres (control=1762 cells; CD4 
depletion=7 cells). 
The migration of B cells is strongly regulated by the B cell chemokine CXCL13 (Huber and Irani 
2015). The expression of CXCL13 was detected surrounding follicle-like aggregates on day 14 after 
stroke (Figure 26C). The mRNA expression of CXCL13 was exclusively increased in the ischemic 
hemispheres (median=0.114 AU) of 2D2 mice on day 14 after stroke compared with that of 
contralateral sides (median=0.0043 AU) (Figure 26D). Since B cells were originally recruited from 
the periphery, the serum levels of CXCL13 in WT and 2D2 mice, both in control and anti-CD4-
depletion groups were compared. While in 2D2 mice, the serum level of CXCL13 was slightly 
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reduced by CD4 depletion (median=572.7 pg/ml) compared with that of the control group 
(median=980.1 pg/ml) (Figure 26E), the serum level of CXCL13 was not affected by CD4 depletion 




Figure 26. CD4 depletion significantly blocks CNS infiltration by B cells in 2D2 mice but not in WT 
mice on day 14 after stroke. 
(A) CD4 depletion significantly depleted CD4+ T cells (Mann-Whitney U Test, p=0.036) and impaired the 
entry of B cells into the ischemic hemisphere (Mann-Whitney U Test, p=0.036). Control N=3, CD4 depletion 
N=6. (B) CD4 depletion still worked effectively to deplete CD4+ T cells (N=5 per group, Mann-Whitney U 
Test, p=0.008), but no significant difference was detected in B cell infiltration between the control and CD4-
depletion group in WT mice. (C) Expression of CXCL13 surrounding follicle-like aggregates (indicated by 
white arrows) increased only in the ischemic hemisphere of 2D2 mice on day 14 after stroke. CXCL13: 
green. DAPI: blue. Magnification: 25X. (D) The mRNA expression of CXCL13 in the ischemic hemispheres 
of 2D2 mice on day 14 after stroke (N=3, Wilcoxon Matched-pairs Signed Rank Test, p=0.25). Reep5 served 
as a housekeeping gene. (E) Serum samples from two treatment groups collected at endpoint (day 14 after 
stroke) were compared with control serum samples from either naïve (N=4) or sham-operated (N=2) 2D2 
mice. There was no significant difference among any groups in 2D2 mice (Kruskal-Wallis, p=0.059; 
corrected for multiple comparisons, not significant). But the serum level of CXCL13 was slightly reduced by 
CD4 depletion compared with the control group. (F) CD4 depletion did not influence the concentration of 
CXCL13 in serum samples in WT mice (naïve N=3, sham N=2, control N=5, CD4 depletion=5, Kruskal-
Wallis, p=0.561; corrected for multiple comparisons, not significant). Abbreviations: ipsilateral (ipsi.); CD4 
depletion (CD4 depl.). All data from multiple groups were analyzed with the Kruskal-Wallis test with Dunn’s 
multiple comparison test. Each p value was adjusted to account for multiple comparisons. Data analyzed with 
non-parametric tests were expressed as median. Significance level was marked as: *p<0.05, **p<0.01. 
 
5.3.2 Significantly more B cells accumulated in the ischemic brain of WT mice on day 49 
compared to day 14 after stroke 
Compared to 2D2 mice, WT littermates have limited potential to induce autoreactivity after stroke. 
Infiltration of CD4+ T cells is significantly less pronounced and slower in WT mice compared to 
2D2 mice (see 5.1.1). Moreover, comparing FACS data from the previous section showed that a 
similar number of B cells accumulated in the ischemic brain of WT mice compared with either 
control treatment or CD4 depletion on day 14 after stroke. However it was not clear whether 
relatively fewer B cells seen in WT mice could still form follicle-like aggregates. To address this 
question, kinetic B cell migration was carefully measured on day 14 and day 49 after stroke. Unlike 
2D2 mice, WT mice had accumulation but no obvious follicle-like aggregates of B cells on day 14 
after stroke (Figure 27A). Compared with day 14 (median=1237 B cells), significantly more B cells 
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with typical follicle-like organization accumulated in the ischemic brain on day 49 after stroke 
(median=7500 B cells) (Figure 27B). The delayed infiltration of CD4+ T cells (see 5.1.1) and 
formation of B cell aggregates in WT mice perfectly indicated the link between autoreactive CD4+ T 
cells and potential autoimmunity driven by B cells. 
 
 
Figure 27. B cells continuously accumulate in the ischemic hemispheres in WT mice between day 14 
and day 49 after stroke. 
(A) Representative counting images of B cells in brains from sham-operated mice and stroke-induced mice. 
Cell counts from two slices at both bregma and hippocampus levels were chosen to represent each mouse. (B) 
Compared to day 14, the accumulation of B cells in the ischemic hemispheres was significantly up-regulated 
on day 49 after stroke (Mann-Whitney U Test, p=0.032). Data analyzed with non-parametric tests were 
expressed as median. Significance level was marked as: *p<0.05. 
 
5.3.3 Stroke-induced expansion of plasmablasts/plasma cells and marginal zone B cells in 
ischemic brain and spleen of WT mice 
In the FACS analysis, the total CNS-infiltrating leukocytes did not significantly decline between day 
14 and day 49 after stroke in the ischemic brain of WT mice (Figure 28A), but the percentage of 
CD19+ B cells in overall infiltrating leukocytes did significantly increase on day 49 (36.80% (20.46-
44.93)%) compared with that of day 14 (7.93% (3.95-12.45)%) after stroke (Figure 28B). Follicular 
B cell was the main B cell subset residing in ischemic brain at both time points (Figure 28C). Both 
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plasmablasts/plasma cells and marginal zone B cells had their highest representations within B cell 
compartment on day 14 after stroke (Figure 28C). The percentage of plasmablasts/plasma cells 
significantly reduced on day 49 (13.91% (9.92-18.70) %) compared with day 14 (24.03% (20.86-
44.79) %) after stroke (Figure 28D). The percentage of marginal zone B cells also significantly 
decreased on day 49 (0.60% (0.36-1.44) %) compared with day 14 (2.21% (1.42-4.22) %) after 
stroke (Figure 28E). However, the absolute counts of both cell types did not significantly change 








Figure 28. Ratios of plasmablasts/plasma cells and marginal zone B cells in ischemic brain are 
significantly higher on day 14 compared to day 49 after stroke. 
 (A) The overall infiltrating leukocytes slightly decreased on day 49 (N=6) compared with day 14 (N=6) after 
stroke (Mann-Whitney U Test, p=0.387). (B) FACS analysis showed significantly increased percentage of B 
cells among total infiltrating leukocytes on day 49 day compared with day 14 after stroke (Mann-Whitney U 
Test, p=0.009). CD45: pan leukocyte marker. CD19: B cell marker. (C) Summary of mean subset 
percentages within B cell compartment in the ischemic hemisphere on day 14 and day 49 after stroke. 
Infiltrating B cells were mainly composed of follicular B cells, while plasmablasts/plasma cells formed the 
second largest population. (D) A significantly higher percentage of plasmablasts/plasma cells were detected 
in the ischemic hemisphere on day 14 compared with day 49 after stroke (Mann-Whitney U Test, p=0.026). 
(E) A significantly higher percentage of marginal zone B cells were detected in the ischemic hemisphere on 
day 14 compared with day 49 after stroke (Mann-Whitney U Test, p=0.024). Data analyzed with non-
parametric tests were expressed as median with interquartile range. Significance level was marked as: 
*p<0.05, **p<0.01. 
 
Not only ischemic brain but also secondary lymphoid organs such as spleen could be involved in 
priming and early proliferation of B lymphocytes following stroke (see 5.1.2). Therefore B cell 
subsets in spleen were also analyzed by FACS at both time points. On day 14 after stroke, the 
influence of stroke-induced immunodepression on splenocytes was already weaker compared with 
that in the acute phase. Total counts of CD45+ leukocytes did not differ between day 14 and day 49 
post stroke compared with naïve mice (Figure 29A). The percentage of CD19+ B cells was 
significantly reduced on day 14 (39.35% (30.13-43.03)%) and recovered on day 49 (46.00% (40.15-
51.53)%) similar to the level in naïve control mice (median=52.00%) (Figure 29B). Furthermore, 
comparing percentages of different subsets within B cell compartment, it became clear that marginal 
zone B cells expanded more compared with plasmablasts/plasma cells on day 14 post stroke (Figure 
29C). The percentage of plasmablasts/plasma cells (17.25% (12.95-24.61)%) prominently up-
regulated on day 14 compared with naïve control (9.91% (7.73-11.15)%) and that of day 49 after 
stroke (10.89% (9.50-11.73)%) (Figure 29D). In addition, the percentage of marginal zone B cells  
also slightly increased on day 14 (22.27% (18.56-34.70)%) compared with naïve control (5.46% 











Figure 29. B cells are significantly reduced in spleen on day 14 with normalization by day 49 after 
stroke. 
(A) The overall CD45+ leukocytes did not differ among naïve control mice (N=3) on day14 (N=12) or day 49 
(N=12) after stroke. (B) The percentage of CD19+ B cells significantly reduced on day 14 compared to naïve 
control mice (Kruskal-Wallis, p=0.011; corrected for multiple comparisons, p=0.032). (C) Summary of mean 
subset percentages within B cell compartment in spleens of naïve mice and mice on day 14 as well as day 49 
after stroke. Infiltrating B cells were mainly composed of follicular B cells, while plasmablasts/plasma cells 
and marginal zone (MZ) B cells formed the second largest populations. (D) There was a trend that the 
percentage of plasmablasts/plasma cells prominently up-regulated on day 14 compared with naïve control 
mice (Kruskal-Wallis, p=0.021; corrected for multiple comparisons, p=0.085) and slightly decreased on day 
49 (Kruskal-Wallis, p=0.021; corrected for multiple comparisons, p=0.062). (E) The percentage of marginal 
zone B cells also slightly up-regulated on day 14 compared with naïve control mice (Kruskal-Wallis, 
p=0.046; corrected for multiple comparisons, p=0.100). Abbreviation: marginal zone (MZ). All data from 
different groups were analyzed with Kruskal-Wallis test and with Dunn’s multiple comparison test. Each p 
value was adjusted to account for multiple comparisons. Data analyzed with non-parametric tests were 
expressed as either median or median with interquartile range. Significance level was marked as: *p<0.05. 
 
5.3.4 Delayed formation of follicle-like aggregates by B cells was associated with delayed 
cognitive impairment 
Previous evidence of B cell follicular aggregates and expansion of plasmablasts/plasma cells as well 
as marginal zone B cells strongly suggested possible development of autoreactivity-induced 
functional impairment during the chronic phase of stroke. A Y maze (Figure 30A) was used in this 
thesis to evaluate spatial working memory. In line with the kinetics of brain-infiltrating B cells, there 
was no detectable memory deficit on day 13 after stroke (Figure 30B), when the accumulation of B 
cells was not yet as prominent as it was on day 48. The significant impairment of spatial working 
memory was detected only until day 49 after stroke (60.00% (43.25-67.00)% alternation) compared 
with naïve control mice (73.00% (60.00-80.00)% alternation) (Figure 30C), indicating a possible 
correlation between autoimmunity-driven B cells and a decline in cognitive function during the 




Figure 30. WT mice develop memory deficits at 48 days after stroke. 
(A) Schematic representation of Y maze test of spatial working memory. The mouse was placed in the maze. 
Subsequent entries to different arms allowed the calculation of percentage alternation which reflects working 
memory performance. (B) On day 13, there was not yet evidence of memory deficits in stroke-induced mice 
compared with their own performance at baseline (N=12 per group, Wilcoxon Signed Rank Test, p=0.365). 
(C) Mice did develop significantly impaired working memory at 48 days after stroke compared with naïve 
mice (Mann-Whitney-U test, p=0.032). Data analyzed with non-parametric tests were expressed as median 
with interquartile range. Significance level was marked as: *p<0.05. 
 
5.3.5 Induced production of autoantibody in serum from WT mice with cerebral ischemia 
The expansion of marginal B cells and plasmablasts/plasma cells is a potential manifestation of 
antigen-specific autoimmune responses in secondary lymphoid organs. All mice were screened to 
explore whether there was stroke-induced synthesis of autoantibody in periphery, which could serve 
as indirect proof of chronic B cell activation and autoantibody synthesis similar to previous findings 
in spinal cord injury (Ankeny, Lucin et al. 2006). It is worthy of note that preexisting serum 
autoantibodies against multiple antigens such as cytoplasmic antigens, Purkinje cells, neuronal 
nuclear antigen (Figure 31A) and universal nuclear antigen beyond CNS location (Figure 31B) were 
detected in more than half of naïve mice (Table 3). When mice were stratified based on sera 
reactivity against autoantigen, there was a clear tendency that mice with preexisting autoantibody 
tended to suffer from larger infarction (33.50% (18.00-39.50)%) than mice with negative sera for 
self-antigens (18.00% (16.00-28.00)%) on day 1 after stroke (Figure 31C). Interestingly, regarding 
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the epitope recognized by autoantibody, reactivity against hippocampal neurons was mainly induced 







Figure 31. Screening of autoantibody in paired serum samples collected at baseline and endpoint. 
(A) Preexisting autoantibody was detected in naïve WT mice. From serum samples collected before MCAo, 
three epitopes with potential localization to purkinje cells (indicated by white arrow) in cerebellum, 
cytoplasm and nuclear in cortex were shown in each representative image. Scale bar: 100µm. (B) Serum 
staining with gut tissue was compared with staining from brain tissue. In this example, it exemplified the 
universal reactivity of autoantibody against nuclear epitope not specific to CNS. The white arrow indicates 
the nuclear staining in epithelium of gut tissue. Scale bar: 50µm. (C) Mice with preexisting autoantibody 
tended to have larger infarction (Yes=14, No=11, Mann-Whitney U Test, p=0.062) compared with mice with 
no autoantibody at baseline. (D) Screening-paired serum samples revealed that small groups of mice had 
autoantibody induced only after stroke. A representative image from the same mouse showed a positive 
signal against dentate gyrus neurons (indicated by the white arrow) on day 14 after stroke while no reactivity 
was detected in baseline serum. Scale bar: 100µm. Data analyzed with non-parametric tests were expressed as 
median with interquartile range. 
 
 
Table 3. Summary of autoantibody screening with paired serum samples. 
Serum type Day 14 Day 49 Sum 
Negative  2 3 5 
Autoantibody only before MCAo 2 1 3 
Autoantibody before and after MCAo 5 2 7 
Autoantibody only after MCAo 2 0 2 






By using 60 min middle cerebral artery occlusion and antibody-based depletion of circulating CD4+ 
T cells in both MOG TCR transgenic 2D2 mice and WT mice, I postulated in the present thesis that 
the delayed infiltration of CD4+ T cells is involved in tissue remodeling and the functional outcome 
after experimental stroke. I confirm that after transient priming and proliferation in the secondary 
lymphoid organs, activated CD4+ T cells with autoreactive potential against MOG can selectively 
and massively infiltrate into the ischemic hemispheres of 2D2 mice during the delayed phase (day 
14) of experimental stroke. In addition, the evidence that CD4 depletion did not influence deposition 
of fibrotic fibers within infarct core or release of TGFβ1 in the ischemic hemisphere indicates that 
CD4+ T cells have no direct role in tissue fibrosis. However, CD4 depletion did impair proliferation 
of activated microglia/macrophages and periendothelial cells in the peri-infarct area, which suggests 
a modulatory role of CD4+ T cells in vascular remodeling. Most importantly, CD4 depletion 
completely blocked infiltration of B cells into the ischemic hemisphere and their formation of 
follicle-like aggregates in 2D2 mice on day 14 after stroke. 2D2 mice with CD4 depletion also had 
significantly reduced impairment of their right hind limb on day 10 after stroke. Moreover, it is 
worth mentioning that B cells did infiltrate the ischemic hemispheres of WT mice but achieved peak 
infiltration with much delay (day 49) compared with 2D2 mice (day 14). The transient 
differentiation of plasmablasts/plasma cells as well as the expansion of marginal zone B cells in both 
ischemic brain and spleen, the production of autoreactive antibodies against CNS antigens in 
circulation jointly point to the possible relationship between the stroke-induced autoreactivity and 
memory impairment observed in WT mice on day 49 after stroke. Taken together, I conclude that 
delayed infiltration of CD4+ T cells plays an important role in autoreactive responses and might 
affect functional long-term recovery after stroke. 
6.1 Transient proliferation of lymphocytes in secondary lymphoid organs and their initial 
infiltration and proliferation in ischemic brain on day 7 after stroke 
Brain injury following stroke releases multiple CNS antigens into the peripheral immune system 
(van Zwam, Huizinga et al. 2009, Planas, Gomez-Choco et al. 2012) where antigen-presenting cells 
(APCs) such as dendritic cells and macrophages can present CNS antigens to naïve lymphocytes and 
activate them toward either autoreactive or regulatory phenotype, depending on the route and mode 
of access of brain antigens to lymphoid tissue (Becker 2009, Urra, Miro et al. 2014). Stroke patients 
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are reported to have increased numbers of autoreactive T cells specific to various CNS antigens 
(Wang, Olsson et al. 1992) in their cerebrospinal fluid and peripheral blood.  
In the present thesis, the increased proliferation of B cells was detected exclusively in spleen on day 
1 (over 5%) after stroke compared with sham control. However, proliferation of B cells significantly 
reduced to less than 2% on day 3 after stroke. Similarly, CD8+ T cells had their peak proliferation 
(over 5%) in superficial cervical lymph nodes, mesenteric lymph nodes and spleen on day 1 after 
stroke and later reduced to the level of sham control (around 2.5%). Even though overall 
proliferation of CD4+ T cells after stroke was relatively less (1-2%) than that of B and CD8+ T cells, 
the proportion of MOG TCR+ cells in overall proliferating CD4+ T cells transiently increased in 
CNS-draining lymph nodes, spleens and mesenteric lymph nodes on day 1 after stroke. This early 
and transient proliferation of both T and B lymphocytes upon CNS-antigen presentation in periphery 
after stroke is in line with a previous study reporting a significant increase in autoreactive CD4+ and 
CD8+ T cells, as well as autoreactive B cells upon ex vivo activation by multiple CNS antigens as 
early as 4 days after stroke onset (Ortega, Noorbhai et al. 2015). The evidence from labeling 
proliferating autoreactive MOG TCR+ CD4+ T cells in vivo provided further support to study 
reporting peak drainage of CNS antigens in cervical lymph nodes on day 1 after 60 min MCAo (van 
Zwam, Huizinga et al. 2009).  
Not only peripheral lymphoid organs are actively involved with the induction of autoreactivity, 
ischemic brain is also the target and final destination for CNS-antigen reactive lymphocytes. 
Recruitment of lymphocytes from adaptive immunity is usually delayed compared with innate 
immune cells, such as monocytes, during ischemic injury (Gronberg, Johansen et al. 2013). 
Activated lymphocytes actually started to selectively infiltrate into the ischemic hemispheres on day 
7 after stroke. On day 7, the number of CNS-infiltrating lymphocytes in the ipsilateral hemisphere 
was a bit higher than in the contralateral hemisphere. But the proliferation of lymphocytes in the 
ischemic hemispheres was much greater than in the contralateral hemisphere. The noticeable 
quantitative and proliferative differences between the two hemispheres suggest that either the 
cytokine environment or antigen-presentation was promoting the autoreactive proliferation of 
lymphocytes exclusively in the ischemic hemisphere. Nevertheless, day 7 was still during the early 
phase of lymphocyte infiltration into the ischemic brain. A significant difference between the two 
96 
 
hemispheres regarding lymphocyte infiltration should be anticipated at a later time point (day 14) 
after stroke (Stubbe, Ebner et al. 2013, Romer, Engel et al. 2015).  
Although CNS-infiltrating MOG TCR+ CD4+ cells proliferated significantly more than the same cell 
types in spleen and mesenteric lymph nodes, the proportion of MOG TCR+ CD4+ cells was 
significantly lower in the ischemic brain compared with peripheral lymphoid organs. This indicates 
stroke can induce clonal expansion of autoreactive CD4+ cells that have diverse TCR repertoires in 
2D2 mice. Indeed, autoreactive T cells, which recognize myelin components such as myelin basic 
protein and proteolipid protein, were detected in the CSF of acute ischemic cerebrovascular disease 
(CVD) patients (Wang, Olsson et al. 1992). It is also notable that the percentage of MOG TCR+ T 
cells in the CD4+ population remained unchanged at different time points in the same secondary 
lymphoid organ and in different secondary lymphoid organs from the same time point, while the 
absolute count of CD4+ T cells did decrease due to stroke-induced immunodepression (SIDS) (Prass, 
Meisel et al. 2003, Dirnagl, Klehmet et al. 2007). This result indicates that autoreactive T cells did 
not undergo more severe apoptosis than non-autoreactive T cells. Insufficient suppression of 
autoreactive T cells by SIDS in periphery allowed their infiltration into ischemic brain during the 
delayed phase of stroke. Altogether, the transient proliferation pattern of T cells in secondary 
lymphoid organs and subsequent targeted infiltration into ischemic hemispheres support the notion 
that adaptive immune cells might first get primed in periphery by CNS-antigen presentation, then 
infiltrate into ischemic brain during the delayed phase (7-14 days) and might contribute to chronic 
autoreactive responses.  
6.2 Delayed infiltration of CD4+ T cells temporally correlates with deposition of fibrotic fibers 
within ischemic tissue 
Tissue fibrosis, or scar formation, is a common result of persistent inflammation as well as failed 
tissue regeneration and represents a repair mechanism which replaces the normal tissue with 
extracellular matrix (ECM) consisting predominantly of fibronectin and type I collagen (Ferguson 
and O'Kane 2004). The central nervous system (CNS) is special because fibrogenic cells such as 
fibroblasts are restricted to vascular and meningeal niches. However, disruption of the blood-brain 
barrier and inflammation can unleash stromal cells and trigger scar formation (Fernandez-Klett and 
Priller 2014). Accordingly, I observed deposition of collagen type I fibrotic fibers within the infarct 
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area on day 14 after stroke. Interestingly, CNS-infiltrating CD4+ T cells distributed in close 
proximity to these fibrotic fibers and temporally matched with scar formation in ischemic tissue.  
In inflamed tissues, both ECM turnover and protease secretion by tissue-resident cells are affected 
by cytokines, such as TGFβ1, TNF, IFNɣ, and PDGF, which are released by the infiltrating cells 
(Sorokin 2010, Murray and Wynn 2011). On the other hand, upregulated ECM fragments can also 
activate immune cells, for example via signaling by the Toll-like receptor family that initiates innate 
immune responses and further influences the nature of the adaptive immune response. Therefore I 
considered there might be an interrelationship between CD4+ T cells and the deposition of fibrotic 
fibers. However, delayed CD4 depletion in 2D2 mice with experimental stroke did not influence the 
process of tissue remodeling, including the deposition of fibrotic fibers (collagen type I) and the 
release of growth factors (BDNF, VEGF and NGF) at mRNA level. The expression of PDGFRβ was 
also not affected by CD4 depletion, indicating that CD4+ T cells did not directly modulate stromal 
cells such as pericytes. Instead, significant correlation was detected between mRNA expressions of 
collagen type I and TGFβ1 in mice with either treatment. Additionally, mRNA expression of CCR2 
(receptor for monocyte chemoattractant protein-1, MCP-1) increased parallel to TGFβ1. Since 
MCP-1/CCR-2 is crucial for the migration of hematogenous inflammatory cells following transient 
cerebral ischemia (Schuette-Nuetgen, Strecker et al. 2012), our findings suggest that resident cells 
and infiltrating macrophages might be the main producers of TGFβ1 (Iadecola and Anrather 2011) 
and therefore play a more direct role than CD4+ T cells in tissue remodeling after stroke (He and 
Marneros 2013). 
6.3 CD4 depletion significantly impairs proliferation of periendothelial cells in the peri-infarct 
area but has no influence on infarct maturation after stroke 
Monocytes or macrophages are pioneers that invade the infarct core and actively take part in control 
of scar tissue resolution and production of growth factors (Raposo and Schwartz 2014, Jiang, Zhao 
et al. 2016). Moreover, myeloid linage antigen CD13, identical with aminopeptidase N (APN) and 
marker for pericytes and periendothelial cells of brain parenchyma vessels (Alliot, Rutin et al. 
can contribute to scar formation in inflamed tissue. Delayed CD4 depletion did not significantly 
reduce the number of CD68+ activated microglia/macrophages in the ischemic hemispheres. But the 
proliferation of CD68+ activated microglia/macrophages showed a trend of reduction by CD4 
depletion. Moreover, the proliferation of CD13+ periendothelial cells in the ischemic hemisphere of 
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2D2 mice were significantly reduced by CD4 depletion on day 14 post stroke. In situ proliferation of 
both myeloid cells and tissue-resident macrophages were reported to be a key feature of the 
inflammatory process (Davies, Rosas et al. 2013). The inflammation-induced activation and 
proliferation of endothelial and periendothelial cells might affect the stability and permeability of 
inflamed vasculature (Bergers and Song 2005). Thus, this finding highlights the potential anti-
inflammatory and vessel-stabilizing roles of CD4+ T cells during the chronic phase of stroke. 
It has been reported that genetic deficiency of T and B cells results in reduction of infarct volume at 
24 hours after experimental stroke (Hurn, Subramanian et al. 2007, Kleinschnitz, Schwab et al. 
2010). RAG1-/- mice reconstituted with only B cells had still smaller infarct size compared to mice 
with combined deficiency (Kleinschnitz, Schwab et al. 2010). This result suggests that early 
infiltrating T cells play an important role in infarct formation. In contrast to previous studies, I 
targeted rather delayed infiltration of T cells by delayed CD4 depletion (starting on day 3 post 
stroke). Delayed CD4 depletion had no effect on infarct maturation on day 7 post stroke. During the 
late phase of stroke, while CD4+ T cells mainly accumulated at the peri-infarct area (see 5.2.1), 
activated macrophages were the main cell population that infiltrated the ischemic hemisphere earlier 
than lymphocytes (Gelderblom, Leypoldt et al. 2009, Gronberg, Johansen et al. 2013) and heavily 
loaded the infarct core (Fernandez-Klett, Potas et al. 2013). Since CD4 depletion had almost no 
effect on the accumulation of macrophages, this might explain why there was no dramatic effect 
from CD4 depletion on infarct size on day 7 after stroke.   
6.4 CD4 depletion exhibits a trend to improve mid-term motor recovery and Neuroscore in 
2D2 mice after stroke 
The promotion of post-ischemic motor recovery remains a major challenge in clinical neurology. 
Locomotor function was monitored with Catwalk on day 10 post stroke to reflect the mid-term 
outcome. In both control and anti-CD4-treated groups, 2D2 mice developed similarly typical stroke-
induced alterations in gait, such as maximum contact area, especially of the right hind paw, 
normalized swing speed, phase dispersion and stride length (Hetze, Romer et al. 2012, Li, Shi et al. 
2013). There were significantly different changes from baseline in run duration and normalized 
swing speed between the two treatments. In general, the control group had more parameters with 
stroke-induced deficits than the CD4 depletion group. Using a post hoc calculation of impairment 
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score of the right hind limb, I detected more obviously functional deficits in the control treatment 
compared with CD4 depletion.  
However, a limitation of Catwalk to analyze mice with experimental stroke is its dependency on 
walking speed because they can hardly walk through the walkway without longer breaks (Hetze, 
Romer et al. 2012). Therefore, additional Neuroscore was evaluated before surgery and at 3, 7, 13 
days after stroke. In both groups, neurological deficits developed immediately after surgery and 
continuously until day 7 after stroke. One week after stroke, functional impairment in 2D2 mice 
with control treatment went further until day 13, while WT mice or 2D2 mice with CD4 depletion 
all experienced recovery, possibly due to the absence or limited amount of autoreactive CD4+ T 
cells.  
Treg cells have been considered to be neuroprotective in ischemic stroke (Liesz, Suri-Payer et al. 
2009, Li, Mao et al. 2013, Liesz, Zhou et al. 2013). However, delayed anti-CD25 depletion had no 
effect on functional recovery (Stubbe, Ebner et al. 2013). CD4 depletion eliminated all circulating 
CD4+ T cells including autoreactive (pro-inflammatory) and regulatory (anti-inflammatory) T cells. 
Since I observed an overall benefit of CD4 depletion promoting neurological recovery in 2D2 mice 
on day 10 after stroke, this indicates that delayed infiltration of CD4+ T cells mainly acts as a 
promotor of chronic inflammation and autoreactive responses which are detrimental to stroke 
outcome. 
In contrast to a study reporting no reduction in infarct volume and no improvement in neurological 
score (up to 4 days) with blockage of infiltrating leukocytes by anti-CD49d treatment at 3 hours post 
stroke (Llovera, Hofmann et al. 2015), our findings suggest that delayed CD4 depletion has a high 
potential to promote functional recovery, compared to the control treatment, and the underlying 
mechanism could be independent of alterations in infarct size.  
6.5 Delayed CD4 depletion robustly inhibits formation of follicle-like aggregates by B cells in 
the ischemic brains of 2D2 mice on day 14 after stroke 
B cell aggregates are found in the meninges of patients with secondary progressive multiple 
sclerosis (MS) and are associated with early disease onset and severe cortical pathology. These 
aggregates show features reminiscent of B cell follicles in lymphoid tissue, such as B cell 
proliferation and differentiation into plasma cells, and the presence of a stromal network producing 
B lymphocyte chemoattractant (BLC) chemokine (C-X-C motif) ligand 13 (CXCL13) (Magliozzi, 
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Howell et al. 2007). Interestingly, condensed cellular clusters of B cells with close contact to CD4+ 
T cells in inflamed CNS resemble peripheral follicles in secondary lymphoid organs, indicating 
possible B cell involvement in autoreactivity (Pitzalis, Jones et al. 2014). Not only autoimmune 
diseases, but also acute injury to the CNS can lead to chronic inflammation and subsequent 
formation of B cell aggregates. A previous study on ischemic spinal cord injury has found B cell 
aggregates which produce antibodies and impede recovery (Ankeny, Lucin et al. 2006). More 
recently, it was reported that C57BL/6L mice with DH stroke (60 min distal MCAo + hypoxia) have 
B cell aggregates in the ischemic hemisphere at 7 weeks after stroke (Doyle, Quach et al. 2015).  
I found that infiltration of B cells into ischemic brain was significantly inhibited with delayed 
depletion of CD4+ T cells in 2D2 mice on day 14 after stroke. For the first time, our data 
demonstrated sound evidence which linked autoreactive CD4+ T cells to infiltration of B cells after 
ischemic stroke. Even though CD4 depletion did not robustly block infiltration of B cells into the 
ischemic hemisphere of WT mice on day 14 post stroke, similar follicle-like aggregates of B cells 
were formed in the peri-infarct areas of both 2D2 and WT mice. This indicates that the development 
of autoimmunity in the chronic phase of stroke includes B cell immunity and humoral autoreactive 
responses. 
Compared with WT mice, 2D2 mice with their MOG-specific T cells with autoreactive potential had 
significantly more infiltration of CD4+ T cells and quicker formation of follicle-like aggregates as 
early as 2 weeks after stroke. In WT mice, early infiltration with sparse B cells already started in the 
ischemic hemisphere at 2 weeks after stroke. B cell infiltration was significantly more severe on day 
49 compared with day 14 after stroke. This delayed infiltration of B cells in WT mice might explain 
why significant blockage of B cell infiltration was not detectable on day 14 after stroke in WT mice 
with CD4 depletion. Even though I detected strongly increased protein and mRNA expressions of 
CXCL13 in the ischemic hemispheres of 2D2 mice, the concentration of CXCL13 in serum 
(periphery) was not significantly affected by CD4 depletion in either 2D2 or WT mice on day 14 
after stroke. If peripheral concentration of CXCL13 remained stable with CD4 depletion, then the 
production of CXCL13 close to the site of B cell infiltration such as CNS parenchyma or other 




There is developing interest in the role of B cells in autoimmune disorders with T cell dependency. 
Buckwalter’s group has compared stroke outcomes in WT mice with either genetic deficiency of B 
cells or with delayed anti-CD20 treatment (beginning on day 5 after stroke). Unlike CD4 depletion, 
neither deficiency of B cells nor CD20 depletion affects recruitment of T cells, but they do prevent 
IgG accumulation. Comparing this finding with our own, it indicates that T cells might play a 
dominant role in facilitating the infiltration of other immune cells into ischemic brain, while B cells 
are mainly responsible for the production of pathogenic antibodies that could directly cause 
cognitive impairment (Kowal, DeGiorgio et al. 2004, Doyle, Quach et al. 2015). 
6.6 Within B cell compartment, proportions of plasmablasts/plasma cells and marginal zone B 
cells in ischemic brain and spleen of WT mice increased transiently on day 14 after stroke 
Germinal center-dependent humoral memory (serological memory) produces long-lived plasma 
cells, while germinal center-independent humoral memory induces extrafollicular foci of antibody 
production (Kurosaki, Kometani et al. 2015). Plasmablasts were reported to be migratory Ig-
producing cells in the pathogenesis of neuromyelitis optica (Chihara, Aranami et al. 2013). In 
multiple sclerosis, the inflammatory CNS provides a unique B-cell-friendly environment in which B 
lineage cells (notably long-lived plasma cells) can survive for many years, perhaps even for a 
lifetime (Meinl, Krumbholz et al. 2006). B cells produce pathogenic antibodies and impair recovery 
after spinal cord injury in mice (Ankeny, Guan et al. 2009). Moreover, the notorious persistence and 
stability of cerebrospinal fluid oligoclonal bands as well as the accumulation of B cells were 
detected in stroke patients (Pruss, Iggena et al. 2012, Doyle, Quach et al. 2015). However, it is still 
elusive as to whether long-lived plasma cells are induced in the ischemic brain of human stroke 
patients.  
After stroke, the number of B cells in the spleen was reduced compared to naïve controls, while B 
cells continuously infiltrated and accumulated in ischemic brain. The percentage of all B cells in 
total infiltrating leukocytes was significantly higher in ischemic brain on day 49 than on day 14 after 
stroke. Contrary to this trend, the percentages of plasmablasts/plasma cells and marginal zone B 
cells in both ischemic brain and spleen were higher on day 14 compared to day 49 after stroke. Since 
marginal zone B cells can contribute to T-cell-dependent (TD) immune responses (Zouali and 
Richard 2011) and even present autoantigen to diabetogenic T cells in nonobese diabetic mice 
(Marino, Batten et al. 2008), the presence of this cell type in ischemic brain suggests that marginal 
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zone B cells might contribute to the activation of autoreactive T cells. A previous study reported 
about 9.1% of CNS-infiltrating B cells at 7 weeks post stroke were plasma cells (Doyle, Quach et al. 
2015). But in our experiment, the percentage of plasmablast/plasma cells was almost 25% on day 14 
and then returned to around 10% on day 49 post stroke. This indicates that B cell autoreactive 
responses could take place as early as 2 weeks post stroke.  
It was reported before that RAG-/- mice reconstituted with CD3+ T cells had a similar infarct size as 
WT mice on day 1 post stroke (Kleinschnitz, Schwab et al. 2010). Recently, the same group 
concluded that B cells do not play a major pathophysiologic role in the acute phase (1-3 days) of 
ischemic stroke in mice (Schuhmann, Langhauser et al. 2017). However, our findings suggest 
infiltration and activation of B cells with expansion of potential autoantibody-producing plasma 
cells and marginal zone B cells during the delayed phase of stroke (14-49 days) are important 
processes for induction of chronic humoral autoimmunity and functional impairment.  
6.7 Stroke induces autoantibody against hippocampal neurons and thus provides a possible 
mechanism for development of delayed cognitive impairment in WT mice 
Circulating autoantibodies directed against CNS antigens have received much attention in recent 
years. Preexisting serum autoantibodies against the NMDAR subunit NR1 can modulate the 
evolution of lesion size in acute ischemic stroke (Zerche, Weissenborn et al. 2015). A high 
prevalence of NMDA receptor IgA/IgM antibodies exists in different dementia types (Doss, 
Wandinger et al. 2014). In animal stroke models, IgG/IgM is produced from week 1 and IgA 
appears with delay at week 7 in the ischemic hemisphere after stroke, and they correlate with 
delayed cognitive impairment (Doyle, Quach et al. 2015). A recent study even found that antibodies 
to myelin basic protein are associated with cognitive decline after stroke (Becker, Tanzi et al. 2016) 
An important aspect of immunoglobulins in ischemic brain is that leakage of peripheral 
immunoglobulins into the ischemic hemisphere might occur at 24h and 72h after stroke due to acute 
breakdown and ensuing compromise of the blood-brain barrier (BBB) (Manwani, Friedler et al. 
2014). I also detected preexisting IgG in over half of the WT mice before stroke. These 
autoantibodies mainly recognized the cytoplasm of cortical cells, neurons in dentate gyrus, neuronal 
nuclear antigen and, in rare cases, universal nuclear antigen beyond CNS. Only 2 out of 17 animals 
had production of autoantibody in the periphery, exclusively induced after stroke. The comparison 
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between autoantibody production and infarct size on day 1 after stroke revealed a tendency that 
animals with preexisting autoantibodies suffered from more severe infarction than animals without 
preexisting autoantibodies, which was consistent with findings from stroke patients (Zerche, 
Weissenborn et al. 2015). Our result reaffirmed that a preexisting autoantibody could modulate the 
evolution of lesion size in acute ischemic stroke and therefore be a risk factor for stroke outcome. 
Over 50% of stroke survivors experience persisting long-term cognitive impairment, which can 
affect their daily functioning and quality of life (Jokinen, Melkas et al. 2015). Besides risk factors 
such as age, white matter lesions, vascular dementia and Alzheimer’s disease for cognitive decline 
(Savva, Stephan et al. 2010, Iadecola 2013, Mahon, Parmar et al. 2017), B cells and autoantibody 
have been associated with cognitive decline in stroke (Doyle, Quach et al. 2015, Becker, Tanzi et al. 
2016). Based on our own finding that ischemic stroke could induce autoantibodies against multiple 
self-antigens including hippocampal neurons, I performed a Y maze test to detect possible cognitive 
deficits in working memory after stroke. Compared to naïve controls, significantly reduced 
alternations towards a less recently visited arm were detected on day 48 rather than on day 13 after 
stroke. This data stressed again that the infiltration of lymphocytes and activation of adaptive 
immunity, especially humoral responses, are indispensable for the induction of delayed cognitive 
decline. 
6.8 Modulation of lymphocytes can influence chronic autoreactivity and stroke outcome 
So far, the most beneficial effects of immunomodulation in experimental stroke have not been 
successfully translated into a clinical trial. The only exception is Natalizumab, a humanized 
monoclonal antibody which binds with α4β1 integrin and prevents leukocytes from transmigrating 
through the BBB. This drug has been approved for clinical use in autoimmune diseases such as MS 
and Crohn’s disease. Though three studies, including a preclinical randomized controlled 
multicenter trial, reported contradictory conclusions when blocking the very late antigen-4 (VLA-
4)-vascular adhesion molecule-1 (VCAM-1) axis in ischemic stroke in mice (Liesz, Zhou et al. 
Langhauser, Kraft et al. 2014, Llovera, Hofmann et al. 2015), a randomized, double blinded, 
placebo controlled trial of Natalizumab (ACTION phase II trial) was carried out in acute ischemic 
stroke (AIS) (Mehta, Mitchell et al. 2016). Even though Natalizumab does not affect infarct volume 
growth on the National Institutes of Health Stroke Scale (NIHSS) score compared with placebo, it 
has a meaningful benefit over placebo treatment for global clinical and cognitive function at 30 and 
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90 days after AIS. Despite Natalizumab showing positive effects on functional outcomes similar to 
what was found in experimental models, further research is required to better understand how this 
happens without reducing the infarct volume (Simats, Garcia-Berrocoso et al. 2016).  
Anti-CD20 antibody treatment was reported to successfully ablate B cells in the circulation, prevent 
the appearance of delayed cognitive deficits, and prevent the recruitment of B cells and IgG to the 
brain (Doyle, Quach et al. 2015). Rituximab (commercial monoclonal anti-CD20 antibody) has been 
approved to treat certain autoimmune diseases and types of cancer. However, insufficient disease 
inhibition by intrathecal rituximab was reported in progressive multiple sclerosis (Komori, Lin et al. 
2016). Until now, no clinical trial has studied its potential benefits in stroke patients. Only the 
plasma-cell-depleting proteasome inhibitor Bortezomib was proved to reduce antibody titers and 
improve the clinical course of patients with severe anti-NMDAR encephalitis (Scheibe, Pruss et al. 
2016). This might be relevant for stroke since autoantibodies were detected in experimental stroke 
and associated with cognitive impairment (Doyle, Quach et al. 2015, Doyle and Buckwalter 2016). 
The delayed CD4 depletion I researched in this thesis has demonstrated benefits for controlling local 
inflammation, stabilizing vasculature from pathological angiogenesis and promoting motor 
recovery. Anti-CD4 treatment could simultaneously deplete circulating CD4+ T cells and block 
infiltration of B cells into ischemic brain, while anti-CD20 treatment had no effect on T cells 
(Doyle, Quach et al. 2015). Therefore, it would be worthwhile to further explore whether delayed 
CD4 depletion has additional benefits such as neuroprotection and prevention of cognitive decline. 
6.9 Considerations of methodology and limitations 
In this thesis, experiments were mainly carried out on 2D2 mice. This strain has over 80% of 
peripheral CD4+ T cells carrying transgenic T cell receptors specifically recognizing MOG fragment 
(pMOG35-55) (Bettelli, Pagany et al. 2003). MOG, a membrane protein expressed on the 
oligodendrocyte cell surface, forms the outermost surface of myelin sheaths (Pham-Dinh, Della 
Gaspera et al. 1995). Due to this localization, MOG is easily accessible to activated immune cells 
and a primary target antigen in autoimmune-mediated demyelination such as multiple sclerosis. 
Synthetic MOG peptide (pMOG35-55) has the highest encephalitogenic potential to induce 
neurological impairment in C57Bl/6J mice (Mendel, Kerlero de Rosbo et al. 1995) by activating 
innate immune cells via Toll-like receptors (TLRs) and promoting the pathogenic function of 
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autoreactive T cells (Mills 2011). However, the percentage of MOG TCR+ CD4+ T cells among all 
CNS-infiltrating CD4+ T cells was only around 30% in the ischemic hemispheres (over 80% in the 
periphery). This indicates that activated T cells with TCRs recognizing multiple CNS antigens can 
accumulate in ischemic brain. Therefore, it is not warranted to attribute autoreactive responses seen 
in 2D2 mice only to autoreactive T cells or autoantibody against MOG. Moreover, compared with 
WT littermates, 2D2 mice have worse survival rate (only around 40%) until 14 days after stroke (see 
5.1.1). The lower survival rate ultimately affected the sample size for statistical analysis. 
The majority of thymocytes, most helper T cells, and a subset of NK-T cells (Bernstein, Plasterer et 
al. 2006) express CD4 on their surfaces, while dendritic cells and macrophages only express CD4 
weakly (Vremec, Pooley et al. 2000). CD4 plays an important role in the development of T cells and 
is required for mature T cells to function optimally. Impairment of T cell function occurs in 
situations where mice were treated with relatively large doses of anti-CD4 antibody, while a low 
dose of anti-CD4 antibody with only 50% reduction of splenic CD4+ T cells led to a significant 
augmentation of certain T-cell-dependent humoral responses (Cowdery, Tolaymat et al. 1991). We 
used the GK1.5 (IgG2b) rat anti-mouse CD4 antibody, which is known to deplete CD4+ T cell in 
vivo and to be immunosuppressive (Rashid, Auchincloss et al. 1992). Splenic CD4+ T cells were 
reduced by over 90% after two i.p. injections (200 ug per injection). The state of CD4 depletion was 
well maintained until day 14 after stroke. Since CD4 molecules can be weakly expressed on the 
surface of monocytes (Crowe, Mills et al. 1987), we also measured monocyte count in peripheral 
blood. No negative influences on mortality or reduction of monocytes were observed. 
Proximal occlusion of the MCA via the intraluminal filament (or suture) method is most frequently 
used to model ischemic stroke (Macrae 2011). The 60 min filament MCA occlusion (MCAo) model 
offers the advantage of inducing reproductive pan-necrotic lesions in the cortex, and striatum was 
used in this thesis (Engel, Kolodziej et al. 2011). However, human strokes are mostly small in size, 
ranging from 4.5% to 14% of the ipsilateral hemisphere (Carmichael 2005). Malignant infarction 
can damage over 30% of one hemisphere. Accordingly, our model is classified as severe stroke and 
causes infarcts involving regions supplied by the MCA but also potentially deep regions such as the 
hippocampus, hypothalamus and/or thalamus (El Amki, Clavier et al. 2015). Therefore, mice with 
lesion in hippocampus were cautiously excluded from the final evaluation of cognitive impairment 
since I was interested only in the role of autoreactivity on cognitive decline after stroke.   
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Immunofluorescent stainings provided direct evidence of the anatomical distribution of CD4+ T cells 
and their location with regard to deposition of fibrotic fibers. However, staining of cytokines and 
growth factors was quite challenging with immunohistochemistry. Therefore, a quantitative 
comparison of dynamic mRNA expression of fibrotic fibers and growth factors related to tissue 
remodeling was performed using qPCR. Contralateral hemispheres without infarction were used as 
internal control to compare stroke-induced changes of tissue-remodeling related genes in ipsilateral 
hemispheres. However, stroke-induced modulation of several genes such as nerve growth factor, 
vascular endothelial growth factor A and platelet-derived growth factor receptor β also affected the 
contralateral hemisphere. Thus, in addition I used hemispheres from the same side of naïve mice as 
a baseline control. However, a new experiment should include brain hemispheres from sham-
operated mice to exclude possible influence from the surgical procedure on the evaluation of tissue 
fibrosis in ischemic brain.  
The Catwalk system was used to detect locomotor deficits after stroke. Severe cerebral ischemia in 
mice disturbs the well-coordinated interplay among the four limbs. Swing subtask, intensity and 
maximal contact area in hind limbs, especially in the contralateral side, are impaired in the mid to 
long-term outcome after stroke (Hetze, Romer et al. 2012). In human stroke research, 3 months after 
stroke are accepted as the time point for assessing long-term outcome. In mice, the acute phase is 
completed within the first week after stroke (Dirnagl, Simon et al. 2003). Accordingly, measurement 
performed at 10 days after stroke reflects mid to long-term outcome (Hetze, Romer et al. 2012). 
Testing novel stroke treatments, there are only a few parameters which show an effect large enough 
to detect gait improvements. Due to high mortality caused by neurological reasons and medical 
complications like infections (Meisel and Meisel 2011) between day 3 and 6 post stroke, there were 
hardly enough animals (15-20 animals are recommended) from the same experiment to detect 
neuroprotective or regenerative effects at this late time point. Therefore stroke-induced mice that 
survived until day 10 were pooled together from 3 experiments. If the baseline parameters were 
significantly different among several experiments, it was not correct to directly compare gait 
parameters post stroke between control and CD4 depletion groups with pooled animals. Thus, I 
normalized the original result by calculating the change from baseline and calculated the post hoc 
impairment score of the right hind limb to detect focused lesion. In addition, an important limitation 
of the Catwalk system is the dependency on walking speed which influences many gait parameters. 
Catwalk can only be used as a measure if the stroke-induced mice are indeed able to walk at 
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minimum. Therefore, Neuroscore was introduced to evaluate not only the general status but also 
focal neurological dysfunction besides gait (Llovera, Hofmann et al. 2015).  
After observing the formation of follicle-like aggregates by B cells in my own experiments and 
reading publications on B cell-mediated cognitive impairment (Doyle, Quach et al. 2015), I 
performed the Y maze test (Dudchenko 2004) to evaluate cognitive deficits in the spatial working 
memory of stroke-induced mice. However, there are limitations to modeling cognitive decline in 
humans by rodents because experimental stroke in young mice does not include typical risk factors 
such as age, white matter lesions, vascular dementia and Alzheimer’s disease for cognitive decline 
(Savva, Stephan et al. 2010, Iadecola 2013, Mahon, Parmar et al. 2017). Since I only detected a 
significant difference between naïve mice and mice on day 48 post stroke, it is necessary to include 
sham-operated animals as a better control and also to evaluate delayed cognitive impairment over a 
longer period (3 months post stroke). It is also important to note that delayed cognitive impairment 
in experimental stroke was reported in distal MCAo plus hypoxia (DH) model (Doyle, Quach et al. 
2015), while I used only distal MCAo. This might explain different courses of developing cognitive 
decline after stroke. Further experiments that include more time points should be planned to detect 
the worsening of cognition in the MCAo model. 
The gold standard for testing patients with the presence of N-Methyl-D-aspartate (NMDAR) 
autoantibodies is the combined use of tissue immunohistochemistry and cell-based assays in which 
the protein of interest is transiently expressed in HEK cells (Pruss, Leubner et al. 2015). Here the 
less complex method with tissue immunohistochemistry was chosen to provide additional proof of 
functional formation of follicle-like aggregates by B cells in ischemic brain. CSF might contain 
more concentrated autoantibodies (Pruss, Leubner et al. 2015). However the negligible amount of 
cerebrospinal fluid collected from each mouse was not enough to complete one single staining. 
Consequently, serum samples were prepared before and after experimental stroke. Mice with either 
preexisting autoantibodies or stroke-induced autoantibodies against CNS antigens were quickly 
screened. However, the number of paired serum samples was too limited to detect any dominant 
epitopes of autoantibodies induced exclusively after stroke. Further experiments are needed to 
explore the complex patterns of autoreactivity after stroke. Moreover, a cell-based assay is still 





In this thesis, I have not investigated all time points of interest, especially in WT mice. I observed 
strong inhibition of B cell infiltration into ischemic brain when circulating CD4+ T cells were 
depleted in 2D2 mice on day 14 after stroke. However, this effect was not detected in WT mice at 
the same endpoint. Because peak accumulation of B cells in the ischemic brains of WT mice was 
actually detected on day 49 after stroke (5.3.2). 2D2 mice with MOG TCR had earlier and more 
severe infiltration of CD4+ T cells and larger infarct volume compared with WT mice (5.1.1). Such 
differences in stroke-induced autoreactivity might lead to a remodeling/recovering differential in 
2D2 mice and WT mice, but I have not validated all findings from 2D2 mice in WT mice, such as 
mRNA expression of growth factors and motor recovery. Moreover, a proper sham-operated control 
was also lacking to confirm whether the observed cognitive impairment on day 48 was indeed 
induced by stroke rather than the surgical procedure. Due to the small group size (N=3-5), I could 
not detect statistically significant differences between the control and CD4 depletion groups in 
accumulation of activated microglia/macrophages, motor recovery or neurological score. The 
limited amount of serum samples made it hard to summarize dominant epitopes of autoantibodies 
and their relevance to autoreactivity and functional recovery after stroke. All these limitations 
should be overcome in future experiments. 
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6.10 Future challenges 
Previous research stressed that stroke does not systematically trigger autoimmunity. Only under 
certain circumstances, such as pronounced systemic inflammation or infection, can autoreactive T 
cells escape the tolerance controls (Urra, Miro et al. 2014). Delayed infiltration of CD4+ T cells and 
differentiation of autoantibody-producing plasma cells in ischemic brain have opened a new avenue 
for the search of immunomodulatory agents to control autoimmune responses and protect neuronal 
function after stroke. The main findings demonstrate that delayed depletion of CD4+ T cells inhibits 
infiltration of B cells and formation of follicle-like aggregates in the ischemic brain of 2D2 mice. 
CD4 depletion also controls local inflammation and instability of the BBB via inhibition of 
proliferation of activated microglia/macrophages and periendothelial cells. Functional recovery, 
especially impairment of the right hind limb, was reduced in 2D2 mice with CD4 depletion on day 
10 after stroke. Further studies are needed to demonstrate whether these findings are causally 
involved in long-term outcome after stroke.  
Even though CD4 depletion had strong effects in 2D2 mice post stroke, delayed CD4 depletion did 
not significantly reduce infiltration of B cells in WT mice on day 14 after stroke. B cells actually 
continued to accumulate in the ischemic hemispheres of WT mice between day 14 and day 49 after 
stroke. Thus, it cannot be excluded that in WT mice blockage of massive B cell infiltration by CD4 
depletion might occur later than 14 days (end point defined for 2D2 mice). Further studies in WT 
mice should be planned with extended duration to detect the effects of CD4 depletion on 
autoreactive responses and functional recovery after stroke.  
The detection of follicle-like aggregates in ischemic brain is consistent with previous findings in 
spinal cord injury (Ankeny, Lucin et al. 2006) and ischemic stroke (Doyle, Quach et al. 2015). 
Nevertheless, the cellular components of follicle-like aggregates, apart from B cells, were not 
investigated in depth. Follicular helper T cells (TFH cells) are present in B cell-rich regions of 
structurally organized lymphoid aggregates (Pitzalis, Jones et al. 2014). TFH cells can induce the 
differentiation of B cells into plasma cells (Ueno, Banchereau et al. 2015) and antibody production 
(Ding, Mountz et al. 2015). Whether TFH cells are detectable in such ectopic follicles in ischemic 
brain remains elusive. In addition, B cells and autoantibodies have been associated with the 
development of delayed cognitive impairment (Doyle, Quach et al. 2015, Becker, Tanzi et al. 2016). 
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B cell depletion with anti-CD20 antibody beginning 5 days after stroke ameliorates the development 
of delayed cognitive deficits (Doyle, Quach et al. 2015). Thus, it would be interesting to study 
further whether delayed CD4 depletion has equivalent protection against delayed cognitive decline 
during the chronic phase of stroke. 
It was reported that B cells and IgG were positively stained in the brain after stroke in humans with 
concurrent dementia (Doyle, Quach et al. 2015). However, not all stroke patients develop delayed 
cognitive deficits and not all stroke-induced dementia have pathological immunoglobulins in the 
brain. In WT mice, I observed a transiently increased percentage of plasmablasts/plasma cells in 
overall infiltrating B cells in both ischemic brain and spleen on day 14 post stroke. With future 
experiments focusing on the effects of late CD4 depletion on composition of B cell subtypes in WT 
mice, it might be interesting to explore whether CD4+ T cells can influence activation and 
differentiation of B cells into long-lived plasma cells during the chronic phase of stroke. In stroke 
patients it is also worth investigating whether plasma cells reside in ischemic brain and whether 
autoantibodies against CNS antigens are induced after stroke. By correlating autoantibodies and 
stroke outcomes, it might be helpful to distinguish between potentially protective and pathological 
autoantibodies (Becker, Tanzi et al. 2016) since only dementia-associated autoantibodies and long-
lived plasma cells should be targeted for pharmacological elimination. 
The findings here jointly demonstrate that modulating adaptive immune cells might be promising 
therapeutic targets in the chronic phase of ischemic stroke. To improve the quality and translational 
predictability of preclinical stroke research and obtain robust effects of immunomodulation on long-
term outcome after stroke, preclinical randomized controlled multicenter trials with larger sample 
sizes and sufficient statistical power are warranted (Mergenthaler and Meisel 2012, Llovera, 




The most important findings of my PhD thesis can be summarized as follows: 
1. Delayed infiltration of CD4+ T cells on day 14 after stroke was more severe in MOG TCR 
transgenic mice (2D2) than WT mice. Autoreactive potential against MOG also led to larger infarct 
size and worse survival post stroke in 2D2 mice. The transient priming and proliferation of naïve 
CD4+ T cells in secondary lymphoid organs was crucial for targeted migration towards ischemic 
hemisphere on day 7 post stroke.  
2. The mRNA expression of TGFβ1 rather than PDGFRβ correlated with deposition of collagen type 
I fibrotic fibers. This indicated that activated macrophages which occupied the infarct core rather 
than pericytes could be the main producer of fibrotic fibers in the ischemic hemisphere. Even though 
infiltration of CD4+ T cells (7 to 14 days post stroke) temporally and spatially correlated with the 
deposition of fibrotic extracellular matrix, CD4 depletion did not directly influence the mRNA 
expression of either collagen type I or TGFβ on day 14 post stroke.  
3. Delayed CD4 depletion had no effect on the infarct size on day 7 nor on the numbers of surviving 
neurons and activated microglia/macrophages on day 14 post stroke. Nevertheless, delayed CD4 
depletion had a trend to impair the proliferation of activated microglia/macrophages and 
significantly inhibited the proliferation of CD13+ periendothelial cells. Importantly, depletion of 
CD4+ T cells in 2D2 mice reduced motor impairment in the right hind limb on day 10 and blocked 
the entry of B cells into the ischemic hemisphere and the subsequent formation of follicle-like 
aggregates on day 14 post stroke.  
4. Depletion of CD4+ T cells in WT mice did not significantly block the entry of B cells into the 
ischemic hemisphere on day 14 post stroke. This was due to delayed peak accumulation of B cells 
(49 days) in WT mice compared to 2D2 mice (14 days). Transiently increased differentiation of 
plasmablasts/plasma cells and expansion of marginal zone B cells on day 14 post stroke in ischemic 
brain and spleen of WT mice could contribute to the induction of B cell autoreactivity with 
production of autoantibodies. Indeed, autoreactivity induced by stroke led to the production of 
autoantibody against hippocampal neurons, which might be one potential mechanism for developing 
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